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Circulating adrenal glucocorticoids exhibit characteristic circadian and ultradian rhythms, important 
for maintaining homeostasis and regulating multiple physiological processes. Glucocorticoids exert 
genomic actions on target cells via a ligand activated transcription factor, the glucocorticoid receptor 
(GR). In the liver, GR regulates transcription of many critical determinants of carbohydrate and fat 
metabolism. Furthermore, glucocorticoids been implicated in metabolic disorders including insulin 
resistance, hyperlipidaemia and non-alcoholic fatty liver disease. Despite the increasing prevalence of 
metabolic disease in western society, the relative contribution of glucocorticoid rhythm disturbance, 
particularly ultradian dysregulation, has been largely unexplored.  
Using GR ChIP-Seq of livers taken from corticosterone treated adrenalectomised (ADX) rats, I have 
found that ultradian replacement induces ~3,000 GR binding events at the pulse peak, all of which are 
lost at the pulse nadir. I have further demonstrated that constant corticosterone infusion results in 
prolonged GR binding. To assess effects on gene transcription, I have also performed RNA polymerase 
II ChIP-Seq with an antibody specific for the actively transcribing form of the complex. Using pSer2 
RNA polymerase II binding as proxy for active gene transcription, I found similarly synchronised, 
predominantly down-regulated transcriptional modulation in response to corticosterone pulses. 
Whereas in response to constant corticosterone, prolonged and mostly upregulated transcription was 
detected.  
Notably, functional pathway analysis showed that differentially regulated targets were involved in 
glucose, carbohydrate, cholesterol, fatty acid, lipid, proliferative and necrotic pathways. My findings 
support the hypothesis that glucocorticoid pattern dysregulation leads to dysregulation of key 
metabolic targets in the liver, potentially contributing to the development of metabolic syndrome.  
Finally, I present the development of a novel rodent corticosterone replacement model that 
incorporates both circadian and ultradian rhythms for use in longer duration studies where I plan to 
test the metabolic outcome of chronic glucocorticoid dysregulation. This approach shows great 
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Chapter 1 Introduction 
GC rapid synthesis and secretion from the adrenal glands fluctuates over a 24-hour period; maximal 
levels recorded prior to the onset of the active period and gradually decreasing within the circulation 
to negligible levels within the inactive period. This pattern of secretion is under the regulation of a 
neuroendocrine circuit first described within the 1950s by Hans Seyle, termed the hypothalamic 
pituitary adrenal (HPA) axis (Selye, 1950; Lightman and Conway-Campbell, 2010). Further investigation 
discovered upon series, short time point blood sampling, that GC levels are not constant within the 
circulating blood plasma, but consists of a series of pulses whose amplitude varies in a circadian 
fashion (Windle, Wood, Lightman, et al., 1998; Windle, Wood, Shanks, et al., 1998; Walker, Terry and 
Lightman, 2010). Despite this being an intrinsic oscillatory and well conserved mechanism within 
mammals, research into dysregulated GC rhythm primarily asses longer time points of up to 6-12hrs 
that do not investigate function or loss of the ultradian intra-rhythm of GC signalling.  
Dysregulation from usual endogenous dynamics occur due to the ability of the HPA axis to respond to 
a range of stimuli including the stress response (Selye, 1950; Lightman and Conway-Campbell, 2010; 
Sarabdjitsingh et al., 2010). Whilst acute activation is thought to be protective, such as within the 
classic fight or flight response, chronic activation is associated with the development of a range of 
metabolic phenotypes such as obesity, type II diabetes and dyslipidaemia to name a few (Deuschle et 
al., 1997; J. Haller et al., 2000; Lightman, 2016; Oster et al., 2016; Kalafatakis et al., 2018). Similar 
presentations are observed within individuals whose activity is out of synchrony with their 
endogenous rhythm, such as workers with variable shift patterns and patients who suffer from 
hypercortisolism (Nieman and Ilias, 2005; Chandola, Brunner and Marmot, 2006; Buliman et al., 2016). 
Additionally, despite the tailoring of synthetic steroid use to recapitulate circadian GC rhythm, similar 
side effects are observed over a chronic time scale and has shown to be a primary cause of type II 
diabetes development (Simmons et al., 2012; Charmandari, Nicolaides and Chrousos, 2014).  
Despite emerging evidence of the importance of ultradian rhythms to homeostatic function, it remains 
relatively un-known how dysregulation of both the circadian and ultradian elements of GC dynamics 
may affect metabolic as well as cognitive homeostatic function (Flynn, Conway-Campbell and 
Lightman, 2018; Kalafatakis et al., 2018). 
1.1 The glucocorticoid receptor 
1.1.1 Glucocorticoid receptor structure 
GCs regulate transcription of specific genes via liganded activation of the glucocorticoid receptor (GR). 




oxosteroid sub-family of steroid hormone receptors within the nuclear receptor superfamily. Other 
steroid hormone receptors include the mineralocorticoid receptor (MR) (encoded by the gene NR3C2), 
progesterone receptor (PR) (encoded by the gene NR3C3) and androgen receptor (AR) (encoded by 
the gene NR3C4) (‘A Unified Nomenclature System for the Nuclear receptor superfamily’, 1999; 
Bledsoe et al., 2002). Steroid hormone receptors are comprised of three main functional domains. The 
N-terminal domain (NTD), DNA binding domain (DBD) and ligand binding domain (LBD) (Figure 1.1). 
This structure is well conserved across mammalian species.  
 
Figure 1.1 Schematic of the GR protein.  
Diagram describes the GR three major domains; the N-terminal domain (NTD) (blue) and a central 
highly conserved DNA binding domain (DBD) which is separated from the ligand binding domain (LBD) 
by a hinge region (HR). GR regions important for dimerization, nuclear localisation, chaperone binding 
(e.g HSP90) and transactivation function (AF1 and AF2) are also indicated. Figure adapted from Robert 
H. Oakley and Cidlowski 2013. 
The N-terminal domain (NTD) is the least well conserved structural domain. It is a highly modifiable 
domain for post-translational events such as phosphorylation, and contains a large transactivation 
region (AF1) through which the GR interacts with a variety of chromatin remodellers and transcription 
factors such as the SWItch/ sucrose non-fermentable (SWI/SNF) complex, TATA binding box protein 
(TBP), cyclic adenosine 3’,5’-monophosphate- response element binding protein (CREB) binding 
protein (CBP) and p300, modulating GR transcriptional regulation (Giguère et al., 1986; Godowski et 
al., 1987; Bodwell et al., 1991; Dieken and Miesfeld, 1992; Dahlman-Wright et al., 1995; Almlöf et al., 
1998; Wallberg et al., 2000).  
The DBD contains a nuclear localisation sequence (NLS1) as well as a p-box of zinc finger motifs, 
termed the D-loop. These zinc fingers directly interact with short consensus 6bp palindromic DNA 
sequences separated by a 3bp spacer (5’-AGAACA-nnn-TGTTCT-3’) (within certain base predictive 
tolerances), termed glucocorticoid response elements (GRE)s (Figure 1.2)  (Scheidereit et al., 1983; 
Luisi et al., 1991; La Baer and Yamamoto, 1994; Savory et al., 1999; Meijsing et al., 2009). Each zinc 




full sequence recognition by the complex (Dahlman-Wright et al., 1991; Oakley et al., 1999; Hudson, 
Youn and Ortlund, 2013). However, this model is further complicated by increasing evidence of higher 
order oligomerisation, such as the discovery of GR tetramers as well as heterodimers with other 
oxosteroid receptors such as MR (Trapp et al., 1994; Mifsud and Reul, 2016; Presman et al., 2016). 
 
Figure 1.2 DBD interactions with DNA and within the GR homodimer. 
GR binds as a homodimer in an inverted manner (classical model) to a GRE consensus sequence within 
the DNA via zinc finger within the P-box of the DBD (blue). Within the D-loop of each GR, the second 
zinc finger forms a dimerization interface (red). GRE consensus sequence required for GR recognition 
in bold. Figure modified from Hudson, Youn and Ortund 2013. 
Finally, the LBD contains a second nuclear localisation region (NLS2) consisting of a canonical three 
layered helical hydrophobic pocket formed from 11-12 α-helices and four β-sheets. These are held in 
a conformational state by a multimeric complex of chaperones including heat shock proteins (hsp) 
hsp40, hsp70, hsp90 and p23 as well as immunophilins such as FKBP51, FKBP52, CYP44 and PP5 
(Bourguet et al., 1995; Renaud et al., 1995; Xu et al., 1999). The multimeric complex plays a key role 
in maintaining the correct conformational state, opening a hydrophobic pocket in the LBD to increase 
binding affinity for ligands such as glucocorticoids (GCs) and preventing proteasome mediated 
degradation (Bresnick et al., 1989; Picard et al., 1990). Upon ligand binding to the LBD hydrophobic 
pocket, the GR undergoes a conformational change, exposing the NLS1 and NLS2 as well as stabilizing 
or de-stabilizing a secondary activatory region (AF2). This regulates the ability of GR to associate with 
co-regulators of transcriptional function (Wurtz et al., 1996; Savory et al., 1999; Bledsoe et al., 2002; 
Kauppi et al., 2003). Deletion studies have shown that NLS2 mediated import of the GR to the nuclear 




1.1.2 GR post-translational modifications 
Over 20 residues (mostly serine and threonine) have been identified within the human GR (hGR) 
structure to undergo post-translational modification, this includes phosphorylation of up to six serine 
(Ser) residues within the AF1 region (Ser-113, Ser-134, Ser-141, Ser-203, Ser-211 and Ser-226) (Figure 
1.3) (Oakley and Cidlowski, 2013; Kino, 2018). Most phosphorylation events occur as a result of ligand 
binding and have distinct and varied effects on GR function. For example, phosphorylation of Ser-203, 
Ser-226 and Ser-404 is required for  hGR nuclear translocation, while cyclin dependent kinase 5 (Cdk5) 
dependent phosphorylation of Ser-203, Ser-211 and Ser226 facilitates recruitment of co-regulators 
such as the histone acetyl-transferases (HAT), CBP and p300, and adenosine triphosphate (ATP) 
dependent chromatin remodelling factors such as the SWI/SNF complex (Itoh et al., 2002; Wang, 
Frederick and Garabedian, 2002; Kino et al., 2007; Blind and Garabedian, 2008; Galliher-Beckley, 
Williams and Cidlowski, 2011).  
Other regulatory mechanisms involve acetylation at Lys-494 and Lys-495, which facilitates GR 
recruitment of histone deacetylase 2 (HDAC2), a factor known to interact with the tertiary structure 
of DNA and facilitate transcription (Ito et al., 2006; Nader, Chrousos and Kino, 2009). Post-translational 
modifications can also repress GR mediated transcription. Genetic mutations which substitute aspartic 
acid residues for Serine residues at positions 226 and 404, produce a GR mutant that is incapable of 
being phosphorylated at these sites and cannot recruit p300, CBP or the nuclear factor kappa-light-
chain-enhancer of activated B cells (NFκB) p65 subunit. These mutations have also been shown to 
attenuate glucocorticoid induced cell death of osteoblasts as well as play a distinct role within 
depression associated with GC resistant pathology (Miller et al., 2005; Chen, Rogatsky and 
Garabedian, 2006; Blind and Garabedian, 2008; Chen et al., 2008; Galliher-Beckley et al., 2008; Simic 
et al., 2013).   
Post-translational modification has also been shown to play a role in circadian rhythms as described 
within  (Chapter 1.2.3) Histone acetyltransferases such as CBP, P300, circadian locomotor output cycle 
kaput (CLOCK) and brain and muscle ARNT-like1 (BMAL1) can directly acetylate GR residues in a daily 
oscillating manner synchronised to the rise and fall of total blood serum corticosterone levels. This 
has been shown to directly regulate the induction of glucocorticoid induced leucine zipper (GILZ) and 
inhibition of glucose-6-phosphatase (G6PC) transcription and regulating gluconeogenesis within the 





Figure 1.3 Post-translational modification of the GR by phosphorylation, acetylation, ubiquitination 
and SUMOylation. 
Within the NTD of the human GR transcript, 7 serine residues are indicated as phosphorylation targets 
(P) within the AF1 region. Serine residues (Ser) directly phosphorylated by cyclin dependent kinase 1 
(CDK1) and 5 (CDK5), activation function-1 (AKT1) as well as adenosine 5’ monophosphate-activated 
protein kinase (AMPK) indirectly via c-Jun N-terminal kinase (JNK) are indicated. Ser-404 outside of 
the AF1 is phosphorylated by glycogen synthase kinase 3β (GSK3β) is also indicated. Lysine (Lys) 
residues Lys-277 and Lys-293 within the NTD and Lys-703 towards the c-termini of the LBD are 
targeted for SUMOylation (S) residues Lys-419 within the NTD for ubiquitination (U) and Lys-494 and 
Lys-495 within the HR are targeted for acetylation (U) are also indicated. All numbers refer to human 
GR structure. Figure modified from Oakley and Cidlowski, 2013; Kino, 2018. 
Proteasomal degradation of the GR is also initiated by a post-translational modification, in this case 
ubiquitination. Phosphorylation of proline, glutamic acid, serine and threonine residues (PEST) 
sequences often precede ubiquitination of proteins by a series of proteins commonly referred to as 
E1 activating, E2 conjugating and E3 ligase enzymes (Jadhav and Wooten, 2009). Mutational studies 
of (Lys) 426 residue within a (PEST) sequence were found to alter the degree of ubiquitination and 
reduce proteasomal degradation of hGR within HeLa and COS cell lines (Wallace and Cidlowski, 2001; 
Wallace et al., 2010). Overexpression of the Ubiquitin E3 ligase, carboxyl terminus of hsp70-interacting 
protein decreases GR transcript levels, indicating a chaperone complex role in proteasomal 
degradation (Ballinger et al., 1999; Vandevyver, Dejager and Libert, 2014). Conversely, inhibition of 
the 26S proteasome complex by the aldehyde peptide MG132 results in increased GR protein levels 
and retention within the nucleus (Wallace and Cidlowski, 2001; Deroo et al., 2002; Han et al., 2009; 
Wilkinson, Verhoog and Louw, 2018). Similarly, GR binding to DNA or ligands can induce small 




Lys-277, 293 within the NTD and Lys-703 in the LBD of the CTD, initiating proteasomal degradation (Le 
Drean et al., 2002; Tian et al., 2002; Holmstrom et al., 2008; Oakley and Cidlowski, 2013). SUMOs 
share 20% homology to ubiquitin and are regulated by the homologous factors SUMO2/ SUMO3 (95% 
homology) and SUMO1 (50% homology) factors (Mahajan et al., 1997; Kamitani et al., 1998; Tatham 
et al., 2001). Classically, SUMOylation is associated with proteasomal degradation during cellular heat 
shock mechanisms (Wallace and Cidlowski, 2001; Tatham et al., 2011). However, as SUMOylation of 
NTD sites affect co-regulator recruitment, transcriptional effects are varied and highly context 
dependent (Davies et al., 2008; Druker et al., 2013; Paakinaho et al., 2014).  
1.1.3 GR splice variants and translational isoforms 
The GR is coded by a single gene consisting of 9 exons within humans. Multiple variants and isoforms, 
however, are present with distinct features and actions of potential importance to function (Figure 
1.4). GR variants are produced from a range of splice events between exons 5-9 within the LBD coding 
region of the gene, and are categorized as GR-α, GR-β, GR-A and GR-P. A further variant, GR-γ, occurs 
due to splicing within exon 3-4 of the DBD coding region of the gene. Relative levels of isoforms can 
be tissue dependent, but GR-α is expressed most abundantly and is commonly described when 
investigating GR function (Hollenberg et al., 1985; de Castro et al., 1996; Oakley, Sar and Cidlowski, 





Figure 1.4 Splice variants and translational isoforms of the GR. 
(A) Exon number found within the GR primary transcript and location of splicing events that create 
alternative splice variants. (B) Schematic of GRα translational isoforms with translational start site (*) 
indicated to produce variable lengths. All numbers refer to human GR structure. Figure adapted from 
Oakley and Cidlowski, 2013.  
GRβ has an identical amino acid sequence to GRα up to amino acid 727, but this splice variant is joined 
further downstream within exon 9. Creating a non-homologous carboxyl-terminal sequence as well as 




of the splicing events, the ability to bind ligand is lost due to the removal of helix 12 within the LBD 
(Bamberger et al., 1995; de Castro et al., 1996; Kino et al., 2009). However, unlike GRα, GRβ is primarily 
located within the nucleus and can occupy GREs in a ligand independent manner, potentially as a 
heterodimer with GRα, to act as dominant negative inhibitor of transcription (Bamberger et al., 1995; 
Oakley, Sar and Cidlowski, 1996; Oakley et al., 1999). Increased GRβ / GRα ratios have been implicated 
in inflammation, major depressive disorder and GC resistance. Notably, GRβ was found to be increased 
in liver during the re-feeding phase of fasted rats and is associated within insulin action within mouse 
embryonic fibroblast cells (Hinds et al., 2010; Carvalho et al., 2014; John et al., 2016).  
Information on the function and distribution of remaining variants are limited. However, insertion of 
an arginine residue at position 454 (exon3-4) is known to produce GRγ which does not affect the LBD 
coding region but does reduce the transactivation potential compared to GRα (Rivers et al., 1999). 
Whereas, splicing between exons 5-7 and 8-9 of the LBD coding region have been shown within 
isolated myeloma cells produces GR-A and GR-B respectively which may mediate function via 
modulation of GRα induced transcription (Moalli et al., 1993; Gaitan et al., 1995; Krett et al., 1995; de 
Lange et al., 2001; Oakley and Cidlowski, 2013). 
Additionally, a variety of GRα translational start sites within the NTD is known to  produce up to seven 
additional isoforms with the nomenclature GRα-A, -B, -C1, -C2, C3, -D1, -D2 and D3 (Lu and Cidlowski, 
2005) (Figure 1.1). Evidence has indicated in their liganded un-bound state, isoforms A-C are found in 
the cytoplasm whilst the two D isoforms can be found within the nucleus. As these translational 
isoforms reduce the length of the NTD from the N-terminus, alterations or loss of the AF1 region as 
well as sites for targeted for post-translational modifications could affect each isoforms capability to 
recruit certain co-regulators and their transactivator/ transinhibitory potential. It has been proposed 
as a mechanism for GRα-A, -B and -C isoform mediated specific regulation of apoptotic genes within 
human osteosarcoma bone cells and T lymphoblastic leukaemia cells (Lu et al., 2007; Wu et al., 2013). 
1.1.4 Ligand induced translocation of the GR 
In the absence of ligand, newly synthesised GR is sequestered within the cytoplasm. Upon ligand 
binding, conformational changes within the GR cause members of the chaperone multimeric complex 
to dissociate, exposing AF regions and the ligand-inducible NLS. Cytoplasmic GRs are shuttled into the 
nucleus by the Importin α/β nuclear import pathway and along microtubule tracks (Savory et al., 1999; 
Bledsoe et al., 2002; Kauppi et al., 2003; Pratt et al., 2004). Hsp90 is known to interact with FKBP52 
and dynein and in turn the microtubule-associated protein doublecortin-like to actively translocate 
GR into the nucleus (Czar et al., 1995; Elbi et al., 2004; Fitzsimons et al., 2008). Upon inhibition of 




(Galigniana et al., 1998; Elbi et al., 2004). Hsp90 also appears to be required for GR recruitment of 
cofactors such as CREB, p300 and CBP, and there are reports indicating a role for these multimeric 
chaperone proteins during rapid GR dynamics (Conway-Campbell et al., 2011). In contrast, inhibition 
of hsp70 had no effect on rapid translocation (Yang and DeFranco, 1994). After ligand loss, GR 
undergoes extremely slow translocation back into the cytoplasm. Therefore, unliganded GR can be 
found within a biochemically defined, low salt extractable, subcellular fraction sometimes referred to 
as the nucleoplasm (Yang, Liu and DeFranco, 1997; Conway-Campbell et al., 2007). Upon GC re-
exposure, GR re-binds ligand and is present within a high-salt extractable DNase-sensitive chromatin 
rich cellular fraction (Yang, Liu and DeFranco, 1997; Liu and DeFranco, 1999). Taken together, these 
findings indicate that the GR can be maintained within the nucleoplasm and become repeatedly 
activated with multiple cycles of ligand exposure. Further evidence shows that clearance from the 
nucleus is proteasome dependent (Stavreva et al., 2004, 2009; Wang and DeFranco, 2005; Conway-
Campbell et al., 2007, 2011). 
1.1.5 DNA structure and organisation of the genome 
Ligand activated GR can interact directly with DNA in a tissue and cell specific manner (John et al., 
2008, 2011; Grøntved et al., 2013) to regulate gene transcription. Within eukaryotic cells, the genome 
is organised into a highly complex structure termed chromatin that is separated into ‘nucleosomes’ of 
highly compacted DNA, coiled typically ~1.7 times around an octamer core of histone proteins (H2A, 
H2B, H3 and H4) (Kornberg, 1974; Hayes, Clark and Wolffe, 1991; Kornberg and Lorch, 1999). The 
density of chromatin is variable throughout the genome and can regulate the ability of factors to either 
bind or interact with the DNA template. It has been shown that nucleosomes packed to within 30nm 
structures are transcriptionally inactive, postulated to be due to inaccessibility of the molecular 
transcriptional machinery (Bednar et al., 1998). The chromatin configuration and corresponding 
densities are modulated by the post-translational status and the variants of histones, the recruitment 
of chromatin re-modelling factors and the degree of DNA methylation (Biddie et al., 2011; George, 
Lightman and Biddie, 2011). Regions of increased chromatin density are termed heterochromatin and 
described as ‘closed’ due to their transcriptionally inactive state, whereas less dense, ‘open’ regions 
of chromatin that are transcriptionally active are termed euchromatin (Archer et al., 1991; Bednar et 
al., 1998; John et al., 2008). Regions of euchromatin are usually comprised of highly methylated and 
acetylated histones (Barski et al., 2007; Bannister and Kouzarides, 2011). Mechanistic experiments in 
yeast have indicated that hyperacetylation of the H4 N-terminal tail can destabilize inter-nucleosomal 
contacts (30 nanometer fiber-like connections between histones) which have been shown to be 




machinery (Shogren-Knaak et al., 2006). Conversely, histone deacetylases (HDACs) have been linked 
to a loss in transcription (Ito et al., 2006). The organisation of hetero- and euchromatin regions present 
fundamentally important tissue and cell specific mechanisms for directed nuclear factor binding. 
Separating binding sites into cell specific regions that are in either a ‘closed’ or ‘open’ chromatin state 
or sites that can be modified into an open or closed stated by external stimuli via intracellular signalling 
and co-factor assembly. Assessment of chromatin density in response to GR binding by formaldehyde-
assisted isolation of regulatory elements (FAIRE) next generation sequencing (Seq) and DNase 
footprinting have indicated that hormone-induced reductions in chromatin density occur at nearly all 
GRE containing GR binding sites (John et al., 2011; Burd et al., 2012). Further, 90% of all GR binding 
sites have been detected within pre-accessible, ‘open’ chromatin regions, which are highly cell-specific 
(John et al., 2008; Reddy, Pauli and Sprouse, 2009; Biddie et al., 2011; Burd et al., 2012). Nuclear 
factors such as the GR are able to initiate the remodelling of chromatin density via the recruitment of 
co-factors such as the HATs CBP and p300 and the ATP dependent chromatin remodellers such as the 
SWI/SNF complex (Lee and Archer, 1994; Archer and Lee, 1997; Kinyamu and Archer, 2004). Nuclear 
factors that initiate the ‘opening’ of the chromatin landscape in this way have been described as 
‘pioneer’ factors. It is further postulated similar mechanisms are involved within epigenetic regulation 
as well as acute and chronic changes of genome transcription and regulation (Archer et al., 1991; John 
et al., 2008, 2011; Reddy, Pauli and Sprouse, 2009; Jubb et al., 2017). 
1.1.6 Models of GR mediated transcription 
Upon ligand binding, GR is classically thought to translocate through the nuclear pore, rapidly diffuse 
throughout the nucleus and bind as a homodimer to specific regulatory elements across the genome. 
However, the homodimer is not essential for transcriptional regulation. GR monomers have been 
observed binding to both full GRE palindromic and half sites with differing transcriptional effects 
(Eriksson and Wrange, 1990; Grøntved et al., 2013; Schiller et al., 2014; Lim et al., 2015; Pooley et al., 
2017). In fact, it has been postulated monomeric binding is more common than the homodimer form. 
There is also evidence that GR forms tetramers, potentially via looping of GR dimers bound at opposing 
sites within the genome (Presman et al., 2016). 
Upon binding to regulatory sites within DNA, liganded GR can recruit numerous co-factors important 
to transcriptional regulation with intrinsic and synergistic acetylation, methylation and 
phosphorylation mechanisms. These interactions have been shown to be rate limiting as well as 
significantly enhancing or repressive of transcriptional capacity for a single transcription factor (De 
Bosscher et al., 2000; Tetel, 2009; Reiter, Wienerroither and Stark, 2017). In the simplest model, the 




positioning ribonucleic acid (RNA) polymerase II (RNA Pol2) at the core promoter (a minimal DNA 
sequence required for the start of transcription) (Wang, Carey and Gralla, 1992; Wiley, Kraus and 
Mertz, 1992). Primarily, canonical TATA sequences within promoter regions direct the pre-Pol via 
interactions with the TATA box binding protein subunit, which in mammalian genes are typically 30b 
upstream of the transcriptional start site (TSS) (Ponjavic et al., 2006). This is however, a simplified 
model, as genome wide studies indicate other initiator sequences and CpG islands can also be 
transcriptionally active (Sandelin et al., 2007). In instances where the DNA cannot spontaneously 
unwind or non-template strands are not complementary, the helicase XPB subunit will melt 
approximately 11-15bp of the promoter, positioning the template strand within the active cleft to 
begin synthesis of RNA (Wiley, Kraus and Mertz, 1992; Holstege, Fiedler and Timmers, 1997; Tirode et 
al., 1999; Hahn, 2004; Luse, 2014). 
It has long been known that a classical promoter GR binding site is not required for transcriptional 
regulation and binding sites are often located many kilobases (kb) from the regulated TSS. These are 
sometimes referred to as ‘enhancer’ sites (Lee et al., 1987). In fact 93% of dexamethasone (Dex) 
induced GR binding sites in mouse 3134 cells were further than 2.5kb away from the TSS (John et al., 
2011). Similarly, in HeLa cells only 7% of GR binding events were within 10kb promoter regions and in 
macrophages, lipopolysaccharide induced <6% within 20kb proximal promoter regions (Rao et al., 
2011; Uhlenhaut et al., 2013). This highlights the question; how do long-distance interactions occur 
between GR binding and their transcriptionally dependent sites? The most accepted model relies on 
folding and organisation of the chromatin architecture within topologically associated domains 
(TADs). Within this ‘looping’ model, GR binding sites that are a very long distance (often many kbs) 
from a target gene’s TSS, loop to within close proximity and are therefore in chromosomal contact 
(Dixon et al., 2012; Nora et al., 2012; Sexton et al., 2012). It is theorised, co-regulated genes and 
appropriate regulating transcription factors all loop from a variety of locations to occupy the same 
spatial region or nuclear hub, termed ‘transcription factories’ (Jackson et al., 1998; Osborne et al., 
2004; Schoenfelder et al., 2010; Aguilar-Arnal and Sassone-Corsi, 2015). This has been shown via 
observations of the co-factor p300 which is considered to be a hallmark of active enhancers and 
commonly interacts with both GR and NFκB (Chakravarti et al., 1996; Gerritsen et al., 1997; Wang, 
Carroll and Brown, 2005; Heintzman et al., 2009). It has been demonstrated, using circular 
chromosome conformation capture coupled with next generation sequencing, that upon stimulation 
both GR and NFκB localise to transcriptionally active TADs. But genes within these TADs do not always 
have a promoter located transcription factor interaction (Kuznetsova et al., 2015). TADs and long-
range interactions as well as short-range loops have been shown to be functionally important to 




condensed within sub-sets of genomic TADs have been observed 12hrs apart within C57BL/6J mouse 
liver which could be modified by altering circadian cues. Implicating the role of the molecular circadian 
regulators such as BMAL1 (Aguilar-Arnal et al., 2013; Zhao et al., 2015; Kim et al., 2018). GR facilitates 
this model of transcription by its ability to recruit co-factors such as CBP, p300 and nuclear co-activator 
1 (NCOA1) & 2 (NCOA2) (a.k.a. SRC-1 and TIF2/GRIP1 respectively) with intrinsic and synergistic HAT 
activity modifying the chromatin architecture (Beato et al., 1989; Lee et al., 1993; Grunstein, 1997; 
Reinke and Hörz, 2003; Conway-Campbell et al., 2011). Complexes can be built via NCOA1 & 2 
interaction with the GR via an activation domain. This same domain will also interact with CBP, p300 
and RNA helicase A of the Pre-pol and are essential for GR mediated transactivation (Hong et al., 1996; 
Nakajima et al., 1997; Spencer et al., 1997; Onate et al., 1998; Szapary, Huang and Simons, 1999). 
NCOA1 has a second activation domain which promotes transcription and a third which interacts with 
the SWI/SNF chromatin remodelling complex, enabling synergistic promotion of transcription and 
chromatin re-modelling (Hong et al., 1997; Koh et al., 2001; Belandia et al., 2002; Daujat et al., 2002; 
Chinenov et al., 2008). Transcription can also be mediated by multiple GR binding sites, as was first 
described at the dual GR binding site regulated gene, tyrosine amino transferase (TAT) in 1987 
(Jantzen et al., 1987).  
In certain situations, GR recruitment can also be repressive. These mechanisms are less well known 
but the recruitment of co-repressors such as sirtuin1 (SIRT1) and GSK3β have been implicated in 
certain situations. Recruitment of the co-repressor SIRT1 can induce inaccessibility of the chromatin 
to co-activators and the RNA Pol2 complex due to its intrinsic HDAC activity (Vaziri et al., 2001; Ito et 
al., 2006; Finkel, Deng and Mostoslavsky, 2009; Moore, Dai and Faller, 2012; Suzuki et al., 2018). Post-
translational modification of GR can also mediate transrepression as de-acetylation has been shown 
to promote binding of methyl-binding proteins which in turn recruit HDACs (Vaissière, Sawan and 
Herceg, 2008). Also, GSK3β modifies the phosphorylation state of GR, that can induce binding of the 
guanine nucleotide-binding protein β and has been postulated to be a mechanism of GR mediated 
transrepression of NFκB regulated targets (Kino et al., 2005; Galliher-Beckley et al., 2008; Kino, 2018).  
Transcriptional repression can also be induced by GR binding to so called negative GRE (nGRE) 
consensus sequences identified as 5’-CTCC(N)0-2GGAGA-3’ (Pei, 1996; Meijer et al., 2000; Surjit et al., 
2011). This proposed response element interacts with two ligand bound monomer GRs on opposing 
sides of the DNA helix in a head to tail configuration (see Figure 1.2 for classic GRE homodimer binding 
and Figure 1.5 for nGRE monomer GR binding schematics) (Hudson, Youn and Ortlund, 2013). nGREs 
enact a transrepressive effect via recruitment of the repressive inhibitors NCoR and SMRT (Surjit et 




binding of a monomer to one side of the nGRE sequence, reduces the affinity for the second monomer. 
Thereby increasing the potential for purely single monomer binding as opposed to dual (Hudson, Youn 
and Ortlund, 2013). The exact role of nGREs, however, remains to be fully elucidated as it has been 
reported mutation of discovered sequences upstream of the 5-HT1a promoter did not affect GR 
mediated repression nor was their a defined link between dexamethasone (Dex) induced repression 
within 3134 mouse mammary adenocarcinoma cell lines (Meijer et al., 2000; Presman et al., 2014). 
nGREs have been shown to provide a role within the HPA axis, mediating repression of CRH and POMC 
genes via associated GR binding (Surjit et al., 2011; Meijer, Buurstede and Schaaf, 2019). It has further 
been postulated that as the nGREs have also been characterised well within macrophages, then 
perhaps nGRE action is a cell and tissue context dependent mechanism of repression (Uhlenhaut et 
al., 2013; Jubb et al., 2016). 
 
 
Figure 1.5 nGRE binding of monomer GR 
A monomeric GR will bind to a negative GRE consensus sequence via a zinc finger within the P-box of 
the DBD (blue). A second monomeric GR can bind on the opposing side of the DNA helix in the same 
manner. There is no direct interaction between GRs within the dimerization interfaces (red). nGRE 
consensus sequence required for GR recognition in bold. Figure modified from Hudson, Youn and 
Ortlund, 2013. 
GR mediated transcriptional control can also work in a composite fashion. Multiple observations were 
made of overlapping as well as adjacent response elements for differing nuclear factors whose 
presence was required for transcriptional output (Biddie et al., 2011; Grøntved et al., 2013; Uhlenhaut 




examples of transcriptional dependent composite interactions (Diamond et al., 1990; Biddie et al., 
2011). Interestingly, these same studies indicated the composite interactions of GR and AP1 occurred 
at AP1 response element regions devoid of GREs. In these situations, it is hypothesized GR is ‘tethered’ 
by another co-factor, which is bound to the DNA template (Schule et al., 1988; Newton and Holden, 
2007; Biddie et al., 2011). Similar observations have been made with other transcription factors 
including signal transducer and activation of transcription (STAT)5 and NFκB to mediate 
transrepressive effects (Jonat et al., 1990; Schule et al., 1990; Yang-Yen et al., 1990; Ray and 
Prefontaine, 1994; Stöcklin et al., 1996; Hudson, Youn and Ortlund, 2013). NFκB is a known mediator 
of inflammation via cytokine transcriptional induction. GCs are a potent anti-inflammatory and will 
interact with NFκB via tethering or as composite binding. Synergistic transcriptional regulation has 
also been shown with STAT3 & STAT5 tethered composites (Stoecklin et al., 1997; Aittomäki et al., 
2000). It has been theorised synergistic transcription mediated at regulatory regions could be 
dependent on the tethered factor bound to the DNA (Stoecklin et al., 1997; Zhang et al., 1997; Takeda 
et al., 1998; Engblom et al., 2007). This was recently shown by observing tethered STAT3 and GR 
complexes; DNA bound GR complexes tethered to STAT3 induced transcription, whereas when the 





Figure 1.6 Diagram of the main pathways of GR mediated transcription. 
(A) Within the simple model of GR transactivation, GR binds as a homodimer to response elements 
(white box) within a DNA (black line) ‘promoter’ region of a gene and transcription can be increased 
(transactivation) (i). GR can also recruit other co-factors (X and Y) as part of a composite complex and 
bind to specific response elements within a shared region (ii). Or GR can be tethered to other DNA 
bound co-factors without the need for direct interaction with the GR DNA binding domain (iii). 
Inhibition (transrepression) maybe observed at response elements that can be termed negative GREs 
for each simple (iv), composite (v) and tethering (vi) model described. GR transactivatory action is 
mediated by the TATA binding protein and RNA polymerase 2 (Pol II). (B) GR transactivatory action 
can be mediated by the recruitment of factors such as CREB binding protein (CBP) and a p160 protein 
family member (p160) and histone acetylases transferases (HAT). The co-factor complex intrinsic 
histone acetylase action promotes opening of the chromatin structure to allow access to the 
transcriptional machinery such as TBP and PolII (i). This action is opposed if the complex recruit’s 
histone de-acetylases (HDAC) that deacetylate histones, closing the chromatin to transcriptional 
machinery. This has been described within a tethered model with NFκB amongst other nuclear 




1.2 The pituitary-adrenal axis 
1.2.1 Corticosterone  
In the 1930s, small amounts of steroid hormones were extracted and isolated from the adrenal cortex, 
however it was only in 1949 that synthetic production of steroid compounds facilitated full scale 
clinical investigation and treatment of their potent anti-inflammatory effects. Originally termed 
compound B and compound E, corticosterone and cortisol (mainly cortisol) were observed to have 
remarkable efficacy in treating inflammatory conditions such as rheumatoid arthritis and rheumatic 
fever and to this day remain one of the most prescribed medicines (Kendall et al., 1936; Mason, Hoehn 
and Kendall, 1938; Hench and Kendall, 1949; Kendall, 1949).  
Corticosterone is the predominate circulating GC found in rodents, whereas in humans it is 
approximately 20 fold lower than cortisol (Underwood and Williams, 1972; Nishida et al., 1977; 
Karssen et al., 2001; Raubenheimer et al., 2006). Despite its prevalence in total circulating blood 
plasma levels, up to 90% of GCs are bound to the major transport protein, corticosteroid binding 
globulin (CBG), reducing free corticosterone levels to approximately 4% of total levels (Chan et al., 
2013). The half-life of circulating corticosterone is variable within biological systems, however studies 
in healthy young adult female rats have calculated total corticosterone half-life to be approximately 
8.6 ± 1.4 min within 10min blood serum sampling (Windle, Wood, Shanks, et al., 1998; Lightman, 
2006). This represents a significantly shorter half-life than the predominant human GC cortisol, which 
has been determined to between 62-97min (Weitsman et al., 1971; Weitzman, 1976; Veldhuis et al., 
1989).  
Free corticosterone and cortisol readily diffuse into cells due to their highly lipophilic nature, however, 
it was noted in 1953 that cortisone incubated in various rat tissues in vitro, could be converted to 
cortisol in a process identified to be the result of the of 11β-hydroxysteroid dehydrogenase enzymatic 
action (Amelung et al., 1953). The type I isoform (11β-HSD1) is the most widely expressed isoform 
throughout the body and is concentrated within the liver (Tannin et al., 1991). 11β-HSD1 is a bi-
directional enzyme, but predominantly acts as an oxidoreductase, converting inactive cortisone and 
11-dehydrocorticosterone to the biologically active cortisol and corticosterone (Duperrex et al., 1993; 
Low et al., 1994). Whereas the type II isoform (11β-HSD2) only works unidirectionally producing 
inactive 11-keto-metabolites (Agarwal et al., 1994). Depending on their selective expression of 11β-
HSD1 and 11β-HSD2, this mechanism enables cells to control the amounts of active GC ligand, 




1.2.2 Anatomy of the hypothalamic-pituitary-adrenal axis 
Hans Selye (1950) was among the first to highlight the importance of the HPA axis in the homeostatic 
regulation of the adrenal cortex stress response, leading to further implications in immunological, 
cognitive and metabolic regulation (Selye, 1950; McEwen, 2007; Lightman and Conway-Campbell, 
2010). The HPA axis is modulated by a variety of inputs such as aversive stimuli (either physical or 
mental) or stress (Pariante and Lightman, 2008; Oster et al., 2016). The primary input is from the 
suprachiasmatic nucleus (SCN) within the anterior hypothalamus of the brain, also termed the ‘master 
clock’. The SCN mediates HPA axis regulation via innervations into the parvocellular subdivision of the 
paraventricular nucleus (PVN) as well as the hypothalamic medial preoptic area and dorsomedial 
nucleus (Figure 1.7) (Berk and Finkelstein, 1981; Vrang, Larsen and Mikkelsen, 1995). Parvocellular 
neuronal projections secrete corticotropin-releasing hormone (CRH) and arginine vasopressin (AVP) 
via the median eminence into the hypophyseal portal circulation to the anterior pituitary (Swanson et 
al., 1983; Sawchenko, Swanson and Vale, 1984) (Figure 1.7). Predominantly, binding of CRH to 
corticotrophs induces production and secretion of pro-opiomelanocortin and adrenocorticotropic 
hormone (ACTH) into the pulmonary network (Kiss, Mezey and Skirboll, 1984; Pariante and Lightman, 
2008). ACTH is transported around the body, diffusing into tissues such as the zona fasciculata of the 
adrenal cortex inducing synthesis and secretion of a range of steroids classed as GCs. ACTH release 
occurs in a highly synchronised, oscillating manner with an intrinsic 10min delay between release from 
the pituitary and the secretion of GCs from the adrenals (Follenius et al., 1987; Carnes et al., 1989; 
Veldhuis et al., 1990; Jasper and Engeland, 1991; D E Henley et al., 2009; Rankin et al., 2012; Walker 
et al., 2012). Adrenal GCs are transported around the body via the circulatory system and their 
lipophilic nature allows diffusion into nearly all tissues of the body, including the brain (M. T. Jones, 
Hillhouse and Burden, 1977). Therefore rising GC levels can act directly on CRH neurons within the 
PVN of the hypothalamus, as well as on ACTH producing corticotrophs of the anterior pituitary gland 
to rapidly and directly inhibit CRH production and ACTH secretion in a classical negative feedback loop 






Figure 1.7 Hypothalamic-pituitary-adrenal axis schematic. 
Activation of the HPA axis, by circadian cues or stress, results in activation of parvocellular neurons in 
the PVN and increased secretion of CRH and AVP into the hypophyseal portal blood system. ACTH is 
secreted from corticotrophs in the anterior pituitary and targets the zona fasciculata of the adrenal 
cortex increasing GC production and release into the peripheral circulation. Figure adapted from 
Lightman and Conway-Campbell, 2010. 
1.2.3 Circadian rhythms 
The daily rotation of the earth as well as its annual rotation around the sun causes distinct and varied 
changes in light, temperature and availability of food. Therefore, mammalian systems have developed 
innate circadian (circa=around, di=day) mechanisms to adapt to daily and seasonal changes in the 
photoperiod, mediating a wide range of behaviour and hormonal release as well as regulating body 
temperature, activity and sleep (Weitzman, 1976; Refinetti and Menaker, 1992). These systems are 
dynamically regulated and can be altered by extension/ shortening of the photoperiod which the HPA 






healthy mammals, GCs such as corticosterone and cortisol are synthesized and released from the 
adrenal glands at maximal capacity prior to waking. Maximal levels continue to be produced and 
secreted well into the onset of the active part of the day before gradually decreasing throughout the 
active period and returning to negligible levels during the inactive period and early sleep phase. This 
cycle continues with a period of 24hrs (Windle, Wood, Shanks, et al., 1998; Lightman et al., 2002; 
Lightman and Conway-Campbell, 2010; Russell et al., 2010). In 1972 it was discovered that bilateral 
destruction of the hypothalamic SCN ablated diurnal oscillations of plasma corticosterone, as well as 
circadian drinking and activity periodicity in rats (Moore and Eichler, 1972; Stephan and Zucker, 1972). 
Study of SCN hypothalamic slices confirmed an innate ability to produce spontaneous neural activity 
at a rate of approximately 24hrs and showed that transplant into SCN lesioned hamsters could restore 
circadian activity. Furthermore, the donor periodicity was preserved despite phase shift experiments 
within the host prior to implantation (Inouye and Kawamura, 1979; Welsh et al., 1995; Silver et al., 
1996). In the absence of light or other Zeitgeiber (Zt) cues, the ‘free running’ circadian period was 
determined to be slightly longer than 24 hours indicating the SCN has a phase advance activity. The 
maintenance of the 24hr rhythm has been found to be primarily regulated by light via impulses from 
activated retinal ganglion cells, along the retinohypothalamic tract and into the SCN (Aschoff, 1965; 
Czeisler et al., 1999; Hattar, 2002). Interestingly, SCN stimulation by light and output into the PVN do 
not differ between diurnal and nocturnal animals. Within SCN ablated rats, AVP infusion into the PVN 
and dorsomedial hypothalamic regions inhibited raised corticosterone levels within circulating blood 
during the active period. This effect could be reversed with an AVP antagonist, raising circulating 
corticosterone within the circadian inactive period (Kalsbeek et al., 1992; Kalsbeek, van der Vliet and 
Buijs, 1996). Opposing effects were observed in the diurnal rodent Arvicanthis ansorgei with the same 
experimental model, suggesting photic regulation of the SCN is conserved, but the downstream effect 
of AVP on the HPA axis is inhibitory in nocturnal and excitatory in diurnal mammals  (Kalsbeek et al., 
2008).  
1.2.4 Ultradian rhythms 
Frequent blood micro sampling methodologies have led to the detection of a pronounced rhythm 
underlying the circadian rhythm; an intra-rhythm of rising and falling phases, the amplitude of which 
followed the circadian 24hour period. This ‘ultradian’ rhythm has been shown to be highly conserved 
across all mammals studied, including rats (Carnes et al., 1989, 1994; Windle, Wood, Lightman, et al., 
1998; Sarabdjitsingh et al., 2010; Walker et al., 2012), hamsters (Loudon et al., 1994), dogs (Benton 
and Yates, 1990), sheep (Engler et al., 1990), horses (Cudd et al., 1995), rhesus monkeys (Holaday, 




al., 1971; Weitzman, 1976; Veldhuis et al., 1989, 1990; Young, Carlson and Brown, 2001; D E Henley 
et al., 2009; Russell et al., 2010). However, there are variations in pulse frequency and duration as rat 
ultradian corticosterone frequency is roughly 56-60min, whereas human cortisol pulse frequency is 
roughly 95-180min (Figure 1.8) (Follenius et al., 1987; Veldhuis et al., 1989; Jasper and Engeland, 
1991). The difference may be due to specific regulation of the HPA axis as well as differing blood 
plasma half-lives of corticosterone (8-9min) and cortisol (62-97min) (Weitzman, 1976; Veldhuis et al., 
1989; Windle, Wood, Lightman, et al., 1998) . 
 
Figure 1.8 Ultradian models of human cortisol and rat corticosterone pulses and their relationship 
with ACTH. 
(A) 10min blood samples were collected over a 24hr period in a healthy human male and total blood 
serum cortisol and ACTH concentrations measured. Circadian changes are present with increases in 
circulating cortisol between 24-9hrs (maximal ACTH and cortisol levels are approximately 550nmol/L 
and 45ng/ml respectively just before 4hr) before overall levels decrease to nadir by approximately 
19hrs. Within overall circadian changes, supra-pulses of ACTH and slightly delayed phase shifted 
cortisol pulses are discernible within the raised cortisol period. Human cortisol and ACTH were 
measured by solid-phase, competitive chemiluminescent enzyme immunoassay. Figure adapted from 
D E Henley et al., 2009. (B) Similar circadian and ultradian changes in total circulating corticosterone 
are observable within the male rat but with an increased frequency of approximately 1hr. Rats are 




(~120ng/ml) and gradually decreases to nadir at 4hrs. Rat lighting schedule was on at 05:00 and off 
at 19:00 (14:10), food and water access ad libitum, total blood serum corticosterone levels assessed 
using an in house radio immunoassay (RIA) (n=8-10). Figure adapted from Seale et al ., 2004. (C) 
Average ACTH (grey line) and corticosterone (black line) oscillations in response to constant CRH 
infusion (0.5µg/hr) (grey bar) within male Sprague Dawley rats over a 3hr period and (D) over a 1hr 
period. Both measurements indicate a synchronised but slightly delayed phase shift in ACTH and 
corticosterone levels. Total blood serum corticosterone levels were assessed using RIA (n=3-7 per time 
point). Figure adapted from Walker et al ., 2012. 
The ultradian rhythm is an intrinsically oscillating system due to the interplay between feed forward 
and feedback pathways of the HPA axis. Even though multiple studies have reported pulsatile AVP and 
CRH secretion within the HPA axis, recent studies have shown ultradian GC secretion can be preserved 
in response to constant CRH and constant light (Figure 1.8) (Engler et al., 1989; Carnes et al., 1990; 
Walker, Terry and Lightman, 2010; Waite et al., 2012; Walker et al., 2012). It is in fact a two-step delay, 
the first delay is between ACTH secretion and induction of GC secretion from the adrenal glands within 
feed forward mechanisms, whilst the second delay occurs between rising GC levels within the 
circulation, acting on the brain and pituitary to inhibit ACTH release with the negative feedback loop 
of the HPA axis. Together this data indicates GC release is naturally oscillatory, due to delayed feed 
forward and feedback mechanisms intrinsic within the HPA axis, whilst the CRH activatory drive 
primarily regulates pulse amplitude in an overall circadian manner (Walker et al., 2012). 
1.2.5 A functional role for corticosterone rhythms in regulation of stress response, physiology and 
behaviour  
HPA axis activation and subsequent GC release has been shown to be a highly plastic system. Not only 
is it dependent on the type and duration of the stressful stimuli but also on the circadian phase. When 
an animal encounters a stressful situation, either real or perceived, during the circadian inactive phase 
when the CRH drive is naturally low and circulating ACTH and adrenal GCs are minimal, the HPA axis 
is highly responsive with rapid and robust activation of hypothalamic CRH and AVP neurons within the 
PVN (although multiple further interactions and sites exist), closely followed by increased ACTH 
secretion then a surge of adrenal GC synthesis and release. However, when a mammal encounters a 
stressful event during the circadian active phase, rapidly oscillating phases of HPA activation and 
inhibition are already underway, and these become very important for regulating outcome (Kyrou, 
Chrousos and Tsigos, 2006; Pariante and Lightman, 2008; Sarabdjitsingh et al., 2010). Stress induced 
GC rises have many implications for memory acquisition, cognition and analgesia as well as 




whilst inhibiting energy consuming functions such as digestion, reproduction, growth and certain 
immune functions (Kyrou, Chrousos and Tsigos, 2006). Thus, providing easily accessible energy for 
‘fight / flight’ mechanisms.   
However, stress induced HPA axis activation can also be dependent on the ultradian phase of GC 
release. Indicating a role for ultradian stress mediated activation (Kyrou, Chrousos and Tsigos, 2006; 
Pariante and Lightman, 2008; Sarabdjitsingh et al., 2010). When ultradian corticosterone rhythmicity 
is lost, such as during constant corticosterone infusion into ADX rats, physiological (ACTH), 
neurological (neuronal activation) and behavioural stress responses were blunted (Sarabdjitsingh et 
al., 2010). Even within the intact, oscillating ultradian endogenous GC release, the amplitude of the 
stress-induced GC release has been shown to be dependent on the timing of the stressful encounter 
relative to the phase of the adrenal GC pulse. In female rats, total blood corticosterone levels 
measured 20min after a 114 decibel (12,000-60,000Hz) noise stress were increased from 136 ±9ng/ml 
to 377 ±87ng/ml, which also marginally increased the subsequent pulse nadir interval even though no 
difference in corticosterone clearance was observed. This increased the average interpulse 
corticosterone peak period from 48±2min (non-stressed controls) to 70±3min (after the noise stress). 
Interestingly, if a noise stressor coincided with the falling phase of a corticosterone pulse, the stress 
induced GC release was blunted (Windle, Wood, Shanks, et al., 1998). Similar behavioural effects have 
been observed when rats were exposed to a male intruder, the degree of self-initiated aggression was 
increased during a rising phase of endogenous corticosterone than during a falling phase (J Haller et 
al., 2000; J. Haller et al., 2000). These observations were made in response to an acute stress, 
however, the period of perceived stress will also affect GC release dynamics as a chronic 30min 
restraint stress of male rats induced prolonged raised total blood corticosterone levels for at least 
60min after the insult (Kitchener et al., 2004). In conclusion, the GC response to stress is highly 
dynamic, dependent not only on the nature of the stressor but also the endogenous corticosterone 
ultradian rhythm. 
These intriguing results, which strongly indicate a functional consequence of rapidly fluctuating GC 
hormones, lead to the question of whether other GC targets and processes also respond in an 
ultradian manner? It is already known that GCs mediate numerous effects on downstream tissues such 
as the brain, liver, skeletal muscle and others, to regulate a wide range of behavioural and metabolic 
processes (Pariante and Lightman, 2008; Lightman and Conway-Campbell, 2010; Sarabdjitsingh et al., 
2010; Walker et al., 2012; Oster et al., 2016). What is not known is how ultradian GC dynamics further 
modulate outcome. I hypothesise that an oscillating system can carry more information due to the 




1.2.6 Ultradian GR regulation 
Even though 90% of circulating corticosterone and cortisol is bound to CBG, oscillating free levels of 
GCs have been measured by microdialysis in blood plasma, intra-adrenal extracellular fluid as well as 
the hippocampus of rats (Ballard et al., 1975; Jasper and Engeland, 1991; Droste et al., 2008, 2009). 
Other studies using multiple simultaneous microdialysis measurements have shown subcutaneous 
tissues do experience GC pulses highly synchronised with those observed in circulating blood (Qian et 
al., 2012). The fact tissues experience changes in GC levels at the uppermost zenith of an ultradian 
pulse has been postulated to re-enforce a ‘digital’ like signal to responsive cellular networks. This has 
further implications when one considers the relative affinities of responsive receptors. The MR has a 
6-10 fold higher affinity for GC ligand than the GR, indicating GRs will be activated within the upper 
range of GC pulses whereas MR could be responsive in a pro-longed manner to GR ligand activation 
and may not react in a pulsatile manner (Reul and Kloet, 1985; van der Laan, de Kloet and Meijer, 
2009; Mifsud and Reul, 2016). As indicated by western blots of nuclear extracts, GR and MR 
translocation within the nucleus of hippocampal cells of ADX rats, was observed in response to hourly 
bolus intravenous injections of corticosterone. Upon hourly corticosterone replacement via 
intravenous (I.V.) infusions, total circulating corticosterone levels were maximal by 1min, however, 
despite this relatively large dose (100µg), corticosterone was cleared from the blood plasma by 60min 
in a similar interphase period to endogenous ultradian frequency. Increased GR and MR nuclear levels 
were reported in response to corticosterone infusion, maximal at 10min and 15min respectively. 
However, nuclear GR levels were found to decrease to basal levels by 60min in synchrony to circulating 
corticosterone dynamics, MR remained elevated within the nucleus (Conway-Campbell et al., 2007). 
The model was expanded upon by investigating how these mock ‘ultradian’ like pulses induced GR 
recruitment to a known GRE upstream of the clock gene Period1 (Per1) as well as measuring 
heterogeneous ribonucleic acid (hnRNA) production within the liver of the rat. As was postulated, GR 
did bind transiently in response to the infusion model, reaching maximal binding levels by 10min in 
response to corticosterone administration and returning to basal levels by 60min at the GRE (Figure 
1.9-A). This corticosterone synchronised GR recruitment could be reinstated repeatedly by multiple 
infusions at hourly intervals, with no loss in maximal binding. Interestingly, hnRNA levels were similarly 
responsive to the corticosterone ‘pulses’, albeit in a slightly delayed manner, peaking 30min after each 
corticosterone peak (Stavreva et al., 2009).  
Expanding upon these experiments in vitro, corticosterone synchronised pulsatile dynamic GR binding 
and dissociation was observed at not just a single, but multiple binding sites. In a series of live imaging 




cassettes within 3617 adenocarcinoma mouse cells, fluorescently tagged GR translocated into the 
nucleus and bound to the concatemerized GREs within the MMTV array after 20min stimulation of 
100nM corticosterone. Similarly to in vivo data, GR would fully dissociate within 40min of total 
corticosterone washout and could be repeated by successive mock ‘ultradian’ pulses of hormone 
(Figure 1.9-B). RNA Pol2 occupancy was shown to be similarly oscillatory indicating pulsatile 
transcriptional recruitment. Observed pulsatile responses were not intrinsic as the induction of 
oscillating ‘ultradian’ hnRNA production of SOUX, GILZ (aka TSC22D3), transglutaminase (TGM2) and 
Metallothionein (MT2)  in response to 8 cycles of corticosterone application and washout, became 
dysregulated upon constant corticosterone stimulation in vitro (Figure 1.9-C) (Stavreva et al., 2009). 
Together, these findings indicate that GR recruitment and resultant transcriptional regulation of target 
genes is highly dynamic in its response to pulses of corticosterone exposure both in cultured cells and 





Figure 1.9 A series of mock ‘ultradian’ pulses of corticosterone induce synchronised GR 
recruitment/ dissociation from the DNA template and resultant mRNA production at select targets 
in vivo and in vitro. 
(A) Three intravenous bolus injections of corticosterone at 0, 60 and 120min in an ADX male rat 
induced maximal circulating corticosterone levels by 1min, which cleared from the circulation within 




site of the clock gene Period1 (Per1) was detected, followed by pulses of heteronuclear RNA (hnRNA) 
(green) at phasic intervals between corticosterone pulses. Maximal phasic dynamics of GR and hnRNA 
levels were detected at 10min and 30min respectively, before returning to basal levels by 60min. 
Circulating total corticosterone was measured using radioimmunoassay, GR binding was measured 
using quantitative ELISA-based assay and heterogenous nuclear RNA (hnRNA) was measured by RT-
qPCR analysis. (B) In a series of live cell imaging studies, green fluorescent protein tagged GR 
recruitment to the MMTV array in 3617 cell lines was induced by a 15min corticosterone 
administration and lost 40min after hormone washout. This was repeatable over three pulses of 
corticosterone (i) and GFP-GR MMTV array intensity against corticosterone concentrations plotted 
over time (ii). (C) Nascent transcript fold change to control were assessed via RT-qPCR analysis of 
selected up-regulated genes within 3134 cell lines in response to a series of eight 15min corticosterone 
administrations followed by 40min post hormone washout period (dotted lines). Results indicated 
pulsed corticosterone administration induced corticosterone synchronised increases in hnRNA of 
SUOX, GILZ, TGM2 and MT2. Oscillating hnRNA levels were lost in response to a constant exposure to 
corticosterone within froth media (black line). Control (C), induction (P) and withdrawal (W) are 
indicated along the x-axis. All error bars represent s.e.m. and figures are adapted from Stavreva et al., 
2009. 
1.2.7 Glucocorticoid regulation of gluconeogenesis 
GCs were so named at the beginning of the 19th century by their ability to alter blood glucose levels. 
Upon further research, additional roles within metabolism was recognised, revealing regulation of 
lipolysis, triglyceride, fatty acid and carbohydrate homeostasis as well as glucose.  
Glucose homeostasis is maintained by a myriad of endocrine signalling such as by insulin, glucagon 
and GC hormones. Indeed, glucocorticoids alter blood glucose levels by reducing uptake and glucose 
oxidation in skeletal muscle and white adipose tissues (WAT) whilst stimulating gluconeogenesis 
(mainly in the liver) and energy store mobilisation in response to a stressor (Kuo et al., 2015). Focusing 
within the liver, GR action has been shown to regulate the gluconeogenic genes pyruvate carboxylase 
(PC), phosphoenolpyruvate (PEPCK1), PFKFB1 (a bi-directional enzyme consisting of 6-phosphofructio-
2-kinase (PFK2)/fructose bisphosphatase2 (FBPase2) action), glucose-6-phosphatase (G6PC) and 







Figure 1.10 The Gluconeogenic pathway. 
Within hepatocytes, non-carbohydrate substrates lactate and alanine are converted to pyruvate 
which is transported into mitochondria and converted by pyruvate carboxylase oxaloacetate (OAA). 
OAA cannot be transported out of the mitochondria, therefore it is converted into malate or aspartate 
within the tricarboxylic acid cycle, shuttled out and converted back to cytosolic phosphoenolpyruvate 
carboxykinase (PCK1) substrate, OAA. Indications have been reported of a PCK1 variant that can 
convert OAA into phospho-enolpyruvate (PEP) directly within the mitochondria (m-PCK1) before 
entering the gluconeogenic pathway. Once converted to glyceraldehyde-3-phosphate (G3P) either 
from metabolism of lactate, alanine or glycerol, G3P can either be metabolised back into lactate or 
alanine as part of the glycogenolysis pathway, or G3P is converted in fructose-1,6-bisphosphate 
(F1,6BP), a substrate for fructose-1,6-bisphosphatase 1 (FBP1). However, conversion to fructose-6-
phosphate (F6P) is dependent on the bi-directional enzyme phosphofructokinase 2 (PFK2)/ fructose 
bisphosphatase 2 (FBPase2) (PFKFB1). In the un-phosphorylated state, PFKFB1 favours its intrinsic 
PFK2 activity which induces phosphofructokinase 1 (PFK1) action via the allosteric activator fructose-
2,6-bisphospate (F2,6BP), converting F6P into F1,6BP within the glycogenolysis pathway. In contrast, 
glucagon signalling phosphorylates PFKBP1, whereupon its intrinsic FBPase2 activity is favoured, 




Hepatocytes can convert the precursor glucose-6-phosphaate (G6P) into glucose within the 
endoplasmic reticulum by the action of glucose-6-phosphatase catalytic subunit (G6PC) before 
transport out of the cell and into general blood circulation via the hepatic portal network. Tricarboxylic 
acid metabolites indicated by blue arrows and GC regulated targets are indicated in yellow. 2-
phosphoglycerate (2-PG), 3-phosphoglycerate (3-PG), 1,3-bisphosphoglycerate (1,3-BPG) and 
dihydroxyacetone phosphate (DHAP) are also indicated. Figure adapted from Kuo et al., 2015. 
Focussing on GC regulated targets within the gluconeogenic pathway, PC catalyses the ATP dependent 
carboxylation of pyruvate into oxaloacetate (OAA) within hepatocyte mitochondria (Utter and Bruce 
Keech, 1960; Menefee and Zeczycki, 2014). This is an important preliminary step  as substrate for the 
tricarboxylic acid cycle but ultimately as a precursor for the action of PEPCK within gluconeogenesis 
(Hanson and Garber, 1972; Arinze, Garber and Hansons, 1973; Hansen and Juni, 1974; Méndez-Lucas 
et al., 2013; Stark et al., 2014). Data regarding direct GC regulation of PC transcription however is 
unclear. Two primary transcripts from alternative splicing events have been identified within rats, 
regulated by two promoter regions. The proximal promoter is active within gluconeogenic and 
lipogenic tissues and regulates production of the first transcript, whereas the distal promoter is active 
within a wide variety of tissues, regulating production of the second transcript (Jitrapakdee and 
Wallace, 1999). Functional GREs have been identified within the bovine PC promoter, but not in rat 
and human where only indirect GR regulation via CREB, nuclear factor 1 (NF-1) and hepatic nuclear 
factor 4 α (NHF4α) has been speculated to be the mechanism of PC transcriptional regulation 
(Jitrapakdee et al., 1997, 2008; White, Koser and Donkin, 2011). Opposing reports however, show 
either increased or no effect of Dex treatment on PC mRNA levels (Martin, Allan and Titheradge, 1984; 
Jones, Hothi and Titheradge, 1993; Kuo et al., 2015). Therefore, PC regulation by GCs requires further 
investigation to determine whether its transcriptional regulation is direct or indirect. 
PEPCK expression is increased in a fasting state synergistically by glucagon and GC administration. It is 
also inhibited by a carbohydrate diet. Both a cytosolic and mitochondrial isoforms of the rate limiting 
enzyme have been identified, converting OAA into phosphoenolpyruvate (PEP) (Hanson and Garber, 
1972; Arinze, Garber and Hansons, 1973; Hansen and Juni, 1974; Méndez-Lucas et al., 2013; Stark et 
al., 2014). PEPCK is a key target within GC regulated glucose homeostasis, mediated by two promoter 
GREs within composite glucocorticoid response units (GRUs), identified between -395b to -349b from 
the TSS within H4IIE rat hepatoma cell lines. The promoter region also contains three other regulatory 
regions at -451b to -431b (gAF2), -420b to -403b (gAF1), -327b to -321b (gAF3) as well as a cAMP 
response element (CRE) -93b to -86b from the TSS (Imai et al., 1990, 1993; Scott, Mitchell and Granner, 




conserved within human hepatoma (HepG2) cell lines, plus a further two at -933b (dAF1) and -1,365b 
(dAF2) (Cassuto et al., 2005). PEPCK transcription appears to require synergistic, multi-factorial 
regulation as reporter gene assays demonstrated that GR binding to individual GREs and AF regions 
did not confer transactivation alone. GRE affinity for GR was also found to be relatively weak and 
mutation of either AF1, AF2, GRU or CRE reduced PEPCK transcription by 50-60% whilst a combination 
completely ablated PEPCK transcription in response to GC stimulation (Imai et al., 1990, 1993; Scott, 
Mitchell and Granner, 1996a, 1996b; Scott et al., 1998). Composite binding complexes have been 
demonstrated in vivo between the GRU and CRE. It has been further postulated interactions also 
include accessory activity of HNF4α and chicken ovalbumin upstream transcription factor (COUP) via 
gAF1, and hepatic nuclear factor 3 (HNF3) α and β via gAF2 (Imai et al., 1993; Hall, Sladek and Granner, 
1995; O’Brien et al., 1995; Scott et al., 1998). Chromatin immunoprecipitation (ChIP) studies have 
indicated FoxA2, CEBPβ, HNF4α and COUP occupation of the promoter occurs prior to and does not 
change following GC treatment, indicating a basal state of occupation of these factors is required. GC 
induced Recruitment of GR transcriptional co-regulators NCOA1, p300, FoxO1, FoxO3 and CREB have 
been shown to be GC dependent, as is Pol2 recruitment (Hall et al., 2007). The gAF2 element also 
contains an insulin response element, however, how this confers inhibitory action is not yet fully 
understood but it has been theorised to have something to do with the loss of histone H3 de-
methylation (O’Brien et al., 1990; Hall et al., 2007). Interestingly, PEPCK is inhibited by GCs in WAT by 
an unknown mechanism (Meisner, Loose and Hanson, 1985; Friedman et al., 1993; Olswang et al., 
2003). The PEPCK promoter provides a detailed example of complex co-operative transcription factor 
binding and co-recruitment that can be required for transcriptional regulation.  
During gluconeogenesis, PEP is converted via 5 enzymatic steps to fructose-1,6-bisphosphate (F1,6BP), 
a pathway which is reversed in glycolysis (Kuo et al., 2015).  It is at this point the bi-directional enzyme 
PFKBP1 regulates the switch between gluconeogenesis and glycolysis pathway directions. PFKBP1 has 
intrinsic FBPase2 and PFK2 activity, of which the latter is favoured in its de-phosphorylated state. PFK2 
induces fructose 2,6-bisphosphatase, an allosteric activator of phospho fructokinase 1 (PFK1) within 
the glycolytic pathway. However, glucagon signalling pathways induce cAMP and AKT1 
phosphorylation of FKB1, favouring its intrinsic FBPase2 activity instead and reducing PFK2 activity and 
increasing FBP1 affinity for F1,6BP and conversion into fructose-1,6-bisphosphate (F6P) (Hue and 
Rider, 1987; Marcus et al., 1987; Rider et al., 2004). Dex treatment of ADX rats increases PFKFB1 
transcription, presumably via two intronic co-operative GREs identified in HeLa cells, the distal of 
which has been observed to mediate the greater transactivation (Zimmermann and Rousseau, 1994; 
McFarlan et al., 1997). As described previously for PEPCK, the PFKFB1 GRU recruits multiple co-factors, 




Within gluconeogenesis, F6P is converted into glucose-6-phosphate by phosphoglucoisomerase, 
transported to the endoplasmic reticulum where it is converted into glucose by the action of the 
membrane bound G6PC (De Duve et al., 1949; Hers et al., 1951; El-Maghrabi et al., 1995; Kuo et al., 
2015). This is the final GC regulated target known to regulate the gluconeogenic pathway. Its 
expression is increased after GC administration and decreased in response to insulin (Vander Kooi et 
al., 2005). Within mouse liver, GR regulation to three identified GREs (-197/-183; -180/-166; -156/-
142) appears to be dependent on the recruitment of multiple forkhead transcription factors (FoxO1, 
FoxO3A) as well as HNF3, HNF4α and CEBP within the GRU of the promoter region (Lin, Morris and 
Chou, 1998; Schmoll et al., 1999; Vander Kooi et al., 2005). Suggesting similar modes of regulation as 
previously described for PEPCK. Three GREs  have been identified. It should be noted that FoxO1 has 
been implicated as a necessary factor for full GC mediated transcriptional output of the genes 
mentioned. Interestingly, FoxO1 has also been shown to be important for insulin’s inhibitory effect as 
FoxO1 liver knockout mice were unable to respond to insulin (Vander Kooi et al., 2005; Onuma et al., 
2006; K. Zhang et al., 2012), thus highlighting its potential role within nuclear factor mediated action. 
Interestingly, G6PC is postulated to be part of a multicomponent enzyme which also includes the 
transporter protein SLC37A4, which is required for translocation of G6P from the cytoplasm to the 
endoplasmic reticulum (ER) for conversion by G6PC into glucose within hepatocytes (Narisawa et al., 
1978; Van Schaftingen and Gerin, 2002; Kuo et al., 2015). 
GCs also interact within glycogen pathways. Even though GC treatment has been reported to increase 
levels of glycogen within the liver, it has been shown that it also regulates the activity of glycogen 
synthase. This is mediated by the GC regulated expression of protein phosphatase 1. In the de-
phosphorylated state, glycogen synthase will liberate glucose from glycogen stores and therefore 
increase glucose levels (Kuo et al., 2015). 
1.2.8 Fatty acid, triglyceride and lipid regulation by GCs 
Fatty acids are mostly dietary in source and transported from the intestine to the liver in chylomicrons 
due to their lipophobic nature and release non-esterified fatty acids and carbohydrates via the action 
of lipoprotein lipase for downstream metabolism. A relatively small amount of cholesterol, however, 
can be synthesized by the liver (Linder et al., 1976; Hellerstein, 1999; Rui, 2014). Briefly, when 
carbohydrates are in abundance, the glycolytic pathway, metabolises glucose via hydrolyses into 
pyruvate and metabolised within hepatocyte mitochondria into actetyl coenzymeA (acetyl-CoA) (a 
product of pyruvate kinase action), converted to the intermediate malonyl-CoA by acetyl-CoA 
carboxylase (ACC) before conversion to fatty acids by fatty acid synthase (FASN) (Chakravarthy et al., 




The two major fat stores within the body are the liver and WAT. Within the liver, fatty acids are 
esterified with glycerol into triglycerides (TG). This is a more efficient method of storage as TGs contain 
twice as much energy per gram than glycerol or glucose (Hillgartner, Salati and Goodridge, 1995). 
Insulin action increases this ‘short term’ storage of TGs within the liver as they are commonly packaged 
within lipoproteins and transported to target tissues (predominantly WAT) around the body 
(Malmström et al., 1997; Gibbons et al., 2004). Non-esterified fatty acid, carbohydrates and glycerol 
are released into the target metabolic tissues via the hydrolytic action of lipoprotein lipase (LPL), 
whereupon fatty acids are metabolised or re-esterified for storage within the said tissue. As previously 
mentioned, WAT is considered to be the major fat depot of the body, however, significant amounts 
are stored in the liver and muscle (Hillgartner, Salati and Goodridge, 1995; Macfarlane, Forbes and 
Walker, 2008; de Guia, Rose and Herzig, 2014).   
A number of key enzymes within carbohydrate and lipid metabolism are under GC control (Gibbons 
et al., 2004; de Guia, Rose and Herzig, 2014). Within the liver, carbohydrates are metabolised into 
lipids for transport around the body within lipoproteins. This process has been shown to be under GC 
regulation as serum cholesterol in obese and control mice were reduced after hepatic specific GR 
knockouts, as well as increased TG accumulation in GR knockout hepatocytes in vivo. This has been 
linked to the GR repressive action on hairy enhancer split 1 (HES1) transcription due to the recruitment 
of HDACs to the promoter (Lemke et al., 2008; Revollo et al., 2013). HES1 is a cAMP inducible 
repressor, indirectly reducing levels of peroxisome proliferator-activated receptor γ (PPARγ) which has 
been shown to be a key inducer of lipogenic genes. Presumably, this action occurs within the liver for 
lipoprotein release (Herzig et al., 2003). There were slight increases in sterol regulatory element 
binding transcription factor 1 (SREBP-1)c, which has also been implicated within lipogenesis and TG 
synthesis. However, this finding was not statistically significant and this variant is involved in fatty acid 
synthesis as opposed to carbohydrate metabolism (Shimomura et al., 1998; Lemke et al., 2008).  
Dex induced increases in mRNA have been reported for the key hepatic de novo lipid synthesis 
enzymes ACC and FASN, the latter of which has been shown to be directly GR regulated (Soncini et al., 
1995; Xu, Viviano and Rooney, 1995; Lu, Gu and Rooney, 2001; Zhao et al., 2010; Gathercole et al., 
2011). Genome wide analysis of Dex treatments in 3T3-L1 cells identified promoter associated GR 
binding sites for lipid synthesis targets Stearoyl-CoA desaturase 1 & 2 (SCD1) (SCD2),  glycerol-3-
phosphate acyltransferase 3 & 4 (GPAT3) (GPAT4) and LPIN1, as well as the lipolytic factor lipase E and 
lipid transporters CD36, LDL receptor related protein 1, very low density lipoprotein (VLDL) receptor 
(VLDLR) and SLC27A2 that facilitate lipid transport. Dex induction of known insulin targets such as the 




insulin resistance), indicated GC induced lipid synthesis and mobilisation (MacDougald et al., 1994; P. 
Zhang et al., 2008; Yu et al., 2010). It should be noted, however, that most studies have focused on 
adipocyte function and require further elucidation within hepatic pathways. 
Apolipoproteins are synthesized within the liver and have a range of functions which are integral to 
lipoprotein synthesis, transport and targeted metabolism (Brown and Goldstein, 1983; Werner, 
Kuipers and Verkade, 2013). In the fasted state, hepatic apolipoprotein synthesis and release into the 
circulation is increased, transporting TGs, carbohydrates and glycerol to target tissues. However, this 
process is attenuated by ADX within rodents (van der Sluis et al., 2012). Within the fasted state, the 
liver will increase synthesis and stability of APOB-100 for VLDL synthesis so as to transport TGs and 
carbohydrate stores to target tissues around the body. As this synthesis requires carbohydrate 
substrates, when stores are low, APOB-100 transcription is decreased. Due to the rapid degradation 
of APOB-100 within the endoplasmic reticulum, the rate of transcription is thought not to be a 
determinant with regard to VLDL synthesis. However, loss of function of APOB or the rate limiting 
microsomal triglyceride transfer protein (MTP) which mediates correct folding of APOB, can inhibit 
the production of VLDL and induce the presentation of the rare conditions familial 
hypobetalipoproteinemia or abetalipoproteinemia, increasing circulating TG and cholesterol levels 
(Feingold and Grunfeld, 2000; Tiwari and Siddiqi, 2012; Hooper, Burnett and Watts, 2015). Reduction 
in LDL receptors within the VLDL (of which APOB contains a similar region), reduces uptake by IDL and 
reduces the body’s capacity to clear VLDLs from the circulation into target tissues for metabolism 
(Feingold and Grunfeld, 2000). 
It has been proposed GCs can induce transcription of apolipoproteins required for assembly and 
recognition by tissues, however, direct evidence for this in hepatocytes has not been shown, as the 
majority of research has focussed on adipocyte lipid regulation. For example, apolipoprotein AI 
(APOAI) and -IV (APOIV) are major constituents of HDLs, some of which are proposed to be transferred 
from chylomicrons and VLDLs during TG transfer (Lagrost et al., 1989). Transcription of APOAI is 
dependent on the co-regulatory action of both promoter bound HNF4α and peroxisome proliferator-
activated receptor γ coactivator-1α, as is HNF3β for APOAIV transcription. No direct GR regulation of 
either apolipoprotein has been identified, although HNF3β binding to APOIV promoter region has 
been postulated to be dependent on GR tethering (Saladin et al., 1996; Taylor et al., 1996; Mooradian, 
Haas and Wong, 2004; Hanniman et al., 2006; Vegiopoulos and Herzig, 2007). As may be expected, 
there are tissue specific differences in regulation between liver and adipocytes. For example, APOE is 
mainly synthesised within the liver and macrophages and is critical to lipoprotein metabolism within 




hepatocytes (in vitro and in vivo) found Dex-induced APOE transcription was increased in macrophages 
but not hepatocytes, despite a conserved promoter GR binding site identified in humans (-111/-104). 
The authors postulated phospholipase A2, phospho lipase C and mitogen activated kinase kinase 
(MEK) pathways mediated inhibition of GR transactivation in hepatocytes (Trusca et al., 2017). 
Therefore, elucidating liver specific regulation of apolipoproteins and lipoproteins from circulating 
levels may lead to false discovery. Lack of function clarity is further compounded by studies reporting 
contradictory data. For example, before TGs are packaged into lipoproteins, they undergo hydrolysis 
by enzymes such as triacylglycerol hydrolysis. However, Dex has been shown to reduce VLDL synthesis 
via a reduction in triacylglycerol hydrolysis mRNA levels within hepatocytes (Lehner and Verger, 1997; 
Dolinsky et al., 2004), whereas other studies have shown Dex increased VLDL production (Mangiapane 
and Brindley, 1986).  
GC regulation of hepatic carbohydrate, fatty acid, lipid synthesis and transport play major roles within 
homeostasis of tissues around the body. Understanding these mechanisms is highly complex as each 
study design must control for age, weight, diet and underlying pathology to elucidate mechanisms. 
Current knowledge of these pathways has been gleaned from adipocyte function studies and is not 
yet at a level to avoid conflicting reports. Therefore, considerably more hepatic focussed research is 
required to fully understand the GC role in Fatty acid, triglyceride and lipid regulation  (Vegiopoulos 
and Herzig, 2007; Werner, Kuipers and Verkade, 2013; de Guia, Rose and Herzig, 2014).  
1.3 Metabolism and dysregulation of glucocorticoid rhythms 
GCs have multi-systemic effects within mammalian systems and their dysregulation can precipitate 
harmful pathophysiological effects including cognitive and memory acquisition impairment, 
depression and osteoporosis. Due to their significant role within metabolic homeostasis, dysregulation 
can also severely impair glucose, lipid, carbohydrate, fatty acid and liver homeostatic control; all of 
which have been implicated in the ever-increasing prevalence of metabolic syndrome (MetS). MetS 
describes an array of phenotypes including visceral obesity, hyperglycaemia and hypertension, 
reduced high density lipoproteins (HDLs) and raised VLDL levels, atherogenic dyslipidaemia, non-
alcoholic fatty liver disease (NAFLD) (TG >55mg/g or 5.5% of liver), hepatic steatosis and type II 
diabetes and can be presented in combination but not all are required for diagnosis (Alberti et al., 
2005; Szczepaniak et al., 2005). MetS presents a significant health burden within western societies as 
the National Health and Nutrition Examination Survey has reported that 23% of the U.S. population 
have presented MetS criteria (Rochlani et al., 2017). This review will focus on how GC dysregulation 




Cushing’s Disease and Addison’s patients represent the two extremes of GC dysregulation. Cushing’s 
disease is caused by hypercortisolism, 70% of which are due to pituitary adenoma overstimulating GC 
release from the adrenal glands (Nieman and Ilias, 2005). Patients present with a number of MetS 
pathology including visceral fat gain and obesity (32-41%), hypertension, impaired glucose tolerance, 
dyslipidaemia (32-41%) and type II diabetes (20-47%) (Nieman and Ilias, 2005; Stratakis, 2008; 
Feelders et al., 2012; Buliman et al., 2016). Conversely, Addison’s disease is characterised as 
hypocortisolism, and can be caused by autoimmune hypothyroidism and type I diabetes as well as 
other rare conditions. Patients present with the opposite symptomology to Cushing’s patients with 
MetS development, as they usually lose weight and suffer from fatigue, anhedonia, hypotension and 
hypoglycaemia (Chakera and Vaidya, 2010). Whilst both conditions are relatively rare and extreme, 
the metabolic phenotypes observed provide the ‘worst case scenario’ example of metabolic adverse 
effects associated with GC dysregulation and can therefore inform about how dysregulated GC levels 
affect metabolism and other functions.  
1.3.1 Dysregulation of the HPA axis and the molecular ‘clock’  
Commonly referred to as the ‘clock’ transcriptome, targets are expressed throughout mammalian 
central and peripheral tissues, highly interconnected and cyclically transcribed within positive and 
negative feedback loops and are centrally timed by circadian / ultradian hormonal release, such as 
GCs (Delaunay and Laudet, 2002; Panda et al., 2002; Staels, 2006; Scott, Carter and Grant, 2008). As 
up to 9% of transcripts within mouse liver have been shown to be under circadian control, the clock 
transcriptome represents a highly adaptable and important system (Akhtar et al., 2002). Common 
targets of investigation include transcription activators such as circadian locomotor output cycles 
kaput (CLOCK), brain and muscle ARNT-like 1 (BMAL1) as well as the inhibitors period circadian 
regulator (PER) 1,2 & 3, cryptochrome1, cyrptochrome2 and nuclear receptors REV-ERB and retinoic 
acid-receptor-related orphan receptors (ROR) (Kume et al., 1999). These targets participate in an 
oscillating system of core clock processes as CLOCK and BMAL1 (which bind as a heterodimer to 
promoter elements) induce transcription of PER1 and cryptochrome 1. However, increased levels of 
PER1 and cryptochrome 1 will negatively feedback and allosterically inhibit CLOCK and BMAL1 binding 
to DNA (Gekakis et al., 1998; Kume et al., 1999; Shearman et al., 2000; Reppert and Weaver, 2002; 
Jetten, 2009; Cho et al., 2012).  
GC transcriptional regulation for numerous clock targets have been described and importantly, 
glucose, lipids, carbohydrates, insulin and leptin all exhibit circadian variations in their expression. 
Therefore, GC dysregulation may mediate its adverse metabolic affects via dysregulation of peripheral 




the liver clock than controls. This is potentially mediated by their regulation of Per1 and Per2 (Le Minh 
et al., 2001). GR has been shown to regulate PER1 transcription via two GREs ~2kb upstream of the 
TSS and within intron 1, whilst PER2 transcription can be induced by BMAL1 dependent GR binding to 
the proximal promoter region (Conway-Campbell et al., 2010; Reddy et al., 2012; Zani et al., 2013). In 
a recent study, it was shown the expression of the rate limiting mitochondrial enzymes required for 
carbohydrate and lipid metabolism accumulated in a diurnal pattern. This was blunted in mice lacking 
Per1 and Per2 as well as a high fat diet (HFD) (Neufeld-Cohen et al., 2016). Per2 knockouts have 
reduced fasting glycaemia as well as altered hepatic glycogen accumulation which is postulated to be 
due to a loss of Per2 direct and indirect induced transcription of glycogen synthase and protein 
phosphatase-1 (Zani et al., 2013).  
The clock transcriptome is highly complex, with a myriad of crosstalk pathways and internally 
dependent regulation, therefore, it is difficult to identify an individual cause of metabolic phenotypes. 
For example, CLOCK and REV-ERBα expression is currently understood to not be directly GR regulated, 
but REV-ERBα has been shown to reduce GR half-life and activity, potentially via HAT activity to the 
GR (Okabe et al., 2016). CLOCK has been implicated in glycogen metabolism via regulation of glycogen 
synthase 2 transcription, a rate limiting glycogenic enzyme and REV-ERBα has been shown to directly 
regulate the expression of gluconeogenic genes PCK and G6PC (Yin et al., 2006; Doi, Oishi and Ishida, 
2010). Loss of Clock and REV-ERBα function induces dramatic metabolic changes, developing obesity, 
hepatic steatosis, hyperglycaemia, hyperleptinemia, hyperlipidaemia, hypoinsulinemia, elevated VLDL 
and hypercholesteremia. Whereas Rorα knockouts present opposing phenotypes, lowering 
triglycerides and increasing glucose and apolipoprotein C levels in the blood, however, dysfunction of 
peripheral clocks may not be the only cause (Raspé et al., 2001, 2002; Turek et al., 2013; Kojetin and 
Burris, 2014). For example, it was recently shown the restricted feeding attenuated MetS pathology 
in Cry1:Cry2 and liver specific Rev-erbα/β or Bmal1 knockouts. Even though elements of the clock 
transcriptome would have been partially intact, the study suggests eating behaviours could be the 
major influence (Chaix et al., 2019). Therefore, GC dysregulation can drive perturbations in the 
oscillatory pattern of the peripheral clock transcriptome, but there are clearly numerous other factors 
that also contribute to the development of MetS. 
1.3.2 Feeding and the HPA axis 
A myriad of studies has focussed on the loss of synchrony between endogenous circadian patterns 
(such as GCs) and environmental cues (light/ dark periods), emulating irregular shift work, 
transmeridian travel and inconsistent sleep patterns and their implication for MetS development. For 




food intake. This was also associated with increased circulating endocrine hormones leptin and insulin 
levels as well as aberrant cognitive ability which was associated with a loss in neuronal plasticity 
(Karatsoreos et al., 2011). These alteration in light:dark periodicity implicate the HPA axis, as even 
though it is a highly plastic system, adaptions to new light periods are possible, that within humans is 
thought to be roughly an hour a day per time zone crossed (Eastman et al., 2005; Bullock et al., 2007; 
Doane et al., 2010). The HPA axis is chiefly regulated by the photoperiod and not activity, therefore 
individuals with permanent night shift work do not alter diurnal photoperiod endogenous melatonin 
and cortisol profiles (Roden et al., 1993). Unsurprisingly, night shift workers have a 2-fold higher risk 
of developing type II diabetes, potentially as consequence of insulin resistant like phenotypes, raising 
both resting insulin and glucose levels as well as increased oxidized carbohydrates (Gan et al., 2015). 
Interestingly, these phenotypes were more notable within phase advance as opposed to phase delay 
conditions  (Roden et al., 1993; Scheer et al., 2009; Gonnissen et al., 2012; Gan et al., 2015; Koopman 
et al., 2017). Similar glucose and insulin insensitivity have been shown in adrenally suppressed 
patients. Bolus cortisol injections during the natural circadian nadir (17:00) induced significantly 
elevated post-prandial glucose and insulin levels, compared to those induced by cortisol injections 
during the natural circadian peak (05:00) (Plat et al., 1999). This finding indicates differences in insulin 
and glucose sensitivity dependent on the phase of circadian cortisol release and could be particularly 
pertinent to shift work.  
It should be noted that dysregulation of circadian rhythms also affects feeding behaviour which may 
further contribute to the development of MetS. For example, mice fed a HFD still retain some circadian 
pattern to their feeding schedule but they consume significantly more during the inactive period 
without increasing their overall intake (Kohsaka et al., 2007). Indeed, the circadian phase an 
organism’s calorific intake occurs could be very important. Restricting feeding to the inactive period 
has been shown to induce MetS pathology in mice without altering their activity or calorific intake as 
well as a loss in synchrony between the SCN (remained intrinsically timed to the photoperiod) and 
peripheral hepatic molecular clock mRNA levels of Bmal1, Cry1, Cry2, Per1, Per2, Rorα, Pparα, Pparγ 
and Rev-Erbα, as well as the metabolic targets Pepck, fatty acid binding protein 1 & 4 and fatty acid 
synthase. Physiologically, these mice developed hypoinsulinemia and raised TG and free fatty acids. 
As Pparα and Gsk3β are not expressed within the SCN, these targets were identified as key drivers in 
peripheral misalignment to the central clock, particularly as they are key targets within glucose and 
lipid metabolism. The adverse metabolic effects were reversed by restricting feeding to the active 
period and targeted inhibitors, which the authors theorise could have therapeutic implications for 
shift workers as these inhibitors are already used clinically for mood and anxiety disorders (Kohsaka 




into circadian signalling mechanisms and dysregulation of meal timing relative to circadian cues may 
be an additionally important factor integrating with GC dysregulation of metabolism.  
1.3.3 Maladaptive stress and metabolism 
Both physiological and psychological stressors are primary modifiers of the HPA axis. As previously 
discussed, stress innervation of hypothalamic CRH neurons activates HPA axis release of ACTH, 
inducing production and secretion of GCs from the adrenal glands. The ultradian regulation of GC 
levels has implications for the stress response as stress related maximal corticosterone increases are 
blunted when the stressor is applied during the falling phase of a GC pulse, as was aggression to an 
unknown male during a self-initiated aggression behavioural task (J. Haller et al., 2000; Sarabdjitsingh 
et al., 2010). Stress also alters the ultradian interpulse period, indicating modification of endogenous 
GC pulse frequency (Windle, Wood, Lightman, et al., 1998). Similar perturbations have been recorded 
in clinically depressed patients who present with increased circulating ACTH and cortisol levels, often 
with a loss in circadian nadir (Deuschle et al., 1997). Association with the loss of ultradian function has 
been shown via the blunted response of the HPA axis to secrete ACTH when corticosterone was 
infused into the circulation constantly as opposed to a hourly pulsatile model (Sarabdjitsingh et al., 
2010; Lightman, 2016; Oster et al., 2016).  
Stress induced GC release is a natural response that has been postulated to mobilise energy stores 
from WAT, skeletal muscle and liver. Raising blood glucose levels to provide energy to tissues such as 
the brain in classic fight or flight responses (Kuo et al., 2015). Under chronic situations, however, these 
changes can become maladaptive and have been associated with the development of MetS pathology. 
For example, the likelihood of developing MetS in workers who experience chronic stress (defined as 
three or more self-determined stressful events a week) were quoted as twice as likely including type 
II diabetes (Chandola, Brunner and Marmot, 2006; Rod et al., 2009; Edwards et al., 2012). Elevated 
cortisol levels have been associated with increased weight gain, elevated TGs and fasting glucose 
levels, and lowered HDL levels in stressed obese individuals when compared to non-stressed obese 
individuals (Vicennati et al., 2009; Bergmann, Gyntelberg and Faber, 2014; Garbarino and Magnavita, 
2015; Ryu et al., 2016). It must be noted that these studies are highly variable as controlling for dietary, 
circadian activity patterns and general lifestyles are difficult. Increased appetite behaviour in response 
to stress and GCs has also been reported due to the increased expression of orexigenic genes such as 




1.3.4 Clinical corticosteroids 
As previously mentioned, the discovery of cortisone and its anti-inflammatory affects in rheumatoid 
arthritic patients in the 1940s garnered huge interest and research (Hench and Kendall, 1949). Soon 
after, the ability to synthetically produce steroids in large amounts became a rapid and lucrative 
avenue of research and clinical treatment. Dehydration of the A ring at the 1, 2, position of cortisone 
or corticosterone, produced prednisone (cortisone derivative) and prednisolone (corticosterone 
derivative) with increased anti-inflammatory properties and the claim of reduced adverse side-effects. 
Dex was also created by combining 16α-methylation, 9α-fluorination and 1-dehydrogenation to 
become the most potent anti-inflammatory of its time (Arth et al., 1958; Hillier, 2007). The desired 
properties of synthetic glucocorticoids (sGCs) included greater anti-inflammatory action and longer 
half-lives compared to their endogenous counterparts and before long became the most commonly 
used anti-inflammatory and immunosuppressive drugs for rheumatic and other inflammatory 
conditions (Stahn et al., 2007). Their clinical use has become so prolific that pre 2007, in the United 
States 44.3 million prescriptions were made annually and in the UK, 0.85% of patients >18 years of 
age were prescribed oral sGCs (0.75% for long time use ≥3 months) over a 20 year period from 1989 
(Fardet, Petersen and Nazareth, 2011; Judd et al., 2014).  
Due to their structural similarity to adrenal corticosteroids, sGCs will act as ligand for the GR, however, 
data on ligand half-life’s and efficacy are varied and limited. Methylprednisolone circulation has been 
measured to just over two hours in separate 5 and 8 healthy male cohorts, whilst Dex plasma half-life 
at just over 3hrs (Al-Habet and Rogers, 1989; Uhl et al., 2002; Nicolaides et al., 2018). An in vitro study 
has shown that Dex treatment can induce GR activation up to 12 hours in AtT20 cells and in the rat 
pituitary in vivo and up to 6hrs in brain regions such as the hippocampus, perirhinal cortex and 
amygdala (Earl et al., 2017). The reduced activation in brain compared to the periphery is known to 
be due to Dex extrusion from the brain by the multiple drug resistant P-glycoprotein (Cordon-Cardo 
et al., 1989; Meijer et al., 1998; Karssen et al., 2001, 2005). 
To investigate the effect of sGCs on GR to DNA binding, GR occupancy at the MMTV array within 3617 
cells was used in response to 15min exposure and washout to a range of sGCs and the endogenous 
counterparts cortisol and corticosterone. Acute GR occupancy was similar for all corticosteroids 
assessed at 15min incubation, but only hydrocortisone, cortisol and corticosterone induced GR 
occupancy in a transient manner as GR was rapidly lost after hormonal washout. In contrast, the longer 
half-life engineered sGCs tested induced maximal prolonged GR binding at the MMTV array 
throughout the wash out period. This experiment was expanded upon using 20min corticosterone or 




bound in response to 20min incubation, but only lost in the corticosterone induced data set, whereas 
Dex induced GR binding in a maximally prolonged manner throughout the wash period. This was 
repeatedly observed over the experimental timecourse, in addition to changes in RNA PolI2 
transcriptional recruitment and DNase hypersensitivity. Together, these data indicate GR binding in 
response to sGCs can be prolonged to the endogenous corticosterone counterpart and consequently 
dysregulate postulated ultradian / circadian cyclical gene induction (Stavreva et al., 2009, 2015).  
As sGCs can regulate GC responsive targets, loss of circadian / ultradian regulation of GC tissues could 
have significant effects. Long term administration of a variety of sGCs have been linked to osteoporosis 
as well as cognitive, memory, learning deficits and depression (Varney, Alexander and MacIndoe, 
1984; Wolkowitz, 1994; Manelli and Giustina, 2000; Blalock et al., 2005). Notably for my work, GCs are 
a principle mediator of metabolic homeostasis, therefore sGCs can induce major adverse side-effects 
on glucose, fatty acid, lipid and carbohydrate metabolism. Hyperglycaemia is a common side-effect of 
chronic corticosteroid treatment, most likely due to insulin insensitivity. For example, sGC treatment 
has been shown to primarily precipitate the development of type 2 diabetes in a cohort of patients 
with no apparent underlying risk such as family history or obesity (Simmons et al., 2012).  
Data on metabolic side effects is highly variable due to differing pharmacological properties of 
different sGCs, dose, prescription length and underlying pathophysiological condition. For example, 
high dose prednisolone (30mg) treatment has been shown to be associated with the appearance of 
insulin resistance urinary markers within 2 days of treatment. A slightly reduced dose of 15mg was 
associated with the appearance of the same markers by day 16 of treatment (Ellero-Simatos et al., 
2012). Similar effects have been reported with doses of 7.5mg, which is also a commonly prescribed 




















Cortisol 20.0 1 1.0 90 
Cortisone 25.0 0.8  80-118 
Intermediate-acting 
Prednisone 5.0 4.0 4.0 60 
Prednisolone 5.0 5.0  115-200 
Triamcinolone 4.0 5.0 4.0 30 
Methylprednisolone 4.0 5.0 4.0 180 
Long-acting 
Dexamethasone 0.75 30 17 200 
Betamethasone 0.6 25-40   300 
 
Table 1 Relative dose, potency, HPA suppression and plasma half-life of a selection of endogenous 
and synthetic glucocorticoids. 
Table adapted from Nicolaides et al., 2018 and based from Chrousos, 2005; Stewart and Newell-Price, 
2016. 
Daily oral Dex treatment over 5 days for paediatric acute lymphoblastic leukaemia, induced raised 
fasting HDL, LDL, cholesterol, TG, glucose and insulin levels. Glucose was also found to be raised 
between treatments, even after Dex should have been metabolised and cleared from the patients’ 
systems. Authors used a homeostasis model assessment of insulin resistance and observed increases 
from 8% to 85% post Dex treatment (‘Global IDF/ISPAD Guideline for diabetes in childhood’, 2011; 
Warris et al., 2016). This could be due to inhibition of insulin binding of its complementary receptor 
which has been observed to be dose dependent, as well as oxidative and non-oxidative glucose 
disposal (Olefsky et al., 1975; Tappy et al., 1994; van Raalte et al., 2011; Petersons et al., 2013; Pasieka 
et al., 2016). There are also indications that Dex could directly regulate adipocyte growth. Dex induced 
reporter gene activity and transcription of VLDLR in adipocyte 3T3-L1 cells via indirect GR regulation. 
Alterations in transcription could have distinct metabolic affects as increased VLDL expression has 
been shown to induce differentiation in adipocyte like cells, and VLDL receptor deficient mice have 
less adipocyte tissue (Ensler et al., 2002).  
There is also evidence of ligand specific GR regulation. A recent study in the 3617 MMTV array  




corticosterone treatment (Stavreva et al., 2015). Specific ligand dependent effects on transcription 
and co-regulator recruitment have also been described for the GC regulated targets GILZ, SLC19A2 
and thrombomodulin within A549 cells (Monczor et al., 2019). This data highlights the potential 
importance of considering which GC ligand is used in experiments for molecular research, especially 
those related to dynamic GR mediated action, but even more importantly the clinical implications for 
GC replacement therapy. 
1.4 Next generation sequencing technology 
1.4.1 Chromatin immunoprecipitation assay next generation sequencing analysis 
The ability to identify multiple transcription factor interactions across the genome as well as de novo 
sites represents a highly powerful tool within molecular research and has been available since the turn 
of the century via utilisation of chromatin immunoprecipitation (ChIP) assays followed by DNA 
hybridization to a microarray (ChIP-ChIP). However, high density tiling arrays are costly, have a low 
resolution of local enrichment due to a high minimal fragment size (200b) and are limited by 
microarray probe capacity (Ren et al., 2000; Iyer et al., 2001).  
The next breakthrough in genome mapping came in the form of next generation sequencing (Seq) in 
2007 (Johnson et al., 2007; Robertson et al., 2007). Isolated genomic fragments are amplified, aligned 
to a reference genome and resulting tag profiles computationally modelled into areas of enrichment, 
the peaks of which associated with protein to DNA points of interaction and height relative to the 
degree of enrichment. Seq is not restricted by the probe capacity as in ChIP-ChIP but able to process 
hundreds of millions of fragments in a single run and load smaller DNA concentrations (10-100 ng 
compared to 2 µg for ChIP-ChIP) and fragment size (~35 b) (Harris et al., 2008). Thus, enhancing spatial 
resolution of localised protein targets, as is particularly important whilst profiling histone variants, 
post-translational modification of chromatin, lineage determinant factors and nucleosome 
positioning (Yuan et al., 2005; Bernstein et al., 2006; Barski et al., 2007; ENCODE Project Consortium, 
2007; Lee et al., 2007; Mikkelsen et al., 2007). For these reasons Seq of ChIP’d DNA has been applied 
to a wide range of transcription factors, histone modifiers and chromatin remodelling complexes in a 






Figure 1.11 Schematic of next generation sequencing methodology. 
Genomic DNA is fragmented, sequences bound to proteins of interest are targeted by antibodies and 
isolated by ChIP assay. Fragments are amplified, 5’ end sequenced and aligned to a reference genome 
and localised tag densities genome wide are computationally analysed to a single peak of enrichments 
via modelling of forward and reverse fragment densities. Peak zenith denotes localised protein-DNA 




Seq produces large data sets requiring powerful analytical packages to identify significant enrichment 
regions across the genome. A range of algorithms have been written to identify enriched regions 
within Seq data. General algorithms include F-Seq  and Hotspot (the only algorithms specifically 
designed to analyse DNase I footprinting data), ZINBA (general peak caller), MACS2 (a model based 
ChIP-Seq analysis approach) and HOMER (Boyle et al., 2008; Y. Zhang et al., 2008; Park, 2009; Rashid 
et al., 2011; Baek, Sung and Hager, 2012; Feng et al., 2012; Yang et al., 2014; Heinz et al., 2015).  
Briefly, F-Seq measures parametric sequence tag density via implementation and estimated localised 
tag sequence centre in a smooth Gaussian kernel density estimation (Boyle et al., 2008). This 
proposedly overcomes histogram bin-boundary interference and introduction of error. This technique 
is noted for long run time during statistical testing (W. Zhang et al., 2012). 
Hotspot identifies regions of enrichment above background and will adjust significance based upon a 
false discovery rate measured from randomly selected Seq sequences. Therefore, Hotspot is regarded 
as the only program to apply statistical significance to DNase I hypersensitive site (DHS) peaks 
(Madrigal and Krajewski, 2012). Hotspot has been widely used by the ENCODE consortium and the 
latest version implements a “second pass” detection to select relatively small enrichment masked 
signal bias by areas of enrichment from other localised targets (Baek, Sung and Hager, 2012). 
ZINBA identifies genomic regions as background, enriched or zero-inflated using a mixture of 
regression models without the need for input control. Detected enriched regions within a defined 
distance are applied to a shape-detection algorithm for sharp signal discovery within broad regions of 
enrichment. The analysis can also be modified to take into account modelled covariate information 
(C/G content etc.) to improve low signal-to-noise ratio or complex analysis (Rashid et al., 2011). 
HOMER (Hypergeometric Optimization of Motif EnRichment) is a suite of tools designed for de novo 
and known motif discovery, however, a ChIP-Seq enrichment analysis tool is also included. findPeaks 
identifies enriched clusters of Seq tags across the genome, filtering significant clusters by estimation 
of a tag threshold according to a Poisson distribution and estimated false discovery rate (FDR). Clusters 
are then identified as significant based on local and clonal signals within the Seq data as well as fold 
change to input or IgG control Seq data (Heinz et al., 2010). 
MACS empirically models shift size enrichment of sequence reads compared to a background using a 





Koohy, H. et al. reported Hotspot and MACS to be comparatively successful in identifying regions of 
DHS in DNase-Seq paradigm experimental results but F-seq peak sensitivity was greatest and ZINBA 
scored the lowest (Koohy et al., 2014).   
1.4.2 Motif discovery 
Genomic DNA contains short (5 to 20b) biologically significant repeated sequences termed DNA 
motifs. Transcription factors such as GR bind to GREs within promoter and enhancer sequences of 
associated targets regulating transcription, and these GREs often have well characterised DNA motifs. 
Therefore identification of these specific motifs in the ChIP-Seq dataset can provide integral 
information about binding regulation in a genomic landscape (Rombauts et al., 1999; Das et al., 2007). 
Motif analysis detects over represented and conserved motifs from orthologous sequences as a 
representation of the most likely transcription factor interacting candidates (Das et al., 2007). There 
are two main types of motif analysis. A word-based (string-based) algorithm enumerates and 
compares oligonucleotide frequencies, restricting analysis to detect identical short motifs and is used 
almost exclusively for eukaryotic genomic and optimised data structures (van Helden, André and 
Collado-Vides, 1998; Sagot, 2009). As transcription factor motif sequences often have longer, weakly 
constrained positions, these parameters restrict its ability to be applied to prokaryotic genomes and 
motifs of relatively low fidelity (Vilo et al., 2000). In these instances, a probabilistic sequence model is 
preferred. Model estimations use a maximum-likelihood principle or Bayesian inference, presenting 
data in a position weight matrix, where by letter height within a stack of predicted bases is 
proportional to the occurrence within over represented regions (Hertz, Hartzell and Stormo, 1990). 
This technique can be particularly sensitive detecting small changes and naturally biologically variable 
data (Bucher, 1990). 
1.5 Research question 
Classically, GR interactions are studied within, ‘promoter’ regions in close proximity to the TSS of 
regulated genes. Long distance interactions via looping and the functionality of TAD domains, 
however, are becomingly increasingly recognised for their fundamental biological role, particularly as 
functional circadian regulated TAD domains have been identified within the mouse liver (Aguilar-Arnal 
et al., 2013; Zhao et al., 2015; Kim et al., 2018).  
These interactions are further complicated by synergistic, GR dependent transcriptional regulation 
which was first identified for the gene TAT and have continued to be documented (Jantzen et al., 
1987). Additionally, GR interactions with STAT3, STAT5 and NFκB have been shown to be either 




regulatory element within a tethered model of transcriptional control (Stoecklin et al., 1997; Zhang et 
al., 1997; Aittomäki et al., 2000; Engblom et al., 2007; Langlais et al., 2012). Highlighting the 
importance of de novo identification of GR binding events as well as sequence analysis to identify 
potential co-regulator response elements. 
As cells have multiple intrinsic post-transcriptional mechanisms regulating mRNA and protein 
production and degradation, as well as the time required for maturity of nascent RNA and translation 
of proteins, analysis of RNA and protein levels can mislead identification of directly regulated genes.  
To avoid false negative or false positive results from non-transcription dependent regulation, analysis 
of both GR binding and RNA Pol2 activity at the level of the genome is paramount to observe direct 
and indirect transcription factor mediated effects. Therefore, ChIP-ChIP, RT-qPCR and RNA-Seq 
analysis is not optimal for this investigative paradigm. Currently, the degree of sensitivity required to 
address and expand basic understanding of direct transcriptional regulation on a genomic scale is only 
achievable via ChIP-Seq methods. 
This has relevance for ultradian dynamics, as oscillations in circulating GCs can range from hourly 
within the rat to every three hours in the human (Follenius et al., 1987; Veldhuis et al., 1989; Jasper 
and Engeland, 1991). As these dynamics are so well conserved across mammalian species, it can be 
postulated oscillations mediate distinct and important regulatory function (Holaday, Martinez and 
Natelson, 1977; Benton and Yates, 1990; Engler et al., 1990; Carnes et al., 1992; Loudon et al., 1994; 
Cudd et al., 1995; Windle, Wood, Shanks, et al., 1998; Russell et al., 2010). Particularly as evidence has 
been published that maximal stress induced circulating corticosterone levels, as well as aggression, 
can be altered dependent on the phase of the GC pulse the stressor is applied (J Haller et al., 2000; J. 
Haller et al., 2000; Sarabdjitsingh et al., 2010). It can be postulated, the advantages of an oscillating 
system is the ability to carry more information for cellular signalling mechanisms than a static profile 
(Walker, Terry and Lightman, 2010; Walker et al., 2012; Lightman, 2016; Oster et al., 2016). 
23% of the united states population were quoted as presenting MetS phenotypes, however, most 
research highlighting the implications of dysregulated GC rhythms for both cognitive and physiological 
aberrant metabolic function have focussed on circadian dysregulation. Cushings syndrome as well as 
chronic stress have been shown to induce raised circulating GC profiles, which effectively dysregulate  
both circadian and ultradian oscillatory profiles (Deuschle et al., 1997; Nieman and Ilias, 2005; Newell-
Price et al., 2006). Despite the fact sGCs are mostly prescribed in a manner that best fits current 
understanding of endogenous hormone rhythms, patients still over-represent metabolic dysfunction, 




1994; Filipsson et al., 2006; Simmons et al., 2012). Therefore, could abolition of ultradian GC 
oscillations induce these phenotypes, either directly or in a combination with other factors?  
Currently, investigation of GR binding dynamics as well as RNA Pol2 activity has only been observed 
on a genome-wide scale in immortalised cell lines. Additionally, many studies use sGCs as ligand for 
GR, despite evidence of ligand dependent effects on transcription (Conway-Campbell et al., 2007; 
Stavreva et al., 2009, 2015; Monczor et al., 2019). Therefore, investigation of corticosterone induced 
regulation in response to circulating ultradian oscillating levels and the potential repercussions of 
dysregulation, have distinct and important implications that could be fundamentally important to 
future circadian research as well as clinical intervention. 
1.6 Hypothesis 
The ultradian rhythm of the circulating glucocorticoid hormone corticosterone is integral to 
homeostatic processes, and controls regulation of target gene transcription. We hypothesise that 
disruption of the pulsatile corticosterone profile will result in dysregulation of GR binding and 
downstream transcriptional processes involved in regulating key metabolic target genes relevant to 
metabolic pathology.   
1.7 Aims 
1) Confirm cell culture evidence of differential regulation of GR binding in the liver during a 
pulsatile and constant corticosterone treatment, with an in vivo rodent model.  
2) Characterise genome wide GR binding patterns and RNA polymerase II activity during pulsatile 
corticosterone infusion compared to a constant delivery.  
3) Identify key differentially regulated metabolic gene targets involved in known metabolic 
syndrome. 
4) Develop a chronic infusion model to investigate if the ultradian pulses of corticosterone that 




Chapter 2 General methods 
2.1 Surgery and husbandry 
Adult male Sprague-Dawley rats (250-300g) (Harlan, Bicester, UK) were individually caged in 
soundproof rooms under standard conditions in 14:10 light/dark cycle (lights on at 05:00hr) with 
standard chow and water available ad libitum. All procedures were carried out in accordance with the 
UK Home Office animal welfare regulations. 
Rats were anaesthetised with a combination of Isoflurane (100% w/w liquid vapour (Merial, UK)) and 
medical air during bilateral ADX, jugular vein or/ and carotid artery cannulation. The cannula (Smith 
Medicals, UK) was exteriorised via craniotomy or a vascular access button and attached to a spring 
and swivel system in individual cages (Figure 2.1). 1mg of Carprofen (Rimadyl, Pfizer, UK) was 
administered post-operatively for pain relief. 25µg Dex (Sigma, UK) and 2.5ml of glucose (5%)/ saline 
(0.9%) injected subcutaneously. Up to 5 days of post-surgical recovery was allocated, during which 
time 0.9% saline drinking water supplemented with 0.15 µg/L of corticosterone (Sigma, UK) was 
provided ad libitum to provide isotonic salt levels and maintenance of HPA axis homeostasis. 16 hours 
prior to experiment, corticosterone saline drinking water was replaced with saline drinking water to 
allow an adequate corticosterone washout period prior to the experiment. In some cases, telemetry 
probes were surgically implanted into the intraparietal space and secured via stitches to the intra-
abdominal epidermal layer in intact or ADX rats. Movement and body temperature were recorded via 
transmitter/ radio receivers (PTD 4000 E-mitter, Starr Life Sciences Corp) placed under the rodent’s 
cage and metal dividers between cages to reduce interference. 
Implanted cannula would be ‘flushed’ daily via withdrawal of blood through the cannula to remove 
any clots that may have formed and replaced with fresh heparanised saline (1:100) to maintain 
patency. 
2.2 Automated blood sampling 
Total corticosterone blood serum samples were taken via an in-house automated blood sampling 
(ABS) system (Figure 2.1). Briefly, blood is withdrawn via the action of the bi-directional pump from 
the indwelling cannula towards the pump. Once the required volume has been withdrawn, the pump 
changes direction and the valve switch system changes the flow direction towards the ABS fraction 
head for collection. Once the desired volume of blood/ heparinised saline has been collected, the 
valve/ switch system changes the flow direction back towards the rat. Delivering sterile heparinised 
saline back into the rat, replacing withdrawn blood volume and maintaining cannula patency. Within 





Figure 2.1. Schematic of programmable pump and automated blood sampling system.  
Rats implanted with intravenous cannulae, exteriorised either via craniotomy, protected by dental 
cement “head cap” or a vascular access “button” over the shoulders. Cannulae were protected by 
spring and attached to a swivel allowing free movement. Programmable pump settings were pre-set 
to infuse corticosterone solution (blue) at the desired time and rate via intravenous cannula. ABS 
system withdraws blood (red) from the intravenous cannula through the swivel and valve/ switch 
system powered by a reversible pump. Once the required volume has been withdrawn, the pump is 
reversed, and the valves direct the flow to infuse the same volume of heparised saline solution (black) 
back through the intravenous cannula. The swivel has been designed to incorporate both 
programmable pump and ABS via two intravenous cannulae if required. Arrows denote direction of 
travel. Rat was kindly animated by Mr. Martin Flynn. 
2.3 Infusion Profiles 
To produce in vivo ‘mock’ ultradian pulses (referred to as pulsatile infusion) a programmable pump 
(PHD Ultra Syringe Pump, Harvard Apparatus, USA) was used to infuse corticosterone solution 
(solubilised 2-hydroxypropyl-β-cyclodextrin (HBC) complex carrier (Sigma, UK) in 0.9% saline solution) 
through the jugular vein at a dose of 3.84 µM. Each pulsatile period began with a 20 min infusion at a 
rate of 1 ml per hour and paused for 40 min and repeated hourly for 3hrs (Figure 2.2). A sustained 
corticosterone-HBC saline solution (referred to as constant infusion) was infused at a reduced rate of 
0.33 ml per hour to match pulsatile corticosterone dose delivered per hour. The constant 
corticosterone infusion was modified to include an initial increased rate of 1 ml per hour for 10 min 
before returning to 0.33 ml per hour for the duration of the experiment to ensure no gaps within 
infusion solution had appeared since charging of cannula and infusion lines. Matched dose was 





Figure 2.2 Schematic and circulating total blood serum corticosterone levels after pulsatile and 
constant corticosterone infusions within freely roaming rats. 
(A) Pulsatile corticosterone (3.84 µM dose) was infused for 20 min at a rate of 1 ml per hour and 
paused for 40 min to generate the pulse peak and nadir (blue). A constant infusion of corticosterone 
was dose matched via reduction of the infusion rate to 0.33ml/hr over 60min (red). The constant 
infusion profile included an increased infusion rate between 0-10min at 1ml/hr before returning to 
0.33ml/hr for the duration of the experiment. Both patterns were repeated for three hours. (B) To 
confirm infusion model, 10min blood samples from the carotid artery were collected via the ABS over 
the three-hour corticosterone infusion period. Pulsatile corticosterone infusion total blood serum 
levels peak at 20, 80 and 140min (374ng/ml ±83), corresponding with the end of hourly 20min 
corticosterone infusions. corticosterone levels reduced to 68ng/ml ±20 within 40min of each pump 
cessation. The preliminary increased constant corticosterone infusion rate promotes maximal 
corticosterone levels at 10min (353ng/ml ±42) before reducing and flattening to 201ng/ml ±51 over a 
60-120min period. Between 140-180min corticosterone levels appear to fluctuate between 180-
240ng/ml. In response to a pulsatile corticosterone infusion, corticosterone levels were 387ng ±34 and 




of 261ng/ml ±51 and 194ng/ml ±13. (C) Area under the curve analysis confirmed no difference in 
circulating total corticosterone between pulsatile and constant corticosterone infusions over the 
experimental period. Total blood serum corticosterone levels were measured by RIA trunk blood 
samples. Pulsatile AUC mean= 39,087(ng/ml) x min ±1,025 s.e.m. and constant AUC mean= 
38969(ng/ml) x min ±1,007 s.e.m..  
A pulsatile HBC complex dissolved in saline solution was used as matched vehicle control infusion 
(VEH) where indicated. Euthanasia time points corresponded to the third corticosterone pulse zenith 
and nadir at 140min and 180min infused timepoints respectively. Trunk blood samples were collected 
for each rat at the point of euthanasia with 40 µl of 0.5M ethylenediaminetetraacetic acid (EDTA) and 
total blood serum corticosterone levels assessed by radioimmunoassay (RIA). 
2.4 Tissue Collection 
Liver was dissected and 0.4g was fixed in 1% (v/v) formaldehyde (Sigma, UK), phosphate buffered 
saline (PBS) (1.37 M NaCl, 2.68 mM KCl, 10.14 mM Na2HPO4, pH 7.4) solution for 10 min at room 
temperature (RT). Formaldehyde cross-linking was quenched with addition of Glycine (final conc. 125 
mM) for 5 min and washed three times in ice cold PBS supplemented with 2 mM NaF, 0.2 mM Na 
Orthovanadate and 1X Complete protease inhibitor (Roche Diagnostics). Fixed liver was stored at -
80°C in 0.2g samples in 500 µl of S1 Buffer (10 mM HEPES, pH 7.9, 10 mM KCl, 15 mM MgCl2, 0.1 mM 
(EDTA), pH 8) supplemented with 0.5 mM Dithiothreitol and 2 mM NaF, 0.2 mM Na Orthovanadate 
and Complete protease inhibitor.  
2.5 Corticosterone radioimmunoassay (RIA) 
Plasma was separated from whole blood by centrifugation at 4000 rpm, 4°C. Samples were diluted 1 
in 50 with citrate buffer, processed in triplicate and incubated overnight in 50 µl of 125I corticosterone 
tracer (Oxford BioInnovation DSL Ltd, Oxford, UK) and 50 µl of rabbit anti-rat corticosterone antibody 
(kindly donated by G. Makara, Hungary). Free/bound separation was performed using charcoal 
dextran precipitation, centrifuged at 4000 rpm, 4°C and the solution aspirated before the 125I 
corticosterone tracer in the resulting pellets was read using a gamma counter (Wizard-2470, Perkin 
Elmer, MA) (Atkinson et al., 2006; Waite et al., 2012). Concentrations of corticosterone in each plasma 
sample were interpolated from a standard curve. Intra- and inter-assay coefficient of variation of this 
in house corticosterone assay have been established as 16.65% and 13.30%, respectively (Conway-




2.6 Chromatin Fragmentation 
Samples were thawed slowly on ice and adjusted to a final volume of 1ml/sample with supplemented 
S1 buffer, then homogenised on ice using a Dounce homogeniser.  The resulting lysate was centrifuged 
at 4000 rpm at 4°C to collect a crude nuclear pellet, which was then lysed in sodium dodecyl sulphate 
(SDS) lysis buffer (2% SDS, 10 mM EDTA, 50 mM Tris-HCl (pH8.1) supplemented with NaF and Na 
orthovanadate and 1X Complete Protease Inhibitor). Chromatin was sonicated using a Branson 
Sonifier 450 (Branson Ultrasonics, Danbury, CT, USA) to 300-500 bp fragments with multiple 10-sec 
bursts at 10% output and centrifuged at 13,000 rpm at 4°C to remove cellular debris from the 
chromatin suspension. Sheared chromatin was stored at -80°C.  
2.7 ChIP assay 
ChIP buffers were prepared in house, as described in the EZ ChIP kit protocol (Upstate Biotechnology, 
Lake Placid, NY, USA) with some modifications for use with animal tissue (as described where 
relevant). Sheared chromatin was removed from -80°C storage and thawed slowly on ice, diluted to 
desired input concentration in a final volume of 100 µl of SDS lysis buffer, then made up to a final 
volume of 1 ml with ChIP dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-
HCl pH8.1, 167 mM NaCl). For the ChIP assay, each input consisted of 50µg of sheared chromatin and 
individual inputs from each sample were immunoprecipitated against either a GR cocktail (2µg of PA1-
510A, 4µl of PA1511A (Thermo Fisher, USA)) (4µg of M-20X sc-1004X (Santa Cruz, USA)) or the serine 
2 phosphorylated RNA Pol2 complex (pSer2 Pol2) (2µl ab5095 (Abcam, UK)). Rabbit IgG antibodies 
were used as negative control (2µg of sc-2027 (Santa Cruz, USA)). All antibodies were incubated 
overnight at 4°C overnight then incubated with protein A Dynabeads for 4 hours (Sigma-Aldrich, UK). 
To reduce non-specific binding, the DNA-Antibody-Dynabead slurries were sequentially washed with 
150 mM salt buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH8.1), 500 mM salt 
buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH8.1), LiCl buffer (0.25 M LiCl, 1% 
IGEPAL-CA630, 1% deoxycholic acid sodium salt, 1 mM EDTA, 10 mM Tris-HCl pH8.1) and twice in TE 
buffer (10 mM Tris-HCl, 1 mM EDTA) (pH 8.0). Complexes were eluted from the Dynabeads in 1% SDS 
100 mM NaHCO3. NaCl was added (300mM final concentration) and crosslinks reversed overnight at 
65°C in. RNA was removed using RNase treatment (Roche Diagnostics), then protein was digested 
using proteinase K (Ambion, Huntington, UK) after adjusting each solution with EDTA (1 mM final) and 
Tris-HCl (4 mM final). DNA was then extracted using 25:24:1 phenol-chloroform-isoamyl alcohol 
(Sigma, UK) followed by 24:1 chloroform-isoamyl alcohol (Sigma, UK). DNA in the aqueous phase was 
then precipitated overnight at -20°C with the addition of 2.5 VOL 100% ethanol and 20 µg glycogen 




and washed in 70% Ethanol (13,000 rpm, 4°C), then air dried and suspended in 40 µl nuclease free 
water (Ambion, Huntington, UK). 
2.8 Quantitative Real- Time Polymerase Chain Reaction (RT-qPCR) 
Quantitative real-time polymerase chain reaction (RT-qPCR) was used to analyse relative quantities of 
immunoprecipitated DNA in each ChIP sample at specific sites in and near target genes of interest 
(Table 1). Primers were designed using the NCBI Primer Design Tool 
(www.ncbi.nlm.nih.gov/tools/primer-blast/) to selected target regions, as indicated in Table 2. Each 
reaction was performed in a final volume of 25 µl, with 0.5 µl of template DNA, forward and reverse 
primers (0.3 mM final concentration) and Fast SYBR Green (Applied Biosystems, Life Technologies, UK) 
reaction buffer depending on individual assay requirements. Assays were performed on a 
StepOnePlusTM PCR machine (Applied Biosystems, Life Technologies, UK) using 0.1 ml fast optical 96-
well reaction plates (Applied Biosystems, Life Technologies, UK). 
Gene of interest Forward primer sequence Reverse primer sequence 
rn6 Per1 (Intron 16) CCCGGGTCTTCCTCTGGGCA CCTGTCCAACGGCCAAGGCC 
rn6 Per1 Distal GRE -2500bp 
from TSS 
CCAAGGCTGAGTGCATGTC GCGGCCAGCGCACTA 
Table 2. RT-qPCR primer sequences. 
Primer sequences used to test GR and RNA Polymerase II, phospho-Serine 2 binding. 
2.9 Infused circulating corticosterone levels of sequenced samples 
Total blood serum corticosterone levels from trunk blood samples collected at the point of euthanasia 
were used to assess circulating corticosterone dynamics in response to either infusion pattern and/ or 
time point by RIA. Data were assessed using two-way ANOVA followed by Bonferroni’s multiple 
comparisons test adjusted for multiple comparisons. Significant relationships were found in response 
to infusion pattern, time and interaction (p<0.0001). In response to a pulsatile infusion of 
corticosterone at 140min (pulsatile peak) total blood serum corticosterone levels were raised (670 
±41 ng/ml) to 180min (pulsatile nadir) (64 ±17 ng/ml) (p<0.0001). Similarly, 140min and 180min of 
constant corticosterone infusion produced raised levels of circulating corticosterone compared to 
pulsatile 180min (625 ±38 ng/ml and 461 ±21 ng/ml respectively) (p<0.0001). Pulsatile 180min was 
unchanged to VEH controls indicating corticosterone levels clear from total blood serum within 40min 
of corticosterone infusion cessation. There was no difference between pulsatile and constant infusion 
at 140min, however, there was a reduction in corticosterone by 180min of constant infusion (p<0.01). 




in previous studies (data not shown) likely due to the crude method of collection. Trunk blood sample 
volumes are not measured whereas ABS samples are accurately diluted 1:5 in heparinized saline, 
hence ABS data collection is the preferred method modelling circulatory blood total corticosterone 
dynamics. Nevertheless, trunk blood results are appropriate for confirming opposing infusion pattern 
paradigms at the point of euthanasia. These data do confirm total blood serum corticosterone levels 
are increased to VEH in response to 20min and constant corticosterone infusion whereas 40min 
infusion cessation is appropriate to allow levels to return to VEH control. Thus, producing either a 
pulsatile or constant corticosterone pattern within the cardiovascular system albeit with indications 
of fluctuating constant corticosterone infused levels. All bar graphs were plotted using GraphPad 
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Figure 2.3 Circulating total blood serum corticosterone levels of corticosterone or VEH infused 
sequenced ChIP samples at the point of euthanasia by RIA. 
In response to a third 20min infusion of corticosterone at 140min, circulating corticosterone levels 
were significantly higher than VEH control (p<0.0001) before significantly dropping after 40min pump 
cessation (p<0.0001) returning to baseline by 180min. In response to a constant corticosterone 
infusion, levels were raised at both 140 and 180min to VEH control (p<0.0001). There was a slight but 
significant reduction from constantly corticosterone infused levels at 140min to 180min by ~150ng/ml 
(p<0.01) indicating the possibility that corticosterone levels can fluctuate between time points. 
corticosterone levels after 180min constant corticosterone infusion were also reduced to pulsatile 
140min by ~200ng/ml (p<0.05) whereas no difference was detected at 140min constant 
corticosterone infusion. Changes in corticosterone levels are replicable to ABS data previously 
Time dependent changes 
** p-value <0.01 
**** p-value <0.0001 
 
Pattern dependent changes 
$$$$ p-value <0.0001 
 
Changes to either VEH control time point 




described. Total blood serum corticosterone levels were measured by RIA from trunk blood samples 
and analysed by two-way ANOVA with Bonferroni’s test adjusted for multiple comparisons. Results 
after 140min infusion are indicated by white bars whereas 180min by grey bars and data is expressed 
as mean ±s.e.m.. Pulsatile or constant corticosterone infusion time dependent p-value changes are 
indicated by **<0.01 and ****<0.0001, 140min and 180min infusion pattern dependent p-value 
changes are indicated by $$$$<0.0001 and corticosterone infused p-value changes to either VEH 
control infused time point are indicated by &&&&<0.0001. 
2.10 ChIP-Seq quality control and alignment 
ChIP-Seq technical replicates for each corticosterone infusion pattern time point consisted of n=6 
biological ChIP repeats, bolstered to n=10 with technical repeats where required in line with the 3Rs 
guidelines. Biological and technical repeat ChIP samples were selected around the mean based on 
pSer2Pol2 ChIP assay results to two sites associated with the transcriptionally GR regulated clock gene 
Per1 (Figure 3.1 & Figure 4.1). 10 ChIP samples were pooled and concentrated using a UniVapo 
Vacuum concentrator (Transcriptomics facility, UOB) from approximately 400 µl to 35 µl. Samples 
were shipped to the National Institute of Health (NIH), Intramural Sequencing Centre (NISC) 
(Bethesda, MD) on dry ice. Two pooled replicate ChIPs and matched 1% input samples per group 
underwent library preparation (TrueSeq SBS v3-HS kit (illumina, US)) and sequencing using the Illumina 
HiSeq2000 platform (Illumina, USA) to 50b at the National Cancer Institute Advanced Technology 
Center (ATC, Rockville, MD, USA). 
Adapters were removed from the sequenced FASTQ files, filtered for a base quality of 33 and 
sequences of 50b were isolated using Trimmomatic-0.36 (Bolger, Lohse and Usadel, 2014). Trimmed 
FASTQ files were aligned to the rat genome (UCSC rn6 assembly) using bowtie2 (Langmead and 
Salzberg, 2012) and duplicate tags removed using SAMtools 1.3.1 (Li et al., 2009). Subsequent analysis 
was performed using HOMER v4.9 (Heinz et al., 2010).  
Counts were normalised to 10 million tags (makeTagDirectory) to allow for cross sample comparisons 
and visualised using the UCSC genome browser (Kent et al., 2002) (http://genome.ucsc.edu/). 
2.11 Identification of GR ChIP-Seq enriched regions 
Enrichment of GR tags to 1% input control, were identified (findPeaks) using relaxed settings (-F1 -L1 
-P.1 -LP.01 -poisson .1 -style factor). Replicate concordance was assessed using an irreproducible 
discovery rate (IDR v2.0.3) set to 0.01. Overlapping enrichments between replicates were merged 
using mergePeaks (HOMER v4.9.1) and filtered according to the IDR estimated confidence threshold. 




enriched GR locations across conditions (Heinz et al., 2015). Visualisation of tag densities, histograms 
plots and Pearson correlation coefficient calculations were done using EASeq v1.101 (Lerdrup et al., 
2016) 
2.12 Analysis of differential enrichments 
Analyses of pSer2 Pol2 ChIP-Seq enrichment was restricted to genes larger than twice the fragment 
length (>320b) and transcript coding regions limited to 10Kb from the transcriptional start site (TSS) 
(Ensemble release Rnor_6.0.92). Raw input ChIP-Seq tag counts were subtracted from both GR and 
pSer2 Pol enrichment regions (annotatePeaks.pl – HOMER v4.9.1). 
Differential GR and pSer2 Pol2 enrichment fold changes were assessed to VEH and between 
corticosterone infusion time points using getDiffExpression.pl (HOMER v4.9.1) that pipes to DESeq2 
(Heinz et al., 2010; Love, Huber and Anders, 2014). For DESeq2 analysis, tags were normalised to tag 
count within de novo binding regions whilst pSer2 Pol2 tag counts were normalised to total sequenced 
tags across replicates. Differential GR and pSer2 Pol2 enrichments were considered significantly 
different if fold change >1.5-fold and p-value <0.05 adjusted for multiple measurements and FDR 
<0.05. Duplicate variant gene Ensemble accession numbers were filtered for the variant reporting the 
greatest fold change across all conditions and time points. Differential GR enrichments were 
annotated to the closest pSer2 Pol2 differentially regulated TSS. Fold changes were visualised using 
heatmap.2 (RStudio 1.0.153). 
Distances between TSSs and GR binding regions were assessed using annotatePeaks.pl. 
2.13 Motif analysis 
Twice the average fragment length (446b) across the centre of GR binding sites were analysed for both 
de novo and known motifs using findMotifsGenome.pl (HOMER v4.9.1). Repeat sequences were 
masked and optimised for motifs 8, 10 and 12b long. Calculations of motifs per base pair per peaks 
were calculated using de novo motif matrices within HOMER v4.9.1 and histograms indicate location 
of the motif relative to the GR binding site centre and plotted using GraphPad Prism v6.07 for Windows 
(La Jolla California, USA, www.graphpad.com). 
nGRE motif sequences were based on published inverted repeat sequences located in the upstream 
promoter of both the human and mouse thymic stromal lymphopoietin TSS. Motif files were created 
using seq2profile.pl (HOMER v4.9.1) based in the published sequence CTCCN(0-2)GGAGA (Surjit et al., 




2.14 Pathway analysis 
pSer2 Pol2 ChIP-Seq DESeq2 data were analysed via Ingenuity Pathway Analysis ©IPA (Qiagen Inc., 
https://www.qiagenbioinformatics.com/products/igenuity-pathway-analysis). Enrichment of 
pathways were identified from genes with fold changes >1.5-fold and adjusted p-value <0.05 to VEH 
control and z-score predictions assessed from liver tissue and HepG3, hepatoma, hepatocyte cell lines 
as well as mice, rat and human published data. Positive and negative z-scores represent either 
predicted activation or inhibition respectively based upon the fraction of genes known to regulate the 
pathway and degree of fold change and significance. The greater the predictive confidence, the 
greater the z-score. Documentation indicates a z-score >2 (or <-2) represents a significant prediction. 





Chapter 3 Genome wide binding of the glucocorticoid receptor in the 
liver during ultradian or constant corticosterone replacement in 
ADX rats.  
3.1 Background 
The GR is a member of the nuclear receptor superfamily and is a transcription factor with ligand 
dependent activity (‘A Unified Nomenclature System for the Nuclear receptor superfamily’, 1999; 
Bledsoe et al., 2002). The adrenal GC hormone is the endogenous ligand for the GR, which upon 
activation will translocate into the nucleus, where it can bind to GREs, recruit co-factors and regulate 
transcription of target genes (Meijsing et al., 2007; Oakley and Cidlowski, 2013; Ratman et al., 2013).  
Adrenal GC secretion is under HPA axis control and is conserved across mammalian species. 
Synchronised to the photoperiod, the SCN regulates HPA axis activity which in turn induces maximal 
GC secretion from the adrenal glands into the circulatory system prior to the active period and 
gradually decreasing towards the onset of the inactive period. Thus, a ‘circadian’ profile of GC release 
is produced and due to the lipophilic molecular structure, GCs will readily diffuse across into nearly all 
cells within the body. Oscillations in circulating levels have also been recorded in the hippocampus 
and subcutaneous tissue within the rat (Jasper and Engeland, 1991; Droste et al., 2008, 2009; Qian et 
al., 2012). However, studies with more frequent blood sampling have shown an underlying oscillating 
rhythm of GC pulses, termed the ‘ultradian’ profile (Windle, Wood, Shanks, et al., 1998; Lightman and 
Conway-Campbell, 2010). Recent studies have shown that intrinsic delays within both the positive 
feed forward and negative feedback arms of the HPA axis naturally produce oscillations in GC 
secretion, which result in discrete pulses measured in circulating blood serum and some tissues 
(Droste et al., 2008; Walker, Terry and Lightman, 2010; Qian et al., 2012; Walker et al., 2012). It is the 
amplitude of these pulses that is under circadian control.  
The predominant GC in rodents is corticosterone whereas cortisol is predominant in humans. This has 
implications for the ultradian pulse frequency as corticosterone has a shorter half-life than cortisol, at 
8-9min and 62-97min respectively (Weitzman, 1976; Veldhuis et al., 1989; Windle, Wood, Lightman, 
et al., 1998). Presumably, the differing half-lives contribute to a different pulse frequency, as 
corticosterone pulses occur at intervals of 56-60min whereas cortisol pulses in humans occur at 
intervals of 95-180min (Follenius et al., 1987; Veldhuis et al., 1989; Jasper and Engeland, 1991).  
Genome wide ChIP-Seq investigation of GR binding in mouse liver  found ~11,000-13,000 binding sites 




binding sites were tissue specific (Grøntved et al., 2013; Lim et al., 2015). This was associated with a 
change in RNA Pol2 occupancy at ~400 genes, indicating significant transcriptional change, presumably 
in response to Dex induced GR binding (Grøntved et al., 2013).  
Recent studies modelling ultradian corticosterone replacement within the rat, have indicated the GR 
binds at characterised GREs known to regulate the GC target gene Per1, in the liver and hippocampus 
during the rise (maximal at the peak) of a corticosterone pulse before fully dissociating after 
corticosterone clearance from the circulation within 40min (Conway-Campbell et al., 2010, 2012). This 
mock ultradian model of corticosterone replacement, synchronises binding and loss of GR from the 
DNA template, which can be repeated over a series of pulses, inducing pulsatile transcriptional 
occupancy as well as hnRNA production (Stavreva et al., 2009; Conway-Campbell et al., 2010, 2011; 
George et al., 2017). Additionally, a genome wide GR ChIP-Seq study within derived murine mammary 
adenocarcinoma epithelial cells (3617) confirmed ‘slow cycling’ of GR binding, synchronised to the 
ultradian corticosterone rhythm at a large number of GC target sites which was markedly altered by 
constant corticosterone treatment (Stavreva et al., 2015). Regardless of this very compelling data, the 
question remains whether similar genome wide regulation occurs in a more physiologically relevant 
cell type or tissue? 
To date, in vivo investigation of GR binding dynamics during ultradian pulses have only been 
investigated at a small selection of target sites and genomic studies have utilised artificial constructs 
within cell lines. It is therefore not presently known whether ultradian GR recruitment occurs across 
all GR binding sites and if dynamics can be altered by dysregulated GC exposure in vivo, for example 
by constant corticosterone treatment. Within this chapter, I plan to assess genome-wide GR binding 
profiles in the liver in response to infused mock ‘ultradian’ pulses of corticosterone within ADX rats. 
These results will be used to confirm whether the observed in vivo pulsatile recruitment to the Per1 
hypersensitive GRE in hippocampal and liver tissue also occurs across all GR binding sites or whether 
it is selective to a subset. Further, it will be determined whether a constant corticosterone infusion 
disrupts any observed dynamics. 
3.2 Hypothesis 
Within the liver, GR recruitment to the DNA is differentially regulated in a pattern dependent manner 
by a pulsatile or constant corticosterone infusion into the circulation of ADX rats. 
3.3 Aims 




2. Assess, if any, changes in recruitment dynamics in response to a matched constant GC 
infusion. 
3. Characterise GR binding within the liver 
3.4 Method 
All methods of GR ChIP-Seq analysis were done according to general methods discussed within 
Chapter 2. 
Briefly, FASTQ files were assessed and trimmed to desired settings using Trimmomatic-0.36 (Bolger, 
Lohse and Usadel, 2014) and aligned to the Rn6 genome using Bowtie2 (Langmead and Salzberg, 
2012).  
De novo GR binding sites were identified within each replicate against corresponding 1% input controls 
using findPeaks (HOMER v4.9.1) with relaxed settings (Heinz et al., 2010). Confident and concordant 
GR enrichments across replicates were identified using an irreproducible discovery rate (IDR v2.0.3) 
analysis. All concordant binding regions were analysed and any that overlapped were merged into a 
single region by mergePeaks (HOMER v4.9.1) (Heinz et al., 2010). 
Tag density and distribution across GR binding regions were visualised using EASeq (Lerdrup et al., 
2016) and the UCSC genome browser (Kent et al., 2002) (https://genome.ucsc.edu/).  
Enriched sequenced tag densities at every de novo GR binding region in response to a corticosterone 
infused time point was assessed against pooled VEH controls as well as between corticosterone 
infused time points by DESeq2 analysis, normalised to total tag count within identified enriched 
regions. Comparisons were filtered for significance by a fold change >0.585 (log2) and p-value <0.05 
adjusted for multiple measurements. All other results were assigned the value 0. Results were 
visualised using heatmap.2 (RStudio 1.0.153) and eulerr (Larsson et al., 2019). 
Overrepresented palindromic sequences, masked for repeating sequences, were identified within 
446b region at the centre of corticosterone regulated GR binding sites using findMotifsGenome.pl 
(HOMER v4.9.1). Histograms indicate location of the motif relative to the centre.  
All histograms were plotted using HOMER and GraphPad Prism v6.07 for Windows (La Jolla California, 





3.5.1 ChIP assay validation 
ChIP-Seq samples were aligned to the Rn6 genome and normalised to 10million tags for comparison 
and visualisation using the UCSC genome browser. Prior to Seq, single aliquots of each ChIP assay were 
analysed for GR binding at the known GC regulated target, the clock gene Per1. A GRE containing 
region, 2.5kb upstream of the TSS has previously been characterised as a GR binding site in liver as 
well as other cell and tissue types (Stavreva et al., 2009; Conway-Campbell et al., 2011; Reddy et al., 
2012). No GR binding, to our knowledge, has been described for an intragenic region between intron 
16 and 17, therefore, primers were designed for both regions to respectively act as positive and 
negative controls for GR binding in RT-qPCR analysis.  
In response to three hourly 20min pulses of corticosterone infusion, GR binding was assessed at the 
characterised GRE containing GR binding site, at time points corresponding to the peak (140min) and 
nadir (180min) of the third pulse of the pulsatile corticosterone infusion as well as matched constantly 
infused time points. Two-way ANOVA indicated a significant effect of time (p=0.0156), infusion pattern 
(p<0.0001) as well as a significant interaction (p=0.0312) between the two. Post-hoc analysis revealed 
GR binding was significantly increased ~3 fold (p<0.01) at the corticosterone pulse peak (140min) 
compared to nadir (180min) (1.24 ±0.19 and 0.47 ±0.05 respectively) (Figure 3.1 A). GR binding in 
response to the constant corticosterone infusion were raised and not significantly different between 
140min and 180min infused time points (1.33 ±0.15 and 1.20 ±0.14 respectively). Results indicate 
prolonged GR binding, as no change was detected between the pulse peak of the pulsatile 
corticosterone infusion and the matched constant infused time point. There was a significant ~3 fold 
increase (p<0.01) in GR binding after 180min of constantly infused corticosterone compared to pulse 
nadir (180min). GR binding in response to the VEH infusion was unchanged between 140min and 






Figure 3.1 Assessment of positive and negative control sites for GR binding in the clock gene Per1. 
ChIP assay samples used in the next generation sequencing analysis, was evaluated by RT-qPCR to the 
distal GRE 2.5kb upstream of the clock gene Per1 (A). For GR binding at the distal GRE site, significant 
effects of time (p=0.0156), infusion pattern (p<0.0001) and interaction (p=0.0312) were detected by 
two-way ANOVA. (B) At the Intron16 site, a highly significant effect of infusion pattern (p<0.0001) and 
a significant effect of time and interaction (p<0.05) were detected by two-way ANOVA. All significant 
differences detected by Bonferroni multiple comparison post-hoc tests are shown on the graphs, with 




comparisons between cort infused time points (within infusion pattern) represented by * and 
comparisons between infusion pattern (at the same timepoint) represented by $ symbols. Significance 
values are *,$,&p<0.05, **,$$,&&p<0.01, ***,$$$,&&&p<0.001, ****,$$$$,&&&&p<0.0001. All data are 
expressed as mean ± s.e.m. (C) GR binding was visualised using the UCSC genome browser for ChIP-
Seq tag density enrichment in the vicinity of the Per1 gene (maroon track at top of figure) on 
chromosome 10 (chr10:55,682,284-55,700,077). The site of the distal GRE is indicated by the left black 
line and intron16 by the right black line. Increased tag density was observed at the Per1 distal GRE 
site in response to the pulsatile corticosterone infusion (blue) at 140min. Reduced tag density was 
observed at this site in the pulsatile corticosterone infusion (blue) at 180min. With constant 
corticosterone infusion, further increased tag density (red) was observed at the distal Per1 site for 
both time points. No visible peak in tag densities was seen at Per1 intron16 (black line to the right) for 
any of the treatment and/or time conditions. Genome browser shots describe Per1 as transcribed from 
the anti-sense strand (left to right) and intron/ exon coding region (exons represented as maroon 
blocks in gene track) locations from Ensembl rn6 co-ordinates. Data normalised to 10million tags and 
y-axis 0-250. 
Within the negative control, intronic region, two-way ANOVA indicated a significant effect of time 
(p=0.0001) as well as infusion pattern and interaction between the two (p<0.05) (Figure 3.1 B). Post-
hoc analysis revealed GR binding was low at both pulsatile infused time points and not significantly 
changed between 140min and 180min (0.04 ±0.01 and 0.03 ±0.01 respectively). VEH infusion resulted 
in similarly low GR binding levels at both time points (0.05 ±0.01 and 0.04 ±0.01 respectively), 
however, in response to a constant corticosterone infusion, relative levels of GR were increased by 
~1.5-fold (p<0.05) at the 180min compared to the 140min infused time point (0.19 ±0.02 and 0.12 
±0.02 respectively). Both time points were significantly raised to VEH infusion by 2- (p<0.05) and 5-
fold (p<0.0001) respectively. As a significant elevated result at this intronic site was unexpected, UCSC 
genome browser shots plotting normalised tag density of aligned tags across the Per1 coding region 
and primer sites have been included (Figure 3.1 C). At the positive (GRE containing) control primer 
site, relative increases in tag density are consistent with RT-qPCR results. Interestingly, the distal GR 
binding site corresponding to the positive control primer set has been previously described as a 
‘hypersensitive’ site (Reddy et al., 2012). In our data, we can observe a slightly increased tag density 
compared to the site most proximal to the TSS. In contrast, within the negative (intronic region) 
control primer site, no discrete peaks are observable, indicating this region does not contain a GR 




Together these data indicate that pulsatile corticosterone infusion induces GR binding at the pulse 
peak, which is lost to a significant degree within the nadir. In response to constant infusion, GR is 
bound to a similar level as pulsatile peak and remains at this high level after 180min, consistent with 
previous in vivo data (Stavreva et al., 2009; Conway-Campbell et al., 2011). 
3.5.2 GR ChIP-Seq replicate concordance 
Pearson correlation coefficient analysis was used to assess the degree of concordance between 
enriched GR binding regions across replicates at each corticosterone and VEH infused time point. In 
response to a VEH infusion, 118 enrichments were detected with a Pearson correlation coefficient of 
0.797 (Figure 3.2C). The number of enrichments was unexpected, as GR was expected to be unbound 
in ADX rats without corticosterone ligand exposure, however, the Pearson correlation coefficient 
value did indicate positive, strong association and concordance between replicate tag densities and 





Figure 3.2 Replicate concordance and GR enrichment length 
2D histogram of concordant enrichment tag counts (log2) identified by IDR for each replicate in 
response to either pulsatile (A) or constant corticosterone (B) at infusion time points 140min (i) and 
180min (ii) compared to VEH (C). Pearson correlation coefficient analysis indicated acceptable 
concordance between replicates (r>0.88 (A and B) and (r=0.797 (C)). Tag counts were normalised to 




colour coded according to the heatmap. Images produced from EASeq (Lerdrup et al., 2016). (D) 
Histogram plotting the distribution of total GR binding region lengths after overlapping regions 
between infused time points were merged. Minimum =149b, 25th percentile =395b, median =625b, 
75th percentile = 625b, Mean =558b and maximum =1,071b. 
In response to pulsatile corticosterone infusion, 3,210 enrichments were detected at the pulse peak, 
but only 73 were detected at the pulse nadir (Figure 3.2 A). Pearson correlation coefficient values were 
0.92 and 0.98 respectively, indicating a positive, strong association and concordance between 
replicates. In response to 140min constant corticosterone infusion, the total number of identified 
enrichments was reduced in comparison to the pulsatile peak to 1,721. Enrichment numbers were 
slightly increased by 180min of constant corticosterone infusion to 2,428 compared to 140min but still 
less than corticosterone pulse peak. A slight drop in Pearson correlation coefficient values to 0.93 and 
0.886 respectively were recorded but are still considered strong inter-replicate concordance values. 
Taken together, we concluded that both corticosterone and VEH infused time point replicates were 
concordant for use in downstream analysis. Overlapping enrichments between all conditions were 
merged into a single list of 3,980 GR binding sites for comparative analysis (Figure 3.2 D).  
3.5.3 GR tag density and distribution at merged enrichment regions 
Assessment of raw tags at merged enrichments and across conditions indicated increased tag intensity 
in response to the pulsatile corticosterone peak as well as at both constantly infused time points 
(Figure 3.3). All conditions associated with raised circulating corticosterone levels (Figure 2.2). 
Intensity was decreased in response to the pulsatile nadir and either VEH time point; conditions 
associated with negligible circulatory corticosterone levels. Pulsatile nadir tag intensity appeared 





Figure 3.3 GR tag density and distribution between replicates. 
Heatmap plots visualise changes in tag intensity at merged enrichment regions within each replicate 
in response to either pulsatile corticosterone (A), constant corticosterone (B) or VEH (C) at infusion 
time points 140min (i) and 180min (ii). Tag intensity across enrichment regions were increased at 
140min pulsatile corticosterone (Ai) and at both constant time points (Bi and Bii) to a similar degree 




enrichment regions was reduced to similar levels as those observed in the VEH infusion groups (Ci and 
Cii). Tag count intensity normalised to 1million reads per 1kb is plotted on the x-axis, with 5kb in either 
direction from the centre segmented into 200 bins. The degree of intensity is indicated by heatmap, 
according to the 0-5 scale bar. Graphs were plotted using EASeq (Lerdrup et al., 2016). Histograms of 
tag distribution 5kb in either direction of the merged enrichment centre was plotted for pulsatile 
corticosterone (D), constant corticosterone (E) or VEH (F) at infusion times 140min (i) and 180min (ii). 
In all cases, peaks in tag density were observed at enrichment centre and reduced to negligible levels 
within 1kb in either direction. High tag density levels were seen in pulsatile corticosterone at 140min 
(Di) compared to low tag density levels seen in pulsatile corticosterone at 180min (Dii) and VEH at 
both time points (Fi and Fii). Relatively high tag density levels were seen in constant corticosterone at 
both time points (Ei) (Eii). Raw tags (log2) were segmented in 5b bins, spanning 5kb in each direction 
from enrichment centre. Graphs were plotted using GraphPad Prism 6 for windows. 
Histograms of raw tag distribution was maximal at the centre of de novo enrichment regions and was 
reduced in either direction to negligible counts within 1kb, indicating GR binding locations were most 
likely at the enrichment centre. Pulsatile corticosterone peak appeared to induce a much larger tag 
pile up than pulsatile corticosterone nadir (Figure 3.3 D) and VEH (Figure 3.3 F). Taken together, these 
data indicated high levels of GR recruitment at the pulse peak were rapidly returned to baseline within 
the pulse nadir. In response to constant corticosterone infusion, tag intensity was concentrated at the 
centre of enrichments and increased to similar levels as pulsatile peak, across both time points (Figure 
3.3 E).  
3.5.4 Filtering significant induction of GR binding 
Prior to any differential analysis, VEH replicates were analysed across binding regions by DESeq2 and 
no significant differences in tag density were detected (data not shown); therefore, both VEH 
replicates were pooled.  
To investigate statistically relevant corticosterone induced changes in GR binding relative to VEH 
control, normalised raw tag counts within binding regions were analysed by DESeq2. In response to a 
pulsatile corticosterone peak, increases in enrichment were detected at 2,658 sites, whilst a loss was 
detected at 50 sites (Figure 3.4 A). No enrichments passed significance thresholds at the pulsatile nadir 
(Figure 3.4 B). In response to a constant corticosterone infusion, gains in GR enrichment were detected 
at 1,263 and 1,953 sites after 140min (Figure 3.4 C) and 180min (Figure 3.4 D) infused time points as 
well as losses at 10 and 9 sites respectively. Results corroborate previous intensity and histogram data 




140 and 180min time points during constant infusion. Interestingly, pulsatile peak was more effective 
at inducing changes in enrichment than either constant corticosterone time point.  
 
Figure 3.4 Differential GR binding over time during pulsatile or constant corticosterone infusion. 
Volcano plots showing GR enrichment fold change (log10) and adjusted p-value (-log10) relative to 




corticosterone infusion at 140min (C) and 180min (D). Enrichments were filtered for significant 
changes (red). (E) Table reports the number of differentially regulated enrichments and direction of 
change by either pulsatile or constant corticosterone infusion at 140 and 180min time points, relative 
to VEH control. Tags were normalised to total tags within enrichments and fold change >0.176 or <-
0.176 (log10) (latitudinal lines), p-value adjusted for multiple comparisons <0.05 (-log10) (longitudinal 
lines) and FDR<0.05 are plotted in red on volcano plots. All other values are plotted in black. 
3.5.5 GR binding dynamics during pulsatile versus constant corticosterone infusion 
Fold changes in enrichment at identified GR binding sites were hierarchically clustered and visualised 
within the heatmap (Figure 3.5 A). The corticosterone pulse peak induced significant GR binding at 
68% of identified sites; 24% of which were unique to this condition as shown in the Venn diagram 
(Figure 3.5 B). Constant corticosterone infusion induced GR binding at a reduced 32% of total sites, at 
the 140min time point matched to pulse peak. However, in contrast to the pulsatile nadir’s lack of 
detectable GR binding; constant corticosterone infusion was able to induce GR binding at 49% of total 





Figure 3.5 GR binding sites inducible by infused patterned corticosterone time points (PCTs). 
(A) Visualisation of differentially regulated GR binding in response to either pulsatile or constant 
corticosterone infusion at times 140 and 180min. GR binding regions were hierarchically clustered 




to VEH. Heatmap colour intensity indicates degree of fold change (log2) as shown within the legend 
(top left) as well as distribution (white trace). Tags were normalised to total tag count within merged 
GR binding regions and filtered for log2 fold changes >0.585 or <-0.585, p-value adjusted for multiple 
comparisons <0.05 and FDR <0.05 to VEH control are plotted. All other enrichments were given the 
value 0. (B) VENN diagram of the number of differentially enriched regions to VEH control in response 
to 140min pulsatile and 140min and 180min constant corticosterone infused time points were plotted 
using eulerr (Larsson et al., 2019). (C) Little difference in distribution of corticosterone infused time 
points induced fold change to VEH control was found. Percentiles of corticosterone infused time points 
fold change to VEH control min: -6.9, -7.3, -7.3; 25th percentile: 5.0, 5.0, 4.7; Median: 5.7, 5.8, 5.3; 75th 
percentile: 6.5, 6.6, 6.0; max: 9.8, 9.6, 9.3 values for 140min pulsatile, 140min and 180min constant 
corticosterone infusions respectively. Y-axis is split into -10 to 4 and 4 to 10 segments of fold change 
(log2). 
GR binding events that were unique to either 140min or 180min constant corticosterone infusion 
occurred at just 2% and 5% of sites respectively, and a further 1.6% were present at both time points 
(Figure 3.5 B). However, 33.4% of GR binding events were common to pulsatile peak and both constant 
corticosterone time points, indicating GR binding across all corticosterone regulated sites are distinctly 
phasic in response to pulsatile corticosterone infusion. Of those, a proportion that are bound at the 
corticosterone pulse peak are subjected to prolonged GR occupancy over time during constant 
corticosterone infusion, however, pulsatile infusion at the corticosterone pulse peak was further 
capable of inducing a large proportion of GR binding not induced by any other corticosterone infused 
time point. Only a relatively small subset of GR binding events was constant corticosterone responsive 
only. The data further shows a greater number of GR binding events in common after the 180min 
constant infused time point (16%) than the 140min infused time point (2%) when compared to the 
corticosterone pulse peak, potentially suggesting constant corticosterone infusion induced gradual 
increases in GR binding over time. 
As previously mentioned, a number of sites reported significantly reduced tag densities relative to VEH 
control. Despite these representing just 1.4% of total binding sites, these reductions were unexpected 
as we hypothesised we would only detect GR binding in response to corticosterone ligand exposure. 
Interrogation of these sites indicated the majority were decreased by pulsatile peak only (1%), which 
returned to VEH levels in the nadir, indicating a transient loss of GR from these sites. Only a relatively 
small number of sites were reduced in response to 140min and 180min constant corticosterone 




site reported a loss in enrichment in response to each corticosterone infused time point (0.03%). No 
increases were recorded at these sites to VEH control.  
During the analysis of these sites, I referred to the concordant GR binding region results (findPeaks 
and IDR analysis of Seq replicates) for each corticosterone and VEH infused time point. 38 of the 56 
sites reduced by corticosterone infusion were within VEH identified GR binding regions, 19 of which 
were specifically found in response to the VEH infusion and no corticosterone infused time point. Plus, 
the presence of a GRE within 15 of the 56 sites suggest at least a proportion could be classical GR 
binding events, despite the opposing effect of corticosterone exposure. Additionally, analysis of tag 
density distribution around the centre of these enrichments (Figure 3.6) reports a distinct loss of tag 
density in response to 140min pulsatile corticosterone infusion compared to all other conditions. 
Indicating not only transient corticosterone exposure is more effective at reducing tag density within 
these regions, but also any loss is recoverable within the pulse nadir after 180min. Taken together and 
as pearson correlation coefficient analysis and differential analysis by DESeq2 indicated non-
significant change between VEH 140min and 180min samples, we have no reason to disregard these 
sites as false positives. 
 
Figure 3.6 Tag density histograms of regions that report a CORT dependent loss in enrichment 
compared to VEH control. 
Histograms of tag distribution 5kb in either direction of the merged enrichment centre was plotted for 
pulsatile corticosterone (A), constant corticosterone (B) or VEH (C) at infusion times 140min (i) and 
180min (ii). In all cases, peaks in tag density were observed at enrichment centre and reduced to 




pulsatile corticosterone after 180min and either constant infusion (Bi) (Bii) compared to VEH control 
(C). 140min of pulsatile corticosterone did report a marked loss in tag density compared to all other 
conditions (Ai). Raw tags (log2) were segmented in 5b bins, spanning 5kb in each direction from 
enrichment centre. Graphs were plotted using GraphPad Prism 6 for windows. 
3.5.6 Time and pattern dependent GR binding 
As a pulsatile corticosterone infusion induced a cohort of GR binding events that was not significantly 
detected in response to a constant corticosterone infusion compared to VEH control, it raises the 
question about time and pattern corticosterone dependent differences. Therefore, out of the 3,098 
GR binding regions that were induced to VEH control, time dependent and pattern dependent changes 
in GR enrichment were investigated between corticosterone infused time points. 
In response to a pulsatile infusion, 50.7% of corticosterone inducible sites were regulated in a time 
dependent manner, with 50.6% significantly increased by the pulse peak compared to nadir (Figure 
3.7). In contrast, constant infusion only significantly regulated 2.5% of GR binding events in a time 





Figure 3.7 Time and pattern dependent changes in GR binding. 
Heatmap visualisation of regions that were differentially enriched to VEH in response to corticosterone 
infused time point, compared to another corticosterone infused time point. Enrichments of log2 fold 
change were hierarchically clustered according to amplitude of change in response to each pattern of 
infusion. First four rows indicate fold change in GR enrichment in response to a corticosterone infused 
time point against VEH. Time dependent rows represent 140min vs 180min pulsatile and then constant 
corticosterone infusion. Subsequent double rows represent 140min and then 180min corticosterone 
infusion time points vs either constant infused time points.  Heatmap colour intensity indicates degree 
of fold change as shown within the legend (top right) as well as distribution (white trace). Tags were 
normalised to total tag count within merged enriched regions and fold change >0.585 or <-0.585, p-
value adjusted for multiple comparisons <0.05 and FDR<0.05 are plotted. All other enrichments were 





Changes in enrichment, between inducible sites in response to pulsatile peak and to either 140min 
and 180min constant corticosterone infusion time points, were 7.1% and 6.1% respectively. Of these, 
6.2% and 5.5% respectively were enriched by the pulsatile peak, indicating pulsatile peak was more 
effective at inducing GR binding at these sites. Comparison of the corticosterone pulse nadir to either 
constant infused time point reported 16.7% and 30.0% of sites were down regulated at the pulse nadir. 
Indicating an increase in GR binding across both constantly infused time points to nadir. 
3.5.7 Motif analysis of GR binding sites 
GR binding to the genome can be directed to regulatory elements such as the GRE, however, the GR 
can also interact with binding sites via response elements complimentary to other nuclear factors 
either as a composite or tethered co-factor complex (Biddie et al., 2011; Grøntved et al., 2013; 
Uhlenhaut et al., 2013). De novo motif analysis of sequences from GR binding regions differentially 
enriched to VEH control (total of 3,098 regions) indicated the most significant over-represented 
homologous palindromic sequence resembled a GRE motif (0.92 score) within 39% of target 
sequences (Table 3). However, out of the top 6 most significant motifs (including the GRE), the most 
abundant resembled a forkhead box M1 (FOXM1) transcription factor motif (0.92 score) within 43% 
of binding regions. Despite this increased abundance, significance of representation in target 
sequences compared to background was greatly reduced from a p-value of 1e-458 to 1e-95. 
Sequences resembling known GR co-regulator motifs for HNF4α (0.94 score) and AR half-sites (0.76 
score) were identified in 31.2% and 24.1% of target sequences respectively (Biddie et al., 2011; Biddie, 
Conway-campbell and Lightman, 2012; Grøntved et al., 2013). Other over-represented motifs 
resembled CCAAT enhancer binding protein alpha (CEBPA) (0.95 score) and the STAT5 (0.97 score) 





Table 3 De novo motif analysis of GR binding site sequences. 
Table reports, identification and occurrence of the top 6 significantly over-represented sequences 
within corticosterone regulated GR binding sites to VEH control and restricted to an area of 233b in 
either direction of the centre. P-value represents significance of identified sequence to randomly 
selected background DNA sequences, score is equal to the degree of similarity between de novo and 
known motif sequence, motif base logo indicates specific probability (s.p.) of base occurrence. 
All top 6 significant de novo motifs identified were located around the centre of the GR binding region, 
but GREs reported a greater occurrence to other motifs (Figure 3.8 A). Motif occurrence within regions 
that were induced by pulsatile peak or 140min and 180min constant corticosterone infusion time 
points were investigated separately but little difference was observed. Finally, the occurrence of 
potentially co-operative motif sequences within GRE containing regions were investigated. HNF4α and 
STAT5 were the most abundant (55.8% and 54.2% respectively) followed closely by AR half-sites 
(45.4%); representing the most likely to co-operatively direct GR binding to the genome (Figure 3.8 B). 





Figure 3.8 Distribution and percentage of discovered motifs within PCT induced GR binding regions. 
3,098 corticosterone regulated binding regions differentially enriched to VEH control in response to 
either pulsatile or constant corticosterone infusion after 140min and 180min were assessed identified 
de novo motif sequences. (A)(B) Of the top six significant motifs identified, GREs reported the largest 
occurrence at the centre of the enriched regions. CEBPA, HNF4A, STAT5, FOXM1 and AR half-sites were 
similarly distributed but occurrence was distinctly reduced. (C) GR binding regions were separated into 
the 2,708 regions differentially enriched by 140min pulsatile, 1,273 by 140min constant and 1,962 by 
180min constant and motif occurrence was plotted. De novo motif distribution of GREs was the most 
prevalent at 66-74% of enrichments whilst FOXM1 was the least at 14-20%. However, there was no 
distinct difference in percentages of motif occurrence in response to a PCT corticosterone over 
another. (D) The presence of one of the top six most significant motifs was investigated within GRE 
containing enrichments significantly changed to VEH control by patterned corticosterone infusion. 
HNF4A was present in the most GRE containing sequences (56%) with STAT5 (54%) and AR half-sites 




19% of GRE containing enrichments. De novo motifs were identified within 233b regions in either 
direction from the centre. 
GR enrichment regions were further investigated for the presence of a nGRE like sequence as 
identified by Surjit et al., within the upstream promoter of both the human and mouse thymic stromal 
lymphopoietin TSS. Of the 3,098 sites, just 2.23% regions contained a nGRE related sequence. Only 
two of these regions (0.06%) report a loss in GR enrichment. 
3.6 Discussion 
GR binding at the peak of the third corticosterone infused pulse via the jugular vein, can induce phasic 
genome-wide GR binding within the ADX rat liver. Interestingly, this phenomenon is not limited to a 
subset of sites but is observed at the vast majority (~90%) of our identified corticosterone regulated 
GR binding sites. Furthermore, bound GR was reported to dissociate from all binding sites, returning 
to baseline levels within the corticosterone pulse nadir. This phasic GR recruitment was not an intrinsic 
rhythm, as a constant corticosterone infusion prolonged GR binding. 26% of sites were induced by 
both corticosterone pulse peak and the matched constant corticosterone infused time point (140min) 
whilst only a small subset were induced by constant corticosterone infusion uniquely (~12%). Despite 
these subsets, GR binding was more effectively induced by the corticosterone pulse peak than any 
single corticosterone infused time point. Together, these observations indicate GR recruitment to the 
genome is highly corticosterone regulated and synchronised to hourly ultradian pulses.  
As several sites were significantly bound at the pulse peak and no other corticosterone infused time 
point, it was theorised these could represent dose dependent sites. To match the dose delivered 
between 20min pulsatile and 60min constant corticosterone infusion, a lower rate was used which 
induced a slightly lowered circulating corticosterone measurement (Figure 2.3). Levels at the infused 
pulsatile peak (140min) were at 387ng/ml ±34, whereas constant infused corticosterone levels were 
reduced at 261ng/ml ±51 at the matched time point. Therefore, this subset of GR bound at the 
pulsatile peak only are either exclusively responsive to a transient, rising phase of corticosterone or 
are dose dependent.  
Phasic GR binding in response to the pulsatile corticosterone infusion was dysregulated and prolonged 
by a constant corticosterone infusion. Additionally, there were indications that not all sites were 
maximally bound, as an increase in the number of significant binding sites over time was detected by 
180min of infusion compared to 140min. Perhaps indicating constant corticosterone infusion was 




This study discovered 3,980 binding sites after merging all de novo GR binding regions from all 
corticosterone and VEH infused time points, however, I present evidence that several sites were either 
not significantly regulated by corticosterone infusion or significantly decreased relative to VEH control. 
Whether the non-inducible sites are bound but at very low levels or represent corticosterone ligand-
independent/ VEH induced GR binding is unclear without further investigation. Disregarding potential 
Seq error, extra-adrenal de novo GC synthesis has been identified within intestine, skin, brain and 
lymphoid tissue within rodents and therefore presents the possibility of GR activation irrespective of 
adrenalectomy and independent of the corticosterone infusion (Vacchio, Papadopoulos and Ashwell, 
1994; Taves, Gomez-Sanchez and Soma, 2011). There is further evidence GR can be bound by a 
selection of co-factors in the absence of ligand. Perhaps this is an example of an active co-factor with 
the capacity to recruit GR to the genome within a tethered model of binding (Pfaff and Fletterick, 
2010; Monczor et al., 2019). This model may require a loss of corticosterone induced inhibition. 
Furthermore, non-liganded GR translocation into the nucleus has also been reported in response to 
shear stress, abnormal pH and temperatures as well as activation by tumour necrosis factor (TNF)α in 
COS-1 cells, but I would consider inductions by these methods unlikely and does not adequately 
explain the return of GR enrichment within the nadir of the pulsatile corticosterone infusion to VEH 
control levels (Ji, Jing and Diamond, 2003; Verhoog et al., 2011; Scheschowitsch, Leite and Assreuy, 
2017). If we consider these are real binding events via mechanisms not controlled for, I would 
hypothesise losses in response to corticosterone are most likely due to chromatin re-organisation in 
response to the large number of infused corticosterone induced GR binding across the genome. 
Multiple studies have shown GR binding induces re-organisation of the chromatin architecture and we 
could be observing increasing chromatin density and ‘closing’ at these sites, dis-placing GR (John et 
al., 2008, 2011; Grøntved et al., 2013; Kuznetsova et al., 2015; Stavreva et al., 2015). This would 
explain why there is a recovery of enrichment within the nadir of the pulsatile corticosterone infused 
time point (180min). However, this would require much further study, primarily to validate extra-
adrenal stimulation of GR that is bound to these select sites and chromatin accessibility. 
The number of potential GR binding sites discovered is lower than two recent studies within the mouse 
liver (11,000 sites). The first study used Dex treatment and a GR enrichment detection algorithm called 
hotspot to identify bound sites, so discrepancy may be due to differences in affinity, half-life and 
efficacy between ligands as well as the analysis algorithm (Baek, Sung and Hager, 2012; Grøntved et 
al., 2013). The second study however, was conducted within adrenally intact mice and found 
endogenous circadian variation in corticosterone induced GR binding at 11,000 sites despite similar 
HOMER detection methods. It should be noted, peak identification thresholds would be highly varied 




between replicates (Heinz et al., 2010; Lim et al., 2015). I hypothesise discrepancies between GR 
enrichment detection and stringency limits for statistically significant GR binding regions reduced the 
number of GR binding sites to other studies, however, determination of this hypothesis could only be 
completed upon parallel analysis of published sequenced data. As I have successfully identified robust 
changes in GR binding, I would conclude analysis parameters were suited to my research question. 
Similar to other published studies, characterisation of inducible GR binding sites revealed not only GRE 
motifs, but other known co-factor motifs (Grøntved et al., 2013; Lim et al., 2015; Sasse et al., 2015; 
Hemmer et al., 2019). Comparison between studies of the relative occurrence of motifs within GR 
binding regions is difficult to ascertain from the literature due to tissue and cell type variability as well 
as analytical methods applied which were not always detailed within methods. For example, the two 
previously mentioned mouse liver studies quote a wide range of GRE occurrence within GR binding 
sites of 60% to 12% respectively, therefore, rates found within this study are difficult to compare 
(Grøntved et al., 2013; Lim et al., 2015). However, select motifs were identified that have been 
previously characterised as co-regulators for the GR and within the liver, such as STAT5, HNF4α and 
CEBP. Potentially indicating co-operatively directed binding and regulation of GRs (Hemmer et al., 
2019). Examination of the GR enrichment sequences revealed little evidence of nGRE like sequences 
(2.21% of regions). It has been postulated that as binding affinity to these sequences is reduced 
compared to classic GRE sequences and could therefore make detection of these sites difficult. 
Additionally, nGRE sequences have been characterised within macrophages and as GC action is to 
suppress the immune response, perhaps nGRE sequences are mostly relevant within that cell type 
(Uhlenhaut et al., 2013; Jubb et al., 2016). Either way, this study did not find robust evidence for a 
potential interaction between the GR and nGRE like sequences. 
In conclusion, this data presents strong, robust evidence that GR binding to the genome within an 
ultradian modelled system occurs in a phasic manner, synchronised to the rising and falling levels of 
corticosterone. GR dynamics can be dysregulated in a prolonged manner by alteration to a constant 
level of corticosterone, without changing the overall dose delivered and identifies potential GR co-
regulator motifs characterised within other in vivo liver studies. These data highlight the distinct 




Chapter 4 Genome-wide RNA polymerase II binding in liver during 




Transcription of genes is dependent on the recruitment of the pre-Pol complex to regions typically 
30b upstream of the TSS. This is usually directed by interactions between the TATA box binding protein 
subunit of the pre-Pol complex and TATA sequences within the DNA as well as other initiator 
sequences (Wang, Carey and Gralla, 1992; Wiley, Kraus and Mertz, 1992; Ponjavic et al., 2006; 
Sandelin et al., 2007). The pre-Pol complex can then direct RNA Pol2 to the core promoter as well as 
unwind DNA via the action of the helicase XPB subunit of the pre-Pol complex prior to active synthesis 
of complimentary RNA sequences (Wang, Carey and Gralla, 1992; Tirode et al., 1999; Hahn, 2004; 
Luse, 2014).   
The phosphorylation of specific carboxy-terminal domain residues within RNA Pol2 directs multiple 
RNA processing factors. Investigation of residues within this region has identified phosphorylation of 
Ser5 (pSer5 Pol2) by Kin28 occurs predominantly within the promoter region and has been observed 
to be lost within the elongation phase of RNA synthesis (~200 nucleotides) (Corden, 1990; Hengartner 
et al., 1998; Komarnitsky, Cho and Buratowski, 2000). In contrast, phosphorylation of Ser2 by the 
carboxy terminal domain kinase 1 (Cdk1) occurs during the transcriptional elongation phase. 
Enrichment of Ser2 phosphorylated RNA Pol2 complexes (pSer2 Pol2) has been reported to increase 
towards the 3’ end of actively transcribing genes and may be important for the efficient recruitment 
of 3’ polyadenylation factors (Cho et al., 2001). Importantly, phosphorylation of Ser2 is associated with 
actively transcribing RNA Pol2 and hence provides a valuable tool for assessing dynamic changes in 
transcription (Ahn, Kim and Buratowski, 2004).   
Using specific antibodies for either phosphorylated state, occupation of RNA Pol2 at intragenic regions 
can be investigated using ChIP-Seq methods. However, identification of de novo enrichment and 
downstream analysis of RNA Pol2 occupied regions presents systematic challenges different to 
transcription factor ChIP-Seq analysis. These challenges include the identification of de novo enriched 
sites relative to background controls, such as with the GR analysis presented in Chapter 3. Algorithms 
of this type have been primarily designed to identify localised, discrete regions of enrichment as 
transcription  factors (such as GR) bind to short specific recognition elements  (Harmanci, Rozowsky 




chromatin fragments of ~300b and identified enriched regions were on average 558b long, with the 
centre of the enrichment indicating the site of GR binding. Similar discrete enriched regions are not 
commonly observed in RNA Pol2 ChIP-Seq analysis. Creation of disulphide bonds during the fixing of 
tissue will trap RNA Pol2 as it actively transcribes through the gene’s coding region, which will vary 
greatly. Further, RNA Pol2 sequenced tag heights are highly stochastic throughout broad enrichment 
regions as low mappability and repeat regions do not sequence as efficiently as others. This is a 
problem for de novo identification as algorithms will identify sharp rises or falls within broad enriched 
regions as multiple single regions, fragmenting enrichments throughout the broad coding region (Lee 
and Schatz, 2012; Harmanci, Rozowsky and Gerstein, 2014). Some commonly used ChIP-Seq analysis 
tools have been designed to identify these RNA Pol2 enrichment traces via local thresholding and 
merging of proximal enriched region methods, but very few algorithms (such as PeakSeq and MUSIC) 
have been designed to specifically analyse RNA Pol2 enrichments (Y. Zhang et al., 2008; Rozowsky et 
al., 2009; Heinz et al., 2010; Harmanci, Rozowsky and Gerstein, 2014). Alternatively, Bayesian change-
point, local island identification and clustering methods have also been used, but ChIP-Seq analysis of 
RNA Pol2 occupancy still appears to be a relatively underexplored area of research with regard to 
analytical provision (Zang et al., 2009; Xing et al., 2012; Harmanci, Rozowsky and Gerstein, 2014). 
Despite analytical challenges, pSer2 Pol2 ChIP-Seq can provide important information regarding 
dynamics of active transcription, particularly relevant to my work investigating rhythmic GR regulation 
over a short time frame. Previous in vivo studies investigating the effects of corticosterone induced, 
transient binding of GR to the regulatory GRE of the Per1 gene in rat liver identified slightly delayed 
but phasic increases and decreases in nascent Per1 transcript production synchronised to 
corticosterone/ GR binding dynamics that are repeatable. Similar RNA Pol2 phasic dynamics of 
occupancy were reported within promoters across the MMTV array within 3134 cells in a series of 
photobleaching experiments. These changes were validated as transcriptionally active by phasic 
hnRNA production at a selection of targets. As previously shown with the GR, these phasic dynamics 
are not intrinsic and are dysregulated in a sustained manner by the sGC Dex, which has a prolonged 
half-life compared to corticosterone (Stavreva et al., 2009). Cell line work was expanded upon using 
ChIP-Seq analysis of pSer5 Pol2 occupation within MMTV array promoters, reporting similar phasic 
increases that were dysregulated and remained increased throughout corticosterone exposure over 
60min at majority of targets, as opposed to a 20min increase that returned to basal levels within 40min 
hormone washout (Stavreva et al., 2015). 
In Chapter 3, I demonstrated that genome-wide GR recruitment to corticosterone regulated binding 




these findings by investigating whether resultant RNA Pol2 occupancy can be synchronised in a 
similarly dynamic manner by pulsatile or constant corticosterone replacement in ADX rats. As 
phosphorylation of the Ser2 residue wtihin the RNA Pol2 complex is associated with the actively 
transcribing RNA Pol2 complex, the liver pSer2 Pol2 ChIP-Seq data will be considered a proxy for active 
transcription, so that we can begin to understand how the ultradian profile, as well as its 
dysregulation, regulates overall transcriptional output within this key metabolic target organ.  
4.2 Aims 
1. Identify pSer2 Pol2 recruitment at the peak and nadir of a mock ‘ultradian’ GC infused pulse. 
2. Assess, if there are any changes in recruitment dynamics in response to a dose-matched 
constant GC infusion. 
4.3 Method 
All methods of pSer2 Pol2 ChIP-Seq analysis were done according to general methods discussed within 
Chapter 2. 
Briefly, ChIP-Seq quality control and alignment to the genome was handled in parallel to GR Seq 
analysis up to identification of de novo enrichment regions. Instead, regions for differential 
enrichment analysis were defined from gene transcript loci according to the Ensembl Rn6 genome 
build (Rnor_6.0.92). To mitigate bias of micro RNAs and increased significance to extremely long 
genes, coding regions smaller than twice the fragment length (<320b) were removed and regions were 
restricted to a maximum length of 10kb from the TSS. 
Histograms of pSer2 Pol2 tag density were restricted to transcripts that exceeded a 10kb coding region 
length and transcribed from the sense strand. This was to keep the TSS aligned across transcript 
regions for accurate assessment. 
All other analysis settings were used in parallel to GR ChIP-Seq methods except for the DESeq2 
analysis. Raw tag counts were normalised to total sequenced tags within replicates to avoid individual 
tags being counted multiple times and biasing the normalisation. These were based on methods 
previously published (Stavreva et al., 2015). 
4.4 Results 
4.4.1 ChIP assay validation 
ChIP-Seq samples were aligned to the Rn6 genome and normalised to 10million tags for comparison 




analysed for pSer2 Pol2 enrichment at the known GR regulated target, the clock gene Per1. Previously, 
increased Per1 nascent RNA production has been reported to be synchronised to rising and falling 
corticosterone levels, which were also associated to phasic GR binding at the distal upstream 
regulatory GRE (-2.5kb from the Per1 TSS) (Stavreva et al., 2009; Conway-Campbell et al., 2011). RT-
qPCR primers designed as positive and negative controls for GR binding at the distal GRE and an 
intronic region (intron 16) (Table 2) respectively, can still be used to investigate pSer2 Pol2 occupancy, 
but as recruitment is expected to be confined to within coding regions, the intronic primer becomes 
the positive control whilst the intergenic, distal GRE site would act as negative control.  
Two-way ANOVA of pSer2 Pol2 occupation of the distal GRE site indicated an effect of infusion pattern 
(p<0.0001) but not of time (p=0.2137), however, there was a significant interaction between the two 
(p=0018). Post-hoc analysis revealed a lack of significant differences in pSer2 Pol2 enrichment 
between the corticosterone pulse peak (140min) and nadir (180min) (0.72 ±0.11 and 0.41 ±0.04 
respectively) and neither was significantly different to VEH control at either 140min or 180min infused 
time points (0.46 ±0.06 and 0.48 ±0.06 respectively) (Figure 4.1 A). Therefore, no change in pSer2 Pol2 
was detected at the upstream GRE in response to a pulsatile infusion of corticosterone as expected at 
an intergenic site. In contrast, constant infusion resulted in ~2-3 fold increase in pSer2 Pol2 enrichment 
at both 140min and 180min infused time points, which were significantly raised to matched VEH and 
pulsatile corticosterone infused time points (p<0.001 and p<0.0001 respectively). Despite two-way 
ANOVA indicating a significant interaction between time and infusion pattern, there was no significant 
difference of RNA Pol2 enrichment detected between 140min and 180min of constantly infused 
corticosterone (1.36 ±0.16 and 1.46 ±0.1 respectively). I postulate the observed significant interaction 
is due to the non-significant trend of increased pSer2 Pol2 enrichment at the corticosterone pulse 





Figure 4.1 Assessment of positive and negative control sites for pSer2 Pol2 occupation to the clock 
gene Per1. 
ChIP assay samples used in the Seq analysis, were evaluated by RT-qPCR to the distal GRE 2.5kb 
upstream of the clock gene Per1 (A). For pSer2 Pol2 enrichment at the Per1 distal GRE, two-way 
ANOVA detected a highly significant effect of corticosterone infusion pattern (p<0.0001), no 
significant effect of time (p=0.2137), but a significant interaction between pattern and time (p=0018). 




(p<0.0001), no significant effect of time (p=0.3786), but a highly significant interaction between 
pattern and time (p<0.0001). All significant differences detected by Bonferroni multiple comparison 
post-tests are shown on the graphs, with comparisons between corticosterone infused and VEH 
infused controls represented by & symbols, comparisons between time points (within infusion pattern)  
represented by * symbols, and comparisons between infusion pattern (at the same timepoint) 
represented by $ symbols. All data are expressed as mean ± s.e.m. Significance values are *,$,&p<0.05, 
**,$$,&&p<0.01, ***,$$$,&&&p<0.001, ****,$$$$,&&&&p<0.0001. (C) GR binding was visualised 
using the UCSC genome browser ChIP-Seq tag density pile around the Per1 coding region (bottom 
maroon track) of chromosome 10 (chr10:55,682,284-55,700,077). The site of the distal GRE is 
indicated by the left black line and intron16 by the right black line. Replicate traces for pulsatile (blue) 
and constant (red) corticosterone infusions at 140 and 180min timepoints are shown relative to VEH 
(black). pSer2-RNA Pol2 tag density traces within the Per1 gene coding region boundaries (highlighted 
in yellow), as well as upstream and downstream of Per1 coding region boundaries, are visibly and 
markedly increased for all corticosterone infused groups relative to VEH infused control groups. 
Chromosome number as well as 10kb scale bar indicated at the top of the genome browser shots. At 
the bottom, Per1 is transcribed from the anti-sense strand (left to right) and intron/ exon coding region 
(exon within intragenic maroon blocks) locations from Ensembl rn6 co-ordinates are indicated. Data 
normalised to 10million tags and y-axis 0-40. 
Despite the surprising enrichment of pSer2 Pol2 at the intergenic GRE region, occupancy was 
investigated at the Per1 intronic site. Two-way ANOVA analysis indicated an effect of infusion pattern 
(p<0.0001) but not of time (p=0.3786), however, a significant interaction was observed (p<0.0001). 
Post hoc analysis reported no significant difference in enrichment between pulsatile peak and nadir 
(0.65 ±0.07 and 0.44 ±0.04 respectively) or to either VEH infused time point (0.52 ±0.04 and 0.56 ±0.09 
respectively). However, in response to a constant corticosterone infusion, both 140min and 180min 
time points (1.4 ±0.12 and 1.72 ±0.1 respectively) were significantly raised ~2-3 fold to time-matched 
pulsatile corticosterone and VEH time points (p<0.0001) (Figure 4.1 B). 
Interestingly, the pattern of pSer2 Pol2 binding in response to the different patterned corticosterone 
and VEH infused time points were relatively similar at both sites (inter- and intra-genic). Therefore, as 
before, we visually inspected tag enrichment of aligned Seq data using the UCSC genome browser over 
a 17.5kb region encompassing and extending the Per1 TSS and 3’ end (Kent et al., 2002). Subjective 
assessment of the distal primer site indicated tag density in response to pulsatile corticosterone 
infusion was marginally increased at the pulse peak compared to both corticosterone nadir and VEH 




compared to all other patterned corticosterone and VEH infused time points, whilst the tag density 
after 180min of constantly infused corticosterone was more similar to the corticosterone pulse peak. 
Subjective assessment of the UCSC tracks at the position of the intron 16 RT-qPCR primer site, 
indicated overall pSer2 Pol2 tag density levels were much lower compared to the distal GRE site across 
all conditions. However, when comparing between conditions at both distal and intronic sites, pSer2 
Pol2 tag densities appeared to differ in a pattern dependent manner. pSer2 Pol2 occupancy was 
increased at the corticosterone pulse peak (140min) compared to nadir (180min), whereas constant 
corticosterone infusion induced increased occupancy across both matched time points. All of which 
were raised to VEH control. Due to the relatively low tag density at the intronic site however, the 
results observed in the RT-qPCR data are not easily visible. Furthermore, tag density was not 
concentrated within the Per1 coding boundaries and extended well past the distal GRE site. Together, 
data visualised within the UCSC genome browser tracks strongly indicated regions chosen for our 
initial RT-qPCR assessment were far from ideally positioned and not suitable as positive or negative 
controls.  
Unlike at Per1, it was discovered upon further inspection of UCSC genome browser tracks other known 
GC regulated targets such as serine dehydratase (Sds), Tat and Gilz; increased pSer2 Pol2 tag density 
was distributed in a defined manner to distal intergenic region densities, that was within annotated 
gene boundaries (TSS and 3’ boundaries of intergenic regions) but often extended marginally into the 
5’ and 3’ UTR of select genes (Figure 4.2) (Jantzen et al., 1987; Su and Pitot, 1992; Wang et al., 2004).  
In response to a pulsatile corticosterone infusion, pSer2 Pol2 occupancy across all three targets 
appeared to be increased at the pulse peak compared to the nadir, indicating phasic, corticosterone 
synchronised increases in occupation. Interestingly, there was negligible pSer2 Pol2 tag density in the 
VEH control for Sds and Gilz (Figure 4.2). In contrast however, pSer2 Pol2 density within the Tat coding 
region, was visibly enriched in response to the VEH controls. In response to a pulsatile corticosterone 
infusion, tag density was marginally increased at the pulse peak (140min), but noticeably reduced by 
the nadir (180min) in comparison to the raised VEH levels. Indicating modulation of basal active 





Figure 4.2 pSer2 Pol2 tag distribution over intragenic GC regulated gene regions. 
Sequenced tag distribution of pSer2 Pol2 replicates in response to pulsatile, constant and VEH infusion 
after 140min and 180min was visualised using the UCSC genome browser within and extending from 
the TSS and 3’ end of the GC regulated targets Sds (41,613,118-41,635,053b), Tat (41,665,082-
41,696,752b) and Gilz (111,880,663-111,891,528b). pSer2 Pol2 occupation in response to a 
corticosterone or VEH infused time point is concentrated throughout intragenic, coded regions 
(highlighted in yellow) but often extends from the 5’ and 3’ end before returning to negligible levels. 
Chromosome number as well as 10kb and 5kb scale bars are indicated at the top of the genome 
browser shots. At the bottom, Sds, Tat and Gilz intron/ exon coding region (exon within intragenic 
maroon blocks) locations from Ensembl rn6 co-ordinates are indicated as transcribed from the anti-
sense strand (right to left). Data normalised to 10million tags and y-axis 0-230.  
In response to a constant corticosterone infusion, pSer2 Pol2 tag density (whilst variable between 
genes) was similar across time points for each respective gene. Compared to corticosterone pulse 
peak, constant corticosterone induced half maximal pSer2 Pol2 tag density within the Sds intragenic 
region, whilst Tat and Gilz were similar at both 140min and 180min infused time points. Subjectively, 
results indicate pSer2 Pol2 occupancy can be altered by infused corticosterone patterns in a similarly 
dynamic manner to previously reported GR recruitment profiles (Chapter 3). Additionally, I present 
evidence of gene specific basal pSer2 Pol2 occupancy in response to a VEH infusion at GC regulated 




In reference to the suitability of the Per1 primer sites tested as positive and negative controls for pSer2 
Pol2 occupancy; inspection of UCSC track data indicated Per1 was far less ideal for measuring robust 
changes in pSer2 Pol2 occupancy compared to other candidate GC target genes. Intra- and intergenic 
associated tag density levels were very low as the track height was set to 40 for Per1 whereas other 
GC targets were set to 140. Further, tag densities were not defined between coded (intragenic) and 
non-coded (intergenic) regions in comparison to Sds, Tat and Gilz coded regions (Figure 4.1 & Figure 
4.2). Therefore, Per1 primers were determined to be ineffective negative and positive controls for 
pSer2 Pol2 analysis, but as visual inspection of other GC regulated targets indicated patterned 
corticosterone effects, analysis was continued across the genome. 
4.4.2 pSer2 Pol2 tag enrichment detection 
De novo pSer2 Pol2 enrichments were analysed using MUSIC, MACS2, findPeaks and hotspot peak 
detection algorithms. Upon visual inspection, enrichment regions were highly fragmented throughout 
key GC targets due to highly stochastic pSer2 Pol2 broad enrichments, as observed within Figure 4.1 
and Figure 4.2 (Lee and Schatz, 2012; Harmanci, Rozowsky and Gerstein, 2014). Efforts to merge 
regions within suitable distances proved inaccurate, particularly when genes were within proximity to 
other 3’ and 5’ ends of other genes. Therefore, based on previously published methods (Stavreva et 
al., 2015), pSer2 Pol2 enrichment was assessed according to the 5’ and 3’ loci of coding regions from 
the Ensembl genome (Rn6). Transcript regions smaller than twice the sequenced fragment lengths 
were removed, and regions restricted to 10kb if the transcript was longer.  
4.4.3 pSer2 Pol2 assessment of replicate concordance 
Pearson correlation coefficient analysis was applied for each corticosterone and VEH infused time 
point between replicates. Results indicated a large positive strength of association and concordance 
between replicates (>0.91) (Figure 4.3). As the same number of regions were investigated for all 
replicates, no indications can be made of the ability of a patterned corticosterone or VEH infused time 
point to induce changes between conditions. It should be noted, that even though strong Pearson 
correlation coefficients were reported, as a large number of regions are plotted (>11,000), non-
concordant data could potentially be masked. Furthermore, gene variant genomic co-ordinates 





Figure 4.3 Characterisation of replicate concordance and distribution of intragenic region lengths 
investigated. 
2D histograms of concordant enrichment tag counts (log2) within Ensembl coded regions for each 
replicate in response to either pulsatile (A) or constant corticosterone infusion (B) as well as VEH 
infusion (C) at 140min (i) and 180min (ii) time points. Pearson correlation coefficient analysis indicated 




were >620b and limited to 10kb were plotted within the histogram. Percentiles reported minimum = 
321b, 25th percentile = 2,606b, median =10kb, 75th percentile = 10kb, Mean = 10kb and maximum 
=10kb. 2D histograms plot normalised tag counts to 10 million with x and y-axis segmented into 100 
bins; the number of regions within each bin is indicated by legend (log2) and images were produced by 
EASeq (Lerdrup et al., 2016). 
4.4.4 pSer2 Pol2 tag density and distribution from the TSS 
To investigate concordance between replicates, distribution of pSer2 Pol2 sequenced normalised tags 
upstream and downstream of the TSS was assessed for all conditions within 10kb coded regions on 
the sense strand only, to avoid plot misalignment of the TSS within histograms. Across corticosterone 
and VEH infused time points, maximal enrichment of sequenced tags was concentrated at +62.5b 
±5.39 s.e.m. from the TSS (Figure 4.4 C). As the histograms plot a well-defined peak for all conditions 
and replicates, data indicates an increased concentration of pSer2 Pol2 occupancy just downstream 
of the TSS that is maximally variable between infused time points. Greatest tag density was observed 
in response to a constant corticosterone infusion replicates at 140min (4.6 and 3.99 per base per 
region) (Figure 4.2 Bi). The second highest density was observed in a single replicate (2.63 per base 
per region) in response to a pulsatile corticosterone infusion at the pulse peak (140min). In 
comparison, reduced tag density was reported for the second replicate (1.99 per base per region) 







Figure 4.4 Replicate pSer2 Pol2 tag density, distribution and distance from TSS. 
Tag density regions were restricted to coding regions equal to 10kb from the TSS and coded on the 
sense strand. Within these regions, tag density changes within -5kb to +15kb of the TSS were plotted 
using histograms in overlay for each replicate within each group, including pulsatile (A) or constant 
corticosterone (B) infusion at times 140min (i) and 180min (ii), compared to VEH (C) infusion. Some 
variation in replicate tag density and distribution can be visualised in these plots. Therefore, area 
under the curve analysis (D) was used to assess overall changes within a 0-10kb region from the TSS. 




direction from TSS. Tag density area under the curve was analysed between 0kb to +10kb of the TSS 
(un-shaded area). 
Despite the reported changes in maximal tag densities, differential analysis assesses tag enrichment 
across the coding region to a maximal length of 10kb. Therefore, area under the curve analysis was 
used to assess potential changes in enrichment. Similarly to maximal tag density values, the greatest 
value was recorded in response to the constant corticosterone infusion after 140min (11.09 and 10.4 
per base per region x kb) which was reduced by 180min (10.19 and 9.49 per base per region x kb) 
(Figure 4.2 D). Area under the curve results were lowered in response to both VEH (9.14 and 8.54 per 
base per region x kb respectively) and pulsatile corticosterone at 140min (8.92 and 8.50 per base per 
region x kb) and 180min (9.10 and 8.73 per base per region x kb) infused time points. Observations of 
median values indicated a slight drop in response to the corticosterone pulse peak (140min) compared 
to nadir (180min) and VEH infusions, however, as standard deviation between these conditions 
overlapped it is difficult to interpret.  
Together these data indicate that tag density between replicates is similar when viewed across a 10kb 
intragenic region and patterned corticosterone infusion induces alterations in pSer2 Pol2 occupancy. 
4.4.5 Detection of significant changes in pSer2 Pol2 occupancy 
Prior to any differential analysis, VEH replicates were analysed at all binding regions by DESeq2 and 
no significant differences in tag density were detected (data not shown); therefore, both VEH 
replicates were pooled.  
To investigate statistically relevant corticosterone induced changes in pSer2 Pol2 occupancy relative 
to VEH control, total Seq raw tag counts were normalised and analysed by DESeq2. In response to a 
pulsatile corticosterone infusion, a greater number of regions were differentially enriched (relative to 
VEH control) for pSer2 Pol2 at the corticosterone pulse peak (140min) (Figure 4.5 A) compared to nadir 
(180min) (Figure 4.5 B). Volcano plots also indicate data is skewed towards a loss in pSer2 Pol2 







Figure 4.5 Modulation of pSer2 Pol2 enrichment over time during pulsatile and constant 
corticosterone infusion. 
Volcano plots showing changes in pSer2 Pol2 tag density enrichment in response to pulsatile 
corticosterone infusion at 140min (corticosterone pulse peak) (A) and at 180min (corticosterone pulse 
nadir) (B) as well as constant corticosterone infusion at 140min (C) and 180min (D) relative to VEH 
control. Significant changes in pSer2 Pol2 enrichment within Ensembl gene coding regions (indicated 
in red) appeared to be greatest in the 140min pulsatile corticosterone dataset, which was markedly 
reduced in the 180min pulsatile corticosterone dataset. In contrast, number of intragenic regions 
subject to significant increased or decreased pSer2 Pol2 enrichment appeared similar between the 
constantly infused corticosterone time points. X-axis indicates fold change (log10) and y-axis the 
adjusted p-value (-log10). 
Subjectively, little difference was observed between the distribution of significantly gained or lost 




(Figure 4.5 C & D). However, the number of differentially regulated regions appeared to be reduced 
to corticosterone pulse peak but raised to corticosterone pulse nadir with no obvious bias for gain or 
loss in pSer2 Pol2 occupancy. Interestingly, there were no indications within the DESeq2 analysis of 
the increased enrichment of pSer2 Pol2 as indicated by area under the curve data in response to 
constant corticosterone infusion (Figure 4.4 D). This is potentially due to the normalisation of tag 
counts within the DESeq2 analysis. 
With reference to the clock gene Per1 investigated previously (Figure 4.1), DESeq2 analysis indicated 
pSer2 Pol2 enrichment fold change to VEH was greater than significance thresholds. However, the 
adjusted p-value did not pass significance threshold (>0.433) (data not shown). Therefore, this study 
could not identify Per1 as a robust, pattered corticosterone regulated targets within these conditions 
and analyses. 
4.4.6 pSer Pol2 dynamics 
Out of all the regions assessed for pSer2 Pol2 occupancy, only individual Ensembl gene IDs were kept 
for downstream analysis. If multiple variants were significantly regulated, the region with the greatest 
cumulative fold change across corticosterone infused time points was kept. All other regions, as well 
as those with no significant change in response to corticosterone were removed, revealing a total of 
715 targets as differentially regulated by a single, or combination of, pattern corticosterone infused 
time points relative to VEH control (Figure 4.6). 
In response to a pulsatile corticosterone infusion, 77.3% of regulated targets had significantly altered 
pSer2 Pol2 enrichment relative to VEH control at the pulse peak (140min) which was reduced to 14.5% 
of targets within the nadir (Figure 4.6). At both time points, the majority (~3/4) had significantly 
decreased pSer2 Pol2 enrichment relative to VEH control, albeit more distinct within the pulse peak 
due to the greater number of targets. Taken together, these data report that pulsatile corticosterone 
infusion can induce phasic and synchronised changes in pSer2 Pol2 occupation to the corticosterone 
pulse peak over specific genes, which was decreased across the majority of targets. Indicating a down-





Figure 4.6 Pattern and time dependent pSer2 Pol2 genome-wide enrichment profiles. 
pSer2 Pol2 tags were normalised to total sequenced tag counts and significant fold changes were 
defined as >0.585 or <-0.585 (log2), p-value <0.05 adjusted for multiple comparisons and FDR <0.05 
from VEH control. Only the greatest cumulative fold change for each target variant is reported. (A) 
pSer2 Pol2 differentially increased (cyan) or decreased (yellow) enriched regions were hierarchically 
clustered according to amplitude of fold changes in response to each corticosterone infused time 
point. Heatmap colour intensity indicates degree of fold change (log2) as shown within the legend 




intragenic regions and direction of change by either pulsatile or constant corticosterone infusion at 
140 and 180min time points, relative to VEH control.  
In response to 140min constantly infused corticosterone, 35.5% of regions were differentially enriched 
for pSer2 Pol2, which was marginally increased to 38.9% by 180min. Contrary to the pulsatile 
corticosterone infusion effects, ~3/4 regions reported an increased pSer2 Pol2 enrichment at the 
constantly infused matched time point for the corticosterone pulse peak. This was not observed by 
180min, as the total numbers of increased or decreased pSer2 Pol2 enriched regions were equally 
distributed.  
Together, these data indicate that changes in pSer2 Pol2 occupation are synchronised to oscillating 
corticosterone levels and GR binding dynamics at select genes, which became dysregulated by a 
constant corticosterone infusion. I also report distinct differences in transcription between infusion 
patterns, as pulsatile corticosterone exposure was more effective at inducing repression whilst 
constant exposure was more effective at activation of the majority of genes.  
To investigate if an individual corticosterone infused time points was more effective at inducing 
changes in pSer2 Pol2 occupation, the distribution of fold change values to VEH was investigated. Time 
dependent differences in response to either infusion pattern indicated percentile values for both 
increased and decreased pSer2 Pol2 occupancy fold change were greatest at 140min compared to 
180min (Figure 4.7 B).  
Comparison of percentile values between infusion patterns, indicated losses of pSer2 Pol2 occupancy 
were greater at the pulsatile infused, corticosterone peak (140min) compared to either constant 
infused time point, whilst 140min of constantly infused corticosterone induced the greater percentiles 
of fold change for increases in pSer2 Pol2 enrichment. Corticosterone pulse peak nadir (180min) had 
the lowest percentile fold change values whether pSer2 Pol2 enrichment was increased or lost. These 





Figure 4.7 Distribution of fold change and p-values of differentially regulated pSer2 Pol2 intragenic 
regions. 
(A) Distribution of fold increased or decreased (log2) pSer2 Pol2 enrichments within intragenic regions 
against respective p-values were plotted in response to corticosterone infused time points compared 
to VEH control were plotted. (B) Table reports quartile values for both gained and lost fold changes 
(log2) in pSer2 Pol2 enrichment in response to each corticosterone infused time point compared to 
VEH control. pSer2 Pol2 tags were normalised to total sequenced tag counts and regions filtered for 
enrichment fold changes >0.585 or <-0.585 (log2), p-value adjusted for multiple comparisons <0.05 





I then investigated if a combination of patterned corticosterone infused time points were more 
effective at inducing changes in pSer2 Pol2 enrichment within the same region. Results report pulsatile 
corticosterone infusion at the pulse peak (140min) alone induced changes in the greatest number of 
regions, regulating 297 genes (Figure 4.8). Interestingly, the next largest number of regions were 
regulated by a combination of 140min constant only (77 genes), 140min pulsatile/ 180min constant 
(73 genes) or 140min pulsatile/ 140min constant/ 180min constant (78 genes) corticosterone infused 
time points. This is of interest as these combinations of time points are all associated with raised 
circulating corticosterone levels (Figure 2.3), unlike the negligible levels found at the pulsatile 
corticosterone nadir (180min). Indicating a strong correlation between raised circulating 
corticosterone and inducible changes in pSer2 Pol2 occupation.  
 
Figure 4.8 Number of pSer2 Pol2 enrichments regulated by one or multiple corticosterone pattern 
infused time points. 
Intragenic regions were investigated for differential pSer2 Pol2 recruitment, relative to VEH control in 
response to corticosterone infused time points. Regions were plotted according to whether a single or 
multiple corticosterone infused time point induced changes in occupancy. The largest number of 
regions were regulated by 140min pulsatile corticosterone infusion only, equal to 42% of all 
corticosterone regulated regions. The next largest number of regions were regulated by three 
combinations of infused time points including 140min constant only; 140min pulsatile and 180min 
constant; 140min pulsatile, 140min constant and 180min constant corticosterone infusion. These 
represent 10-11% of all regulated regions. Total number of differentially pSer2 Pol2 recruited 




bar chart. Regulation by a single or multiple infused time point are indicated by spots and the number 
directly above the corresponding bar. Colour indicates whether a single (black), two (blue), three 
(green) or all four (red) infused time points differentially regulated pSer2 Pol2 occupancy and were 
plotted using UpSetR (Conway, Lex and Gehlenborg, 2017). 
4.4.7 Time and pattern dependent pSer2 Pol2 occupancy 
Similar to previous GR ChIP-Seq data; because pulsatile corticosterone infusion regulated distinct 
changes in pSer2 Pol2 occupation compared to constantly infused time points, time and pattern 
dependent differences between corticosterone infused time points were investigated by DESeq2 
analysis.  
Significant time dependent changes in pSer2 Pol2 enrichment between the corticosterone pulse peak 
(140min) and nadir (180min) were detected at 60.3% of regions in response to a pulsatile 
corticosterone infusion. This indicated robust phasic changes in pSer2 Pol2 occupation (Figure 4.9), 
whereas, in response to the constant corticosterone infusion, just 14.1% of sites were regulated. 
Significant pattern dependent changes were investigated at either corticosterone pulse peak (140min) 
or at the nadir (180min) and compared to both 140min and 180min of constantly infused 
corticosterone. Pulsatile corticosterone peak induced differential enrichment in 35.4% of regions, 
which was reduced to 15.9% in response to 140min and 180min constant infused time points 
respectively. Though a greater degree of differentially regulated regions were identified between the 
pulsatile corticosterone nadir and either constant infused time point (27.7% and 24.1% respectively).  
Together, these data indicate robust, pulsatile corticosterone synchronised pSer2 Pol2 occupancy 
across majority of targets is dysregulated by a constant corticosterone infusion. Interestingly, unlike 
the GR ChIP-Seq data, there were more differences at 140min between the pulsatile and constant 
infusions compared to the 180min time point, most likely due to the differing induction of inhibition 
and activation by the two patterns. Particularly as these data indicate pro-longed corticosterone 






Figure 4.9 Changes in pSer2 Pol2 occupancy in response to infused patterned corticosterone time 
points. 
Heatmap visualisation of pSer2 Pol2 differentially increased (cyan) or decreased (yellow) enriched 
regions, hierarchically clustered according to amplitude of fold change in response to each 
corticosterone infused time point. First four rows indicate fold change (log2) of corticosterone infused 
time points against VEH control. The next two rows below represent time dependent changes between 
140min and 180min infused time points in response to a pulsatile infusion and then constant 
corticosterone infusion. The next double rows represent comparisons between 140min pulsatile 
corticosterone (corticosterone pulse peak) against either 140min or 180min constant corticosterone 
infusion. Final two rows represent comparisons between 180min pulsatile corticosterone infusion 
(corticosterone pulse nadir) against either 140min or 180min constant corticosterone infusions. pSer2 




changes >0.585 or <-0.585 (log2), p-value <0.05 adjusted for multiple comparisons and FDR<0.05 from 
VEH control. Only the greatest cumulative fold change for each target variant is reported and heatmap 
colour intensity indicates degree of fold change (log2) as shown within the legend (top right) as well 
as distribution (white trace). 
4.5 Discussion 
pSer2 Pol2 enrichment at a selection of targets within the liver has been shown to be highly phasic in 
response to mock ultradian pulses of corticosterone delivered into the circulation of adrenalectomised 
rats that are not intrinsic as dynamics become dysregulated in response to a matched constant 
corticosterone infusion. I therefore report, within the liver, both GR binding as well as transcriptional 
regulation is robustly regulated by ultradian corticosterone rhythms and their dysregulation. 
Interestingly, as with the induction of GR binding, pulsatile corticosterone infusion at the pulse peak 
(140min) induced changes in pSer2 Pol2 occupancy within the greatest number of genes compared to 
any other corticosterone infused time point (Figure 4.6). Further, I report differing patterns of 
corticosterone exposure can opposingly regulate transcriptional activity, as 3 out of 4 differentially 
occupied targets reported a loss in pSer2 Pol2, indicating a repressive transcriptional effect of pulsatile 
corticosterone exposure. In contrast at the matched time point, constantly infused corticosterone 
induced the opposite in 36% of regulated genes, indicating overall activation of transcription. 
Together, these data report differing patterns of corticosterone exposure in vivo can have distinct and 
opposing transcriptional effects within the rat liver. A previous study using Affymetrix GeneChip 
technology to investigate the effects of a 20min 100nM corticosterone administration on nerve 
growth factor-differentiated catecholaminergic (PC12) cells, found only downregulation of GC 
responsive genes within 1hr of hormone washout. However, upregulation of genes was detected 
much later, at the 3hr timepoint (Morsink et al., 2006). This is of interest as my data within the liver 
indicates a predominantly repressive action of transcription in response to acute, transient pulsatile 
corticosterone exposure, but the opposite during constant corticosterone infusion. In contrast, a 
genome-wide study assessing dynamic pSer5 Pol2 occupancy in mouse mammary adenocarcinoma 
cells at the MMTV array found mostly increased pSer5 Pol2 occupancy in response to both a pulsatile 
and constant corticosterone treatment over 60min (Stavreva et al., 2015). Despite similarities in 
analyses methods, there were a number of different conditions; my study investigated occupancy of 
a different phosphorylated forms of RNA Pol2, within an animal model as opposed to an artificial 
construct in a cell line, doses of corticosterone cannot be matched and widely differing time points 
were analysed. Therefore, it is difficult to compare confidently across studies other than identifying 




issues arise when comparing other in vivo studies. hnRNA microarray or pSer5 Pol2 ChIP-Seq analysis 
within adrenalectomised rat livers revealed the proportion of differentially occupied targets was 
slightly skewed towards repression after 6hr or 1hr Dex administration respectively (Duma et al., 2010; 
Grøntved et al., 2013). But, ligand specific effects cannot be discounted, as the study by Stavreva., et 
al. (2015) reported an overall loss of RNA Pol2 occupation in response to Dex, whereas corticosterone 
was inducive (Stavreva et al., 2015). Together, these data highlight the importance of physiologically 
relevant, dynamic GC regulation of transcription as well as the need for clarity in response to differing 
patterns as well as differing GC ligands within in vivo models of biological systems as opposed to 
artificial constructs such as the MMTV array. 
An intriguing density profile was discovered during the interrogation of pSer2 Pol2 tag distribution 
around the TSS. Distinct peaks of sequenced tags were consistently observed in response to any 
corticosterone and VEH infused time point between +35b to +95b from the TSS, which could be 
explained by a promoter-pausing model of transcription (Figure 4.4). When RNA Pol2 is recruited to 
the promoter, the complex can enter the elongation phase and transcribe a short nucleotide sequence 
(about +50b in mammalian cells) prior to pausing that would explain the increased presence of RNA 
Pol2 at these positions (Rougvie and Lis, 1988; Muse et al., 2007; Core, Waterfall and Lis, 2008; Rahl 
et al., 2010; Quinodoz et al., 2014). This process has been described as a common bimodal model of 
RNA Pol2 occupancy and transcription within mammalian cells and to my knowledge has not been 
shown in this manner (Quinodoz et al., 2014).  
The investigation undertaken within this study identified a total of 715 corticosterone regulated genes 
to VEH control (Figure 4.6). This is a relatively restricted list when one considers the total number of 
genes within the Ensembl rat genome build. Whether my analysis was too restrictive or suitably 
sensitive is difficult to ascertain as a major analytical limitation was the inability to perform de novo 
identification of enriched pSer2 Pol2 occupied regions to background. Detection algorithms 
fragmented broad stochastic enrichments that were not overcome via merging of proximal regions 
and was further compounded when analysis was compared across corticosterone and VEH infused 
time points for differential analyses. Therefore, a method was adopted from a previous study by 
defining enrichment regions according to Ensembl (Rn6) genomic co-ordinates (Stavreva et al., 2015). 
It became evident during preliminary analysis via inspection of UCSC genome browser tag density 
traces, that broad pSer2 Pol2 enrichments often did not align with gene intragenic boundaries loci, 
indicating that despite improvements from previous iterations and genomic loci within the rat genome 
may not be suitably accurate for this type of analyses. As loci are based heavily on RNA Seq data, 




error as indicated by UCSC genome browser screenshots for the GC regulated, metabolic target Lpin1 
(Figure 4.10). If the analysis included only the larger single variant, the pSer2 Pol2 enriched region 
would be missed. Due to the same tags being counted within overlapping variants and genes, tag bias 
could also be introduced to the DESeq2 normalisation. Despite these limitations, the method used in 
this study was the best available for this data, and whilst not perfect, still reports a selection of 
statistically significant and robust changes in hepatic transcriptional regulation in vivo. Satisfying the 
original aims of the research. 
 
Figure 4.10 Lpin1 variants and regions of pSer2 Pol2 enrichment analysed.  
Sequenced tag distribution of pSer2 Pol2 replicates in response to pulsatile, constant and VEH infusion 
after 140min and 180min were visualised using the UCSC genome browser within and extending from 
the TSS and 3’ end of the GC regulated target Lpin1 (41,788,031-41,881,762b). pSer2 Pol2 occupation 
in response to a corticosterone or VEH infusion is concentrated within the intragenic region for both 




variants and upstream of the smaller variant TSS. Raised levels continue throughout and marginally 
past the 3’ end of both. As analysis was restricted to a 10kb region from the TSS (highlighted in yellow) 
only analysis of the smaller variant would incorporate increased pSer2 Pol2 tag densities. 
Chromosome number as well as 10kb and 5kb scale bars are indicated at the top of the genome 
browser shots. At the bottom, Lpin1 intron/ exon coding region (exon within intragenic maroon blocks) 
locations from Ensembl rn6 co-ordinates are indicated as transcribed from the anti-sense strand (right 
to left). Data normalised to 10million tags and y-axis 0-230. 
In conclusion, this data presents evidence that pSer2 Pol2 recruitment to a select number of targets 
within an ultradian corticosterone replacement paradigm, is strongly phasic and synchronised to rising 
and falling levels of circulating corticosterone and reported dynamic GR binding to the genome. My 
data further demonstrates that this well-regulated relationship, between ligand, receptor and 
transcriptional outcome becomes dysregulated when exposed to constant circulating corticosterone, 
with marked changes in transcriptional regulation of GC target genes over time. My study highlights 
the potential impact patterned GC exposure can have on a metabolically important target organ such 




Chapter 5 Characterisation of GR binding and RNA Pol2 occupancy 
and pathway analysis reveals potential mechanisms for 
glucocorticoid dysregulated pathologies. 
5.1 Background 
Over the last two chapters, I have shown how ultradian GC pulses induce synchronised phasic GR and 
RNA Pol2 binding across the genome. I report in Chapter 3 that of the 2,708 binding events induced 
at the pulse peak, all were lost by the nadir in response to a pulsatile corticosterone infusion. Similarly, 
but to a reduced degree, I report in Chapter 4 that 553 genes were differentially occupied at the pulse 
peak compared to just 104 by the nadir. Together, these data indicate robust phasic and synchronised 
GR binding as well as transcriptional activity by oscillating corticosterone levels. Interestingly, 
decreased pSer2 Pol2 occupancy was detected within majority of targets at both corticosterone peak 
and nadir; indicating an overall inhibitory effect. These dynamics were dysregulated in response to a 
dose-matched constant corticosterone infusion, as GR binding was no longer phasic but maintained 
in a prolonged manner and pSer2 Pol2 occupancy was also dysregulated. Interestingly, at the matched 
time point for the corticosterone pulse peak, constant infusion increased occupancy for majority of 
genes. Indicating phasic dynamics are distinctly dysregulated by a constant corticosterone infusion 
and I provide evidence that these changes induce opposing transcriptional activity. 
Within this chapter I will investigate the relationship between pattern dependent GR binding and 
pSer2 Pol2 occupancy of GC target genes. Additionally, using pSer2 Pol2 occupancy as a proxy for 
active transcription, I will perform functional pathway analysis on my identified set of pattern 
dependent differentially regulated genes to determine whether changes are associated with 
metabolic dysfunction or other disease states.  
5.2 Aims  
1) Investigate potential GR mediated effects of pSer2 Pol2 occupancy in response to patterned 
corticosterone. 
2) Assess pSer2 Pol2 changes in occupancy and their potential effect on metabolic downstream 
pathways. 
3) Identify key pathways and gene targets that are differentially regulated by different 
corticosterone patterned infusion, with particular focus on any that may play a significant role 





All methods of analysis were done according to general methods discussed within Chapter 2. 
Briefly, GR binding sites as well as pSer2 Pol2 occupied sites that were significantly regulated by 
patterned corticosterone infusion compared to VEH control were used in all downstream analysis.  
Genic locations of GR binding sites as well as measurements of distance from the closest GR binding 
site to the TSS of a differentially pSer2 Pol2 occupied target was calculated using annotatePeaks.pl 
(HOMER) (Heinz et al., 2010) and graphs plotted using Prism v6.07 for Windows (La Jolla California, 
USA, www.graphpad.com). 
For the pathway analysis pSer2 Pol2 ChIP-Seq DESeq2 data were analysed via the Ingenuity Pathway 
Analysis package ©IPA (Qiagen Inc., https://www.qiagenbioinformatics.com/products/igenuity-
pathway-analysis). Enrichment of pathways were identified from genes with fold changes >1.5-fold 
and adjusted p-value <0.05 to VEH control and z-score predictions assessed from liver tissue and 
HepG3, hepatoma, hepatocyte cell lines as well as mice, rat and human published data. Positive and 
negative z-scores represent either predicted activation or inhibition respectively based upon the 
fraction of genes known to regulate the particular pathway and degree of fold change and significance. 
The greater the predictive confidence, the greater the z-score. Documentation indicates a z-score >2 
(or <-2) represents a significant prediction. Z-score values were plotted using GraphPad Prism v6.07 
for Windows (La Jolla California, USA, www.graphpad.com). 
5.4 Results 
5.4.1 Induction of GR binding and pSer2 Pol2 occupancy at select GC regulated targets 
The GC regulated targets Per1, Sds, Tat, Gilz and Lpin1 were visually inspected using the UCSC genome 
browser for validation of GR binding sites characterised within the literature as well as pSer2 Pol2 
regulated occupation. Previously, two transcriptionally regulating GR binding sites have been 
characterised for Per1, the distal of which has been described as ‘hypersensitive’ for GR binding (Reddy 
et al., 2012). In the human alveolar epithelial A549 cell line, these two GRE containing GR binding sites 
were identified 2kb upstream of the TSS and within intron1 according to the hg19 version of the 
human genome (Reddy et al., 2012). Whereas in the mouse liver, as well different cell lines, both GR 
binding sites were found within the first intron. It should be noted, the genome build was not indicated 
by the authors, making it difficult to make comparisons between studies (Grøntved et al., 2013). 
Together this data indicates two GR binding sites are conserved between mammals and genome 




were discovered at ~-1kb (chr10:55,685,633-55,686,257) and ~-3.5kb (chr10:55,683,482-55,684,046) 
upstream of the TSS. Both were bound by GR at all corticosterone infused time points except for pulse 
nadir (180min) (Figure 5.1). However, investigation of significant corticosterone time and pattern 
dependent changes were highly variable. Despite a 16- and 17-fold induction of GR binding at the ~-
1kb and ~-3.5kb binding sites respectively in response to the corticosterone pulse peak (140min), no 
significant changes were reported to the corticosterone pulse nadir (180min) at either site. Indeed, 
no significant changes were detected between corticosterone infused time points at the proximal ~-
1kb site. Whereas, at the distal site (which has been described as ‘hypersensitive’), a 2.4-fold time 
dependent induction of GR binding was detected at 140min compared to 180min constant 
corticosterone infusion. This increase at 140min of constantly infused corticosterone was also 
significantly pattern dependent, as GR binding was ~2.2 fold increased at the corticosterone pulse 
peak (140min). No significant changes in pSer2 Pol2 occupation of Per1, however, were detected in 
response to any infused corticosterone condition compared to VEH control. 
 
Figure 5.1 GR and pSer2 Pol2 sequenced tag density profiles across the glucocorticoid target genes 
Per1, Sds, Tat, Gilz and Lpin1. 
GR and pSer2 Pol2 replicate sequenced tag density distribution in response to pulsatile, constant and 
VEH infusion at 140min and 180min was visualised using the UCSC genome browser. Chromosomal 




41,673,112-41,694,225b (Tat), chrX 111,881427-111,892,292b (Gilz) and chr6 41,790,201-
41,895,649b (Lpin1). Regions analysed for differential pSer2 Pol2 enrichment are indicated in yellow. 
Any GR and pSer2 Pol2 tag densities reported as significantly differentially enriched to VEH control are 
indicated by black boxes underneath replicate traces. Chromosome number as well as 10kb and 50kb 
scale bars are indicated at the top of the genome browser shots. At the left, Per1 is transcribed from 
the sense strand (left to right) whereas Sds, Tat, Gilz and Lpin1 are transcribed from the antisense 
strand (right to left) as indicated by arrows. The reference gene track at base of figure shows the 
Intron/ exon coding region (exon within intragenic maroon blocks) locations from Ensembl rn6 co-
ordinates . Data normalised to 10million tags and y-axis was set to-0-250.  
Sds is an enzyme that catalyses the deamination of serine (derived from glycine) into pyruvate within 
gluconeogenesis and changes in mRNA levels have been shown to be robustly circadian and Dex 
responsive (Sandoval and Sols, 1974; Kanamoto, Su and Pitot, 1991; Ogawa and Ansai, 1995; Ogawa 
et al., 2002). Two synergistic GR binding sites were identified in rat hepatoma (7AD-7) cells >5kb 
upstream of the TSS, of which the distal was reported to confer the greater transactivator effect (Su 
and Pitot, 1992). In my data, three corticosterone induced GR binding sites were identified ~-2kb 
(chr12:41,629,565-41,629,959), ~-5kb (chr12:41,632,348-41,632,972) and ~-8.5kb (chr12:41,636,073-
41,636,697) upstream of the larger coding variant TSS. The previously characterised GR binding sites 
are most likely the two most distal sites in our data (Su and Pitot, 1992). Interestingly, both the 
proximal and distal GR binding sites were bound in response to a corticosterone pulse peak (140min), 
whereas the central GR binding site was responsive to all corticosterone infused timepoints apart from 
pulse nadir (180min). The most proximal and central GR binding sites were induced in a significantly 
phasic, time dependent manner 42- and 24-fold respectively, by the corticosterone pulse peak 
(140min) compared to nadir (180min). None were differentially regulated between constant 
corticosterone timepoints, despite a 4.8-fold enrichment to VEH control at the central binding site. 
Only the central site reported a significant pattern dependent difference with a 10-fold decrease at 
the pulse nadir (180min) compared to constant infusion (180min). pSer2 Pol2 occupation was induced 
in a phasic manner by a pulsatile corticosterone infusion, with occupancy increased 3.3-fold at the 
corticosterone pulse peak (140min) compared to nadir (180min). No changes were detected across 
constantly infused timepoints despite the 5.9-fold enrichment to VEH control. There were significant 
pattern dependent differences in pSer2 Pol2 enrichment, with a 1.9-fold increase at pulse peak 
relative to constant infusion at 140min and a 3.3-fold decrease at pulse nadir relative to constant 
infusion at 180min. This data indicates robust and synchronised corticosterone pattern dependent 




confer the greatest regulatory action, whilst the other two sites may act synergistically to confer 
patterned corticosterone regulation of pSer2 Pol2 occupation.  
Tat is a rate limiting enzyme involved within catabolism of tyrosine into ketogenic and gluconeogenic 
substrates in hepatic mitochondria (Granner and Hargrove, 1983). Transcription of this gluconeogenic 
target was one of the first to be identified as dependent on dual regulatory GR binding regions 
upstream of the TSS (Jantzen et al., 1987). Within our data, four corticosterone inducible GR binding 
regions were identified ~-2.5kb (chr19:41,688,403-41,689,032), ~-3.5kb (chr19:41,689,712-
41,690,106), ~-5.5kb (chr19:41,691,352-41,691,976) and ~-7kb (chr19:41,693,173-41,693,832) 
upstream of the TSS (Figure 5.1). There was also a 3’ GR binding site, ~+11.5kb (chr19:41,674,388-
41,675,013) downstream from the TSS. GR binding, at all sites except for the ~-3.5kb site, was induced 
at the corticosterone pulse peak and both constantly infused timepoints. Whilst, at the ~-3.5kb site 
GR was only bound at the corticosterone pulse peak. All GR binding sites were time dependently 
induced by a pulsatile infusion; increased at the pulse peak as opposed to nadir (+11.5kb: 9.7-fold; -
2.5kb: 170-fold; ~-5.5kb: 9.0-fold; ~-7kb: 36.8-fold) but were unchanged across constant 
corticosterone timepoints despite their enrichment above VEH control. Except for the ~3.5kb GR 
binding site, which was not significantly changed by patterned corticosterone or indeed any other 
comparison. Only the upstream sites -2.5kb, -5.5kb and -7kb were pattern dependent with 100-fold, 
6-fold and 25-fold decreases respectivly in response to the pulse nadir (180min) compared to the 
constantly infused matched time point. The 3’ +11.5kb site was not significantly regulated in a pattern 
dependent manner. Interestingly, there were indications of increased pSer2 Pol2 Seq tags in response 
to both corticosterone pulse peak as well as VEH infused controls, which was not significantly 
different, indicating no change in basally active transcription. There was a significant, 2.5-fold 
reduction in pSer2 Pol2 occupation at the pulse nadir compared to VEH control. Despite an increased 
pSer2 Pol2 enrichment detected in response to 140min of constantly infused corticosterone and not 
180min, relative to VEH control, there was no significant difference in enrichment between constant 
corticosterone timepoints. Finally, there was a 2.4-fold pattern dependent decrease in pSer2 Pol2 
enrichment in the corticosterone pulse nadir, when compared to the constant corticosterone matched 
timepoint of 180min. This data indicates that GR binding at all sites, except for the ~3.5kb site, were 
robustly regulated by infused corticosterone patterns. However, pattern dependent transcriptional 
change was more complicated, with decreased pSer2 Pol2 enrichment at the corticosterone pulse 
nadir and increased enrichment during constant corticosterone infusion.  
Gilz inhibits NFκB and the activation of monocytes and macrophages within anti-inflammatory 




in a circadian manner in adipose tissue and Dex has been observed to induce mRNA expression within 
the liver (Ayyar et al., 2015). Presumably via the two GRE regions identified within a +2.5kb region of 
the TSS in lung adenocarcinoma (A549) cells, but observations within these cells of endogenous mRNA 
profiles were highly variable and not robustly circadian (Wang et al., 2004; van der Laan et al., 2008; 
Monczor et al., 2019). Similarly, pulsatile GC replacement was shown by George et al., 2017 to be 
unable to induce pulsatile expression of Gilz nascent transcript in the prefrontal cortex of the rat 
(George et al., 2017). In my data, two inducible GR binding sites were discovered ~-1kb 
(chrX:111,888,508-111,889,132) and ~-2kb (chrX:111,889,568-111,889,962) upstream of the Gilz TSS.  
Both sites were bound at the corticosterone pulse peak but only the ~-1kb site was bound in response 
to constant corticosterone infusion at the 180min timepoint. Upon further analysis however, neither 
site was significantly changed in a time or pattern dependent manner, even though sites were 
significantly induced to VEH control, the differences in enrichment were not robust enough to 
confidently identify robust pattern or time dependent effects for GR binding. Despite the lack of 
observable corticosterone pattern induced GR binding events, pSer2 Pol2 enrichment was significantly 
regulated in both a pattern and time dependent manner. Increased pSer2 Pol2 was observed in 
response to all infused time points except corticosterone pulse nadir (180min). A significant time-
dependent 9.2-fold increase was found at the corticosterone pulse peak (140min) compared to nadir 
(180min) and a similar but reduced 2.2-fold increase was observed in the same comparison but in 
response to the constant infusion. The increased pSer2 Pol2 occupation at 140min was unchanged 
despite whether a pulsatile or constant corticosterone infusion was used, but there was a significant 
6.7-fold reduction at the 180min time point in response to a pulsatile corticosterone infusion, relative 
to the constant corticosterone infusion. My data indicates that, despite a lack of pattern and time 
dependent GR binding at proximal GR binding sites, pSer2 Pol2 occupation within the Gilz gene was 
significantly modified in a corticosterone pattern and time dependent manner. This may indicate that 
the proximal GR binding sites are not directly regulating dynamic changes in Gilz expression in liver, 
consistent with reports that Gilz can also be regulated by dynamic long-range interactions (Stavreva 
et al 2015).  
LPIN1 is an important PPARα co-factor oxidising fatty acids within the liver as well as inducing 
adipocyte differentiation (Finck et al., 2006). Further, transcriptional regulation has been reported to 
be dependent on GR binding at a GRE upstream of the TSS in mouse liver hepatoma (hepa 1-6) and 
pre-adipogenic mouse embryonic fibroblast (3T3-L1) cells (P. Zhang et al., 2008). In my data, two 
inducible GR binding sites were identified ~-42kb (chr6:41,884,401-41,885,025) and ~-48kb 
(chr6:41,890,043-41,890667) upstream of the TSS of the shorter variant (Figure 5.1). GR binding as 




the pulse nadir (180min). In response to pulsatile corticosterone infusion, GR binding was significantly 
time dependent, with 23-fold increased binding at the ~-42kb site and 16-fold increased binding at 
the ~-48kb binding site, at the pulse peak (140min) compared to nadir (180min). No significant time 
dependent differences were reported in response to a constant infusion, despite increased GR binding 
of 350-fold (140min) and 418-fold (180min) compared to VEH control. Similarly, no significant pattern 
dependent changes in GR binding were detected between pulsatile and constant corticosterone 
infusion at 140min. There was however, a ~17 fold and ~11 fold pattern dependent decrease in GR 
binding at the 180min timepoint in pulsatile compared to constant corticosterone infusion. Similar 
dynamics were reported for pSer2 Pol2 intragenic occupation as phasic, 15-fold increases were 
detected at the corticosterone pulse peak, compared to pulse nadir. No significant time dependent 
changes in Lpin1 pSer2 Pol2 enrichment were reported for constant infusion, despite 13-fold and 10-
fold increased occupation at both 140min and 180min infused time points respectively, relative to 
VEH. No significant pattern dependent differences were reported between pulsatile and constant 
corticosterone infusion at 140min, but there was at 180min with 25-fold decreased RNA Pol2 
enrichment in response to pulsatile compared to constant corticosterone infusion. Together, these 
data indicate robustly corticosterone pattern dependent regulation of both proximal GR binding and 
pSer2 Pol2 intragenic occupation. 
5.4.2 GR binding site distribution is unchanged by patterned corticosterone timepoint 
Genome-wide GR binding locations are highly dependent on cell-specific chromatin organisation. As 
transcriptional control was reported to be modified by infused corticosterone timepoints, GR binding 
site location within intergenic and intragenic regions was investigated for the presence of any 





Figure 5.2 Distribution of GR binding sites within genic regions across the genome. 
The distribution of GR binding sites by intragenic region in response to either pulsatile corticosterone 
pulse peak (140min) (white bar) or constant corticosterone infusion at 140min (grey bar) and 180min 
(black bar). GR binding sites were split into TSS proximal promoter regions (-2.5kb to +0.1kb of the 
TSS) and intragenic binding sites were split into intronic and exonic regions as well as transcription 
termination sites (TTS). All other non-coding regions were classed as intergenic. 
The majority of patterned corticosterone inducible binding sites were found within intergenic regions, 
irrespective of whether they were induced by the corticosterone pulse peak (140min) or either 140min 
and 180min constantly infused timepoints (47.6, 43.6 and 46.9% respectively) (Figure 5.2). The second 
greatest number of sites were induced within intragenic regions, specifically at intronic sites (39.4%, 
39.7% and 38.8% respectively). Exonic sites (2.0%, 3.0% and 2.3% respectively) and transcriptional 
termination sites (TTS) (2.1%, 2.5% and 2.2% respectively) made up only a small percentage of these. 
Interestingly, a concentration of sites was found within promoter regions (9.0%, 11.6% and 10.0%) 
defined as -2.5kb to +0.1kb of the TSS relative to their overall genomic coverage. No obvious 
differences were observed in overall distribution in response to a single or combination of 
corticosterone condition and timepoint. 
5.4.3 Distance to the proximal GR binding site is predictive of pSer2 Pol2 occupancy changes 
GR has been found to exert transcriptional effects over long distances. Within my data, we 
investigated any potential relationship between changes in pSer2 Pol2 occupancy within a gene, and 




interrogated in this way, except for pulsatile corticosterone nadir as no GR binding was detected in 
analysis relative to VEH control (Figure 3.5). 
Interestingly, genes with GR binding sites in closer proximity were more likely to be transcriptionally 
upregulated during the corticosterone pulse peak, i.e. increased pSer2 Pol2 occupancy. Typical 
examples of GR proximal associated increased transcription include the targets Per1 (RT-qPCR only), 
Gilz and Lpin1 as shown above. In contrast, genes without GR binding sites in proximity were more 
likely to be transcriptionally repressed during the corticosterone pulse peak, i.e. have decreased pSer2 
Pol2 occupancy. For example, 25% of gene targets with a GR binding site <860b from the TSS exhibited 
increased pSer2 Pol2 enrichment (Figure 5.3), whereas 25% of gene targets with a GR binding site 
>0.86kb and <20.3kb from the TSS exhibited decreased pSer2 Pol2 enrichment during the 
corticosterone pulse peak. This represents a difference of ~19.5kb (from GR binding site and gene TSS) 
between the two groups. The same phenomenon was observed throughout 50%, 75% and 100% 
percentiles with differences of 83.2kb, 357.6kb and 9,646.5kb respectively. 
Similar distributions were observed in response to either matched constant corticosterone infused 
timepoint to varying degrees. After 140min of constant corticosterone infusion the difference was less 
pronounced at 25%, 50% and 75% percentiles (a difference of 5.6kb, 22.7kb and 221.6kb respectively) 
and relative distances from the TSS were on average double the distance to the most proximal induced 
GR binding site compared to the pulsatile infused matched timepoint (corticosterone pulse peak). 
However, at the 100% percentile the difference in distance was unchanged. 
Similar distributions were observed in response to 180min of constantly infused corticosterone 
between increased or decreased pSer2 Pol2 occupation and the closest GR binding site, however, 
differences between percentiles was increased in comparison to any other corticosterone infused 






Figure 5.3 Distance between GR binding site and the TSS of the closest regulated gene relates to 
probability of pSer2 Pol2 gain or loss in occupancy. 
(A) The percentage of either increased (solid line) or decreased (dotted line) pSer2 Pol2 occupied 
targets was plotted against the distance (log2) to the most proximal induced GR binding site by 
corticosterone to VEH control in response to the  pulsatile infusion at the pulse peak (140min) (black) 
(i) and either 140min (blue) (ii) or 180min (red) (iii) matched constant corticosterone infused 
timepoints. (B) The same comparison was plotted but with total numbers of either increased (i) or 
decreased (ii) pSer2 Pol2 occupied targets to VEH control. Dotted lines indicate at what distance the 
total number of targets that reported a loss in pSer2 Pol2 occupancy was greater than the total 
number of targets that reported a gain in response to the pulsatile corticosterone pulse peak (14.9kb) 
(black) and 180min constant (23.6kb) (red) corticosterone infusion. At no point was this observed in 
response to 140min constantly infused corticosterone. Pulsatile corticosterone pulse nadir (180min) 
was not plotted as no GR binding sites were differentially induced to VEH control. Changes in Pser2 
Pol2 occupancy were analysed in regions >620b and limited to intragenic regions <10kb from the TSS 
according to Ensembl (Rn6) co-ordinates and filtered for unique gene transcripts. Log2 distances were 
measured from differentially regulated target TSSs to the most proximal GR binding site in response 
to a corticosterone infused timepoint. Both pSer2 Pol2 and GR data were normalised to total 




>1.5, FDR<0.05 and p-value <0.05 adjusted for multiple comparisons compared to VEH infused control 
by DESeq2. 
There were further differences observed between corticosterone infused timepoints when total 
numbers of targets were plotted for either increased or decreased pSer2 Pol2 occupied targets. In 
response to a pulsatile corticosterone peak (140min) the number of targets that reported a decrease 
in pSer2 Pol2 occupation was only greater within targets that had an induced proximal GR binding site 
>29.9kb away. Whereas, in response to 180min constant corticosterone infusion, this was reported 
for targets that had an induced proximal GR binding site >12,803,190kb away, a distinct difference in 
GR distribution. Interestingly, the total number of regions with decreased pSer2 Pol2 occupancy in 
response to 140min constantly infused corticosterone was at no point greater than targets with an 
increased occupancy, when sorted by distance to the proximal inducible GR binding site. 
I investigated whether observed effects could be explained via the distribution of nGRE related motifs 
within GR binding regions. Of the GR enrichments closest to the TSS of GC regulated genes, only just 
2.23% of GC regulated targets contained a nGRE related sequence.  
Investigation of the closest identified GR binding site reports just 1.4% of GC regulated targets 
contained a nGRE related sequence. The instances of enriched GR binding in response to a 
corticosterone infused time point did not match up between the GR and pSer2 Pol2 differential results 
i.e. whilst enrichment of a GR binding site occurred at the same infused time point as a change in 
pSer2 Pol2 occupation, there were occurrences where GR was enriched and had no effect on pSer2 
Pol2 occupation. Additionally, no trend was observed between distance of nGRE like motif containing 
GR enrichment and pSer2 Pol2 occupation.Together, these data present evidence that increasing 
distance of GR binding site to a TSS is associated with an increased likelihood of decreased RNA Pol2 
occupancy and hence transcription does not appear to be dependent on the presence of a nGRE 
associated sequence. Observed differences are more likely dependent on distance of GR binding sites 
as well as corticosterone pattern and time of infusion.  
5.4.4 Functional pathway analysis 
As described previously, phosphorylation of the Ser2 residue within the carboxy-terminal domain of 
the RNA Pol2 is associated with the actively transcribing RNA Pol2 complex as it progresses through 
the coding region (Cho et al., 2001; Ahn, Kim and Buratowski, 2004). Therefore, I have interpreted 
changes in pSer2 pol2 occupancy as changes in gene transcription, hence, fold changes in pSer2 Pol2 
occupancy and associated p-values were analysed using the Ingenuity Pathway Analysis software 




inhibitory ‘direction’ according to published literature. This, z-score, is calculated by the ratio of either 
activating or inhibiting effects by the number of targets characterised within a downstream pathway 
and significance is assessed within a binomial model. The IPA analysis recommends any positive 
(predictive activation) or negative (predictive inhibition) z-score >2 is a significant observation. 
5.4.5 Patterned corticosterone regulation of the inflammatory pathway. 
GCs have potent anti-inflammatory properties. Consistent with this, pathway analysis of targets 
regulated by patterned corticosterone predicted inhibition of the inflammatory pathway at both 
140min and 180min infused constant corticosterone timepoints (z-score of -1-15 and -0.59 
respectively) (Figure 5.4 A). Inhibition of the inflammatory pathway was also predicted at the 
corticosterone pulse peak (140min) (z-score of -0.18) but no prediction was made for the pulse nadir 
(180min). As previously described within section 5.3, analysis documentation outlines z-scores >2 (or 
<-2) as a significant prediction, therefore all observations reported are trends of inhibition that may 
facilitate a greater anti-inflammatory effect in response to a constant corticosterone exposure. 
 
Figure 5.4 Predicted modulation of the inflammatory pathway by patterned corticosterone infusion 
timepoints. 
(A) Analysis of pSer2 Pol2 occupied targets in the hepatic inflammatory pathway in response to both 
pulsatile and matched constant corticosterone infusion at 140min (white bars) and 180min (grey 
bars). Fold changes >1.5 from VEH infused control and p-values <0.05 adjusted for multiple 
comparisons were analysed by IPA software. Positive and negative z-scores >2 indicate significant 
predicted activation or inhibition respectively. (B) Differential occupancy of pSer2 Pol2 was 
hierarchically clustered by fold change values and plotted within heatmaps to the centre and right. 
Results were separated into factors known to activate (i) or inhibit (ii) inflammation. Degree of 




within the key towards the top of the figure. Changes in pSer2 Pol2 occupancy to VEH control were 
analysed in regions >620b and limited to intragenic regions <10kb from the TSS according to Ensembl 
(Rn6) co-ordinates and filtered for unique gene transcripts. Z-score p-values are indicated by 
****<0.0001.  
Within the regulated inflammatory genes identified within the analysis, Cdh1 and Mapk9 could 
represent a couple of interesting targets for further study, as they are labelled as activators of 
inflammation, but transcription (pSer2 Pol2 occupancy) is transiently decreased in response to the 
pulsatile corticosterone infusion. Whereas, transcription of several inhibitory targets is increased 
across time points in response to constant corticosterone exposure, including Phyh, Mat1a, Il6r and 
Cbs. These genes could be responsible for the increased predictive trend of anti-inflammatory action.  
5.4.6 Canonical pathways 
Focusing on the canonical metabolic pathways, analysis predicted activation/ inhibition of key 
pathways in a patterned corticosterone dependent manner. In the liver, cholesterol synthesis and its 
metabolism is a primary function, however the liver metabolises a wide range of substrates such as 
melatonin, serotonin and methionine. For example, up to 90% of circulating melatonin is metabolised 
within a single pass through the hepatic portal circulation (Lane and Moss, 1985; Chojnacki et al., 
2012).  
Inhibition of cholesterol biosynthesis was predicted for pulsatile corticosterone, with a trend observed 
at pulse peak  (z-score of -1.89), which was significant within the nadir  (z-score of -2) (Figure 5.5 Ai). 
However, in response to constant infusion, no change was predicted at 140min, and a trend of 
inhibition reported at 180min (z-score of -1). Data indicates overall inhibition of cholesterol 
biosynthesis in response to pulsatile compared to constant infusion, possibly increasing cholesterol 
biosynthesis during constant corticosterone exposure. 
Out of the genes that were differentially regulated by patterned corticosterone, just Dhcr24 reported 
transiently increased transcription during pulsatile infusion, which was prolonged with constant 
corticosterone infusion (Figure 5.5 Bi). Transcription at most targets was decreased however, in 





Figure 5.5 Canonical pathways regulated by patterned corticosterone infusion timepoints. 
Canonical pathway analysis of pSer2 Pol2 occupancy changes in response to both pulsatile and 
matched constant corticosterone infusion at 140min (white bars) and 180min (grey bars). Fold 
changes >1.5 from VEH infused control and p-values <0.05 adjusted for multiple comparisons were 
analysed by IPA software. Positive and negative z-scores >2 indicate significant predicted activation 




change values and plotted within heatmaps to the right. Degree of increased (cyan) or decreased 
(yellow) log2 fold change is indicated by the colour intensity as shown within the key towards the top 
of the figure. Canonical pathway analysis indicated changes in cholesterol biosynthesis I, II (via 24,25-
dihydrolanosterol) and III (via Desmosterol), superpathway of melatonin degradation 1 and 
methionine degradation as well as serotonin degradation.  Changes in Pser2 Pol2 occupancy to VEH 
control were analysed in regions >620b and limited to intragenic regions <10kb from the TSS according 
to Ensembl (Rn6) co-ordinates and filtered for unique gene transcripts. Z-score p-values are indicated 
by *<0.05, **<0.01, ***<0.001 and ****<0.0001. 
Similar trends were observed within degrative pathways of melatonin and serotonin. In response to a 
pulsatile corticosterone infusion, a trend of inhibition was predicted at the corticosterone pulse peak 
(140min), and nadir (180min) for both melatonin (z-scores of -1.07 and -1.63 respectively) (Figure 5.5 
Aii) and serotonin (z-scores of -0.91 and -1.63 respectively) (Figure 5.5 Aiii). In response to constantly 
infused corticosterone, trends of activation were predicted for both pathways at 140min (z-score of 
1.13 and 1.00 respectively) but only at 180min for serotonin (z-score of 0.45). Together, this data 
indicates the potential for increases circulating melatonin and serotonin in response to a pulsatile 
corticosterone infusion. 
pSer2 Pol2 occupation of several genes was increased in response to patterned corticosterone 
infusion including Por, Ugt2b, Sult1b1 and Sult1a1; all of which were also enriched within serotonin 
degradation apart from Por. Occupation of all other 9 regulated genes was decreased in a transient 
manner to pulsatile corticosterone infusion, with indication of dysregulation in response to  constant 
infusion. This was more evident with occupation of genes involved in the serotonin pathway, as 
Ugt1a7c, Sult2a2, Aldh9a1 and Aldh2 were significantly lost to VEH control at the corticosterone pulse 
peak only. 
Significant predicted activations of the methionine degrative pathway were reported in response to 
the corticosterone pulse peak (140min) (z-score of 2.24), as well as in response to 140min and 180min 
constantly infused timepoints (z-score of 2.45 for both) (Figure 5.5 Aiv). No prediction was made for 
the corticosterone pulse nadir (180min). Therefore, this data strongly indicates a prolonged 
methionine degradation in response to a constant corticosterone infusion, as opposed to a transient 
activation that is synchronised to a corticosterone pulse peak, presumably reducing circulating 
methionine. 
Predicted activation of methionine degradation was significant at the corticosterone pulse peak and 
either constant corticosterone timepoints. Out of the six differentially occupied pSer2 Pol2 targets, 




Interestingly, Got1 was similarly increased but also reported a decrease in occupation at the 
corticosterone pulse nadir to VEH control whilst Cbs/Cbsl was only increasingly occupied in response 
to a constantly infused corticosterone. These targets present prime candidates for further 
corticosterone dynamically regulated research. 
5.4.7 Patterned corticosterone regulation of glucose homeostatic pathways. 
Within the liver, dysregulation of glucose homeostasis is an important risk factor in the development 
of MetS phenotypes. Specifically, high glucose and insulin levels are indicators of insulin resistance 
and can lead to obesity and type II diabetes (Vegiopoulos and Herzig, 2007; de Guia, Rose and Herzig, 
2014).  
Pathway analysis reported activatory trends of glycogen quantity in response to pulsatile 
corticosterone at the pulse peak (140min) (z-score 1.67), but not at the nadir (180min) (Figure 5.6 Ai). 
In response to constant corticosterone, trends of activation were predicted at both corticosterone 
infused timepoints (z-score of 0.71 for both), indicating constant corticosterone exposure could 
increase glycogen quantities compared to pulsatile corticosterone induced, transient activation. 
Three corticosterone regulated genes known to activate this pathway, reported increased 
transcription in response to raised circulating corticosterone of Pfkfb1 was highly induced to VEH 
control. It should be noted, transcription of Pfkfb1 has bene characterised as a GC responsive and the 
enzyme is bi-directional, favouring either favoured glycolytic or gluconeogenic pathways within 
hepatocytes which is mostly dependent on glucagon signalling (Hue and Rider, 1987; Marcus et al., 
1987; Rider et al., 2004). Therefore, despite it being quoted as increasing glycogen, it has multi-
regulatory roles. The other two genes were H6pd and Myc. Dusp1 also reported similar dynamics, but 
too a much lesser degree.  
The observed increased confidence predicted at the corticosterone pulse peak is probably due to the 
loss of Jun and Gjb1 transcription at this time point. Together, these represent key genes within this 





Figure 5.6 Predicted modulation of glucose metabolic pathways by patterned corticosterone 
infusion timepoints. 
(A) Predicted activation or inhibition was based upon analysis of pSer2 Pol2 occupied targets involved 
in glucose homeostatic pathways in response to both pulsatile and matched constant corticosterone 
infusion at 140min (white bars) and 180min (grey bars). Fold changes >1.5 from VEH infused control 
and p-values <0.05 adjusted for multiple comparisons were analysed by IPA software. Positive and 
negative z-scores >2 indicate significant predicted activation or inhibition respectively. Differential 
occupancy of pSer2 Pol2 was hierarchically clustered by fold change values and plotted within 
heatmaps to the centre and right. Results were separated into factors known to activate (B) or inhibit 
(C). Degree of increased (cyan) or decreased (yellow) log2 fold change is indicated by colour intensity, 
as shown within the key towards the bottom of the figure. Results indicated quantity of Glycogen (i), 
concentration of D-glucose (ii) and quantity of monosaccharide (iii) were modulated by corticosterone 
infused timepoints. Changes in pSer2 Pol2 occupancy to VEH control were analysed in regions >620b 
and limited to intragenic regions <10kb from the TSS according to Ensembl (Rn6) co-ordinates and 





Similar predictive dynamics were observed for concentrations of dietary D-glucose and 
monosaccharide pathways. Trends of activation were reported in response to the pulsatile 
corticosterone infusion at the pulse peak (140min) as well as both 140min and 180min constantly 
infused timepoints for D-glucose (z-scores of 0.85, 0.90 and 0.90 respectively) (Figure 5.6 Aii) as well 
as for the quantity of monosaccharides (z-scores of 1.41, 1.41 and 1.70 respectively) (Figure 5.6 Aiii). 
Whereas, no prediction was reported at the corticosterone pulse nadir (180min) for either.  In a similar 
way to glycogen; constant corticosterone exposure could increase both glucose and monosaccharide 
levels. 
Interestingly, differentially occupied targets within the monosaccharide pathway were also activatory 
within the D-glucose pathway (Figure 5.6 Bii & Biii). Only Gck (also within the glycogen pathway) was 
exclusive to the monosaccharide pathway. Increased transcription of Foxo1 and Avpr1a was reported 
in response to a constant corticosterone infusion only, whereas Fmo3 was also transiently increased 
in response to a pulsatile exposure. All these were activatory of these pathways, whereas 
corticosterone pattern regulated increases in transcription of the gene Myc (which was activatory for 
glycogen) was inhibitory. 
Together, this data indicates trends of prolonged increases in glycogen, D-glucose and 
monosaccharides in response to constantly infused corticosterone as opposed to transient increases 
synchronised to the corticosterone pulse peak during pulsatile infusion.  
5.4.8 pSer2 Pol2 occupancy predicts modulation of growth and necrotic pathways in response to 
patterned corticosterone infusion. 
Growth hormones and GCs play a distinct synergistic role within energy homeostasis via targeted 
activation of nuclear factors such as STAT5 and GR respectively. STAT5 has been shown to mediate 
cell proliferation, differentiation and survival in a post-natal mouse model that required co-regulator 
interactions with the GR in a composite manner (Stoecklin et al., 1997; Tronche et al., 2004; Engblom 
et al., 2007). Impairment of this interaction can dysregulate lipid metabolism and induce hepatic 
steatosis (Friedbichler et al., 2012; Mueller et al., 2012).   
Analysis of corticosterone regulated genes indicated trends of liver growth in response to the constant 
corticosterone infusion at 140min (z-score of 1.70) and 180min (z-score of 1.77) but not in response 
to the pulsatile corticosterone infusion (Figure 5.7 Ai). Similar trends in response to the constant 
corticosterone infusion were predicted for the proliferation of liver cells (z-score of 1.60 and 1.76 
respectively) (Figure 5.7 Aii), as well as a transient trend of activation predicted in response to the 




suggest transient (if any) activation is prolonged upon the loss of corticosterone oscillations, which 
may increase growth and proliferation within the liver. 
Increased transcription of Nr1i2, Pik3r1, Myc, Nfkbia and Il6r identified in response to the pulse peak 
but not nadir, were prolonged by constant corticosterone exposure, presumably inducing both growth 
and proliferative pathways in corticosterone pattern dependent manner. Whereas, transcription of 
Jun, Il4r, Inhba, Raf1 and Pml was decreased at the corticosterone pulse peak only and would have 
been responsible for the reduced confidence of prediction at this time point. Out of the inhibitory 
genes, transcription of Entpd5, Nr1h4, Dlc1 and Cbp2 was similarly regulated by corticosterone, but in 
a reduced transcriptional capacity. Interestingly the activatory gene Agt (robustly corticosterone 
pattern increased transcription) and inhibitory Igf1 (decreased transcription at the pulse nadir and 
constant corticosterone) were the only genes not enriched in both pathways. 
 
 
Figure 5.7 Predicted modulation of growth and proliferative pathways by patterned corticosterone 
infusion timepoints. 
(A) Predicted activation or inhibition was based upon analysis of pSer2 Pol2 occupied targets 
regulating growth and proliferation in response to both pulsatile and matched constant corticosterone 




and p-values <0.05 adjusted for multiple comparisons were analysed by IPA software. Positive and 
negative z-scores >2 indicate significant predicted activation or inhibition respectively. Differential 
occupancy of pSer2 Pol2 was hierarchically clustered by fold change values and plotted within 
heatmaps to the centre and right. Results were separated into factors known to activate (B) or inhibit 
(C). Degree of increased (cyan) or decreased (yellow) log2 fold change is indicated by colour intensity, 
as shown within the key towards the bottom of the figure. Results indicated growth of liver (i) and 
proliferation of liver cells (ii) modulated by corticosterone infused timepoints. Changes in Pser2 Pol2 
occupancy to VEH control were analysed in regions >620b and limited to intragenic regions <10kb 
from the TSS according to Ensembl (Rn6) co-ordinates and filtered for unique gene transcripts. Z-score 
p-values are indicated by ****<0.0001. 
Interestingly, opposing necrotic and cell death pathways reported similar trends predicted for 
proliferation, in response to the corticosterone pulse peak (140min) (z-scores of 1.24 and 1.15 
respectively) (Figure 5.8 Ai) and at both constant corticosterone timepoints of 140min (z-scores of 
1.65 and 1.90) and 180min (z-scores of 1.34 and 1.10). Together this data indicates transient activation 
of necrotic and cell death pathways in response to pulsatile corticosterone infusion, could be 
dysregulated and prolonged in response to constant corticosterone infusion. 
 
Figure 5.8 Predicted modulation of necrotic and cell death of hepatoma cell line pathways by 




(A) Predicted activation or inhibition was based upon analysis of pSer2 Pol2 occupied targets 
regulating both necrotic and cell death pathways in response to pulsatile and matched constant 
corticosterone infusion at 140min (white bars) and 180min (grey bars). Fold changes >1.5 from VEH 
infused control and p-values <0.05 adjusted for multiple comparisons were analysed by IPA software. 
Positive and negative z-scores >2 indicate significant predicted activation or inhibition respectively. 
Differential occupancy of pSer2 Pol2 was hierarchically clustered by fold change values and plotted 
within heatmaps to the centre and right. Results were separated into factors known to activate (B) or 
inhibit (C). Degree of increased (cyan) or decreased (yellow) log2 fold change is indicated by colour 
intensity, as shown within the key in the middle of the figure. Results indicate necrotic (i) and cell death 
of hepatoma cell lines (ii) modulated by corticosterone infused timepoints. Changes in Pser2 Pol2 
occupancy to VEH control were analysed in regions >620b and limited to intragenic regions <10kb 
from the TSS according to Ensembl (Rn6) co-ordinates and filtered for unique gene transcripts. Z-score 
p-values are indicated by *<0.05, **<0.01 and ****<0.0001. 
Most corticosterone regulated targets that were regulatory of the hepatoma cell death pathway were 
also enriched within the necrotic pathway. Except for the activatory and inhibitory targets, Jund and 
Cdkn1a, which were only regulatory of the cell death pathway. Activatory targets reporting 
corticosterone pattern increased transcription were Nr0b2, Myc, Nr1i2 and Nfκbiα (Figure 5.8 B), 
whilst a loss was reported at the inhibitory targets Rgn, Pzp, Plg, Selenop and Amacr (Figure 5.8 C). 
It is also worthy of note, a proportion of genes were identified as either activatory or inhibitory, for 
growth/ proliferative as well as necrotic/ cell death pathways. This indicates a high level of crosstalk 
between the pathways identified as well as bi-functional responses of genes. Or it could simply be a 
lack of clarity regarding direct target effects within pathways. Together, this data does indicate a 
pulsatile corticosterone exposure, could transiently affect hepatocyte turnover within the liver, which 
upon constant corticosterone exposure would become dysregulated and potentially increased. 
5.4.9 pSer2 Pol2 occupancy predicts modulation of carbohydrate pathways and factors involved in 
lipid homeostasis in response to patterned corticosterone infusion. 
Carbohydrate, fatty acid and lipid metabolism as well as lipoprotein synthesis and packaging for 
distribution around the body (predominantly WAT) is highly dependent on hepatic function 
(Vegiopoulos and Herzig, 2007; Werner, Kuipers and Verkade, 2013; de Guia, Rose and Herzig, 2014). 
Dysregulation of these homeostatic processes can induce raised circulating VLDLs and reduced HDLs, 





Pathway analysis of differentially corticosterone regulated genes that regulate the metabolism of 
carbohydrates, predicted trends of inhibition in response to the corticosterone pulse peak (140min) 
(z-score -1.68) and none by the nadir (Figure 5.9 Ai). In response to a constant corticosterone infusion, 
very weak confidence of inhibition and activation were predicted at 140min and 180min infused time 
points (z-score of -0.04 and 0.12 respectively) indicating a loss of transient inhibition and dysregulation 
by constant corticosterone exposure, which could increase metabolism of carbohydrates within the 
liver. 
Reduced transcription of genes known to activate carbohydrate synthesis was identified in Nr1h4, 
Gpam and Aqp9 in response to the corticosterone pulse peak only and down-regulation of Scd was 
greater at the same time point compared to nadir. Furthermore, Dusp6 transcription was transiently 
reduced in a similar manner but also in response to constant corticosterone exposure. Whilst, 
increased transcription of PPP1r3c, Slc37a4 (translocation protein for G6pc) and Ppp1r3b was in 
response to constant corticosterone only (de Guia, Rose and Herzig, 2014; Kuo et al., 2015). A reduced 
number of inhibitory genes were corticosterone pattern regulated, with H6pd and Nr0b2 transcription 
increased in response to raised circulating corticosterone time points and Avpr1a and Nr1i3 
transcription increased in response to constant corticosterone infusion only.  
Analysis of corticosterone regulated genes that affect carbohydrate quantities, predicted trends of 
activation in a transient manner at the pulse peak (z-score 1.84) but not by the nadir in response to a 
pulsatile corticosterone infusion (Figure 5.9 Aii). In response to a constant infusion, trends of 
activation were predicted in a pro-longed manner across 140min and 180min time points (z-score 1.53 
and 1.64 respectively) Together, analysis indicates trends of transient activation of carbohydrate 
quantity, were dysregulated in a prolonged manner, potentially increasing carbohydrates in response 
to constant corticosterone exposure within the liver. 
Transcription of genes associated with the quantity of carbohydrates that were increased in response 
to raised circulating infused corticosterone included Bhmt, Fmo3 and H6pd, whilst Ppp1r3c, Foxo1 and 
Avpr1a were constant corticosterone dependent only. Transcription of the inhibitory genes Gjb1 and 





Figure 5.9 Predicted modulation of carbohydrate metabolic pathways by patterned corticosterone 
infusion timepoints. 
(A) Predicted activation or inhibition was based upon analysis of pSer2 Pol2 occupied targets 
regulating carbohydrate metabolism in response to pulsatile and matched constant corticosterone 
infusion at 140min (white bars) and 180min (grey bars). Fold changes >1.5 from VEH infused control 
and p-values <0.05 adjusted for multiple comparisons were analysed by IPA software. Positive and 
negative z-scores >2 indicate significant predicted activation or inhibition respectively. Differential 
occupancy of pSer2 Pol2 was hierarchically clustered by fold change values and plotted within 
heatmaps to the right. Results were separated into factors known to activate (B) or inhibit (C). Degree 
of increased (cyan) or decreased (yellow) log2 fold change is indicated by colour intensity, as shown 
within the key. Results indicated metabolism of carbohydrate (i) and quantity of carbohydrate (ii) were 
modulated by corticosterone infused timepoints. Changes in pSer2 Pol2 occupancy to VEH control 
were analysed in regions >620b and limited to intragenic regions <10kb from the TSS according to 
Ensembl (Rn6) co-ordinates and filtered for unique gene transcripts. Z-score p-values are indicated by 
*<0.05, **<0.01 and ****<0.0001. 
Despite multiple studies highlighting the significant role of GCs within TG, fatty acid and lipid 
metabolism, interpretation of patterned corticosterone regulation was difficult due to limited 
numbers of differentially regulated targets. In response to the pulsatile infusion, trends of inhibition 
were predicted at the corticosterone pulse peak for the concentration of triacylglycerol (Figure 5.1 Ai) 




acid concentration (Figure 5.10 Aiii) (z-score of 0.60). Similar but inverted trends were predicted by 
the pulse nadir (z-scores of 0.10, 0.60 and -1.31 respectively) indicating transient regulation. In 
response to constant corticosterone infusion, analysis reported trends of inhibition for TGs (z-score of 
-0.34 and -0.41), fatty acids (z-scores -1.15 and -0.51) and lipids (z-scores of -1.12 and -0.54). These 
data indicate that transient, pulsatile regulation of these pathways which are dysregulated by constant 
corticosterone exposure in a pro-longed and inhibitory action is possible, however, confidence of 
predictions was low. 
Analysis of corticosterone regulated genes reported enrichment of a number of genes with shared 
regulatory function in hyperlipidaemia and dyslipidaemia pathways as shown in Figure 5.10 B, except 
for Srebf1, Hsd11b1, Nr0b2, Apoe and Fasn, but with low confidence predictive trends (data not 
shown). Interrogation of individual corticosterone regulated genes within pathways, indicated 
increased transcription of Lpin1 and to a lesser degree Nr0b2, was induced by raised corticosterone 
infused time points except for pulse nadir. Similar trends but inhibitive, were observed for Apob. 
Transcription of Fasn was inhibited at both pulsatile corticosterone time points, but to a greater 
degree at the pulse peak and Foxo1 transcription was increased in response to a constant 
corticosterone exposure only. 
Together, despite the literature indicating dysregulating GCs can induce raised TG, fatty acid and lipid 
levels, my data indicated loss of transient transcription was potentially inhibitive of these pathways. 
Under further interrogation, I have identified key corticosterone regulated targets that present ideal 





Figure 5.10 Predicted pathway activation or inhibition of lipid, triglyceride and fatty acid 
metabolism. 
Predicted activation or inhibition was based upon analysis of pSer2 Pol2 occupied targets regulating 
the concentration of triacylglycerols (A), fatty acids (B) and lipids (C) in response to pulsatile and 
matched constant corticosterone infusion at 140min (white bars) and 180min (grey bars). Differential 
occupancy of pSer2 Pol2 targets within the hyperlipidaemic and dyslipidaemia pathways were 
hierarchically clustered by fold change values and plotted within heatmaps to the right. Results were 
separated into factors known to activate, inhibit or unknown effects on pathways. Targets apart from 
Lpin1, Angptl8, Insig2, Fdft1 and Fasn are involved in at least one of the three triacylglycerol, fatty 
acid and lipid pathways. Degree of increased (cyan) or decreased (yellow) log2 fold change is indicated 




infused control and p-values <0.05 adjusted for multiple comparisons were analysed by IPA software. 
Positive and negative z-scores >2 indicate significant predicted activation or inhibition respectively. 
Pser2 Pol2 occupancy to VEH control were analysed in regions >620b and limited to intragenic regions 
<10kb from the TSS according to Ensembl (Rn6) co-ordinates and filtered for unique gene transcripts. 
Z-score p-values are indicated by ***<0.001 and ****<0.0001. 
5.5 Discussion 
Multiple studies have demonstrated that GRs are not required to bind within close proximity to a TSS 
or within the ‘promoter’ region to exert transcriptional regulation (Ratman et al., 2013). Indeed, 
further genomic studies have indicated up to ~7% of binding sites were within regions varying from 
2.5kb to 20kb regions of the TSS and that the largest proportion of GR binding sites were within 
intergenic regions (43.6-57.6%) as presented within this thesis (Figure 5.2) (John et al., 2011; Rao et 
al., 2011; Uhlenhaut et al., 2013). An interesting correlation was found within the data when genes 
were sorted into either increased or decreased corticosterone dependent transcription (increased or 
decreased pSer2 Pol2 occupancy) and plotted against the distance from the TSS to closest 
corticosterone induced GR binding event. It was observed that transcriptionally up-regulated genes 
were more likely to have a relatively closer GR binding site than those that were down-regulated 
(Figure 5.3). A similar relationship has been identified with mRNA abundancy in response to Dex 
administration within human alveolar epithelial (A549) cells (Reddy, Pauli and Sprouse, 2009). Due to 
such a limited number of nGRE associated sequence containing GR enrichment regions, no association 
could be made between the observed inhibitive effect of GR binding to nGRE motifs. Particularly when 
one considers just 2.23% of enriched GR regions contained a nGRE like sequence and approx. 75% of 
genes were inhibited by patterned corticosterone infusion. Exact mechanisms, therefore, are yet to 
be elucidated; however, it does provide an intriguing observation of distanced GR transcriptional 
control as well as further evidence that use of pSer2 Pol2 occupancy as a proxy of transcription is 
appropriate. 
 Pathway analysis of corticosterone regulated targets reported non-significant predictions for all 
pathways except cholesterol biosynthesis at the pulse nadir (Figure 5.5 Ai) and methionine 
degradation in response to raised circulating corticosterone time points (pulse peak and both constant 
corticosterone infused time points) (Figure 5.5 Aiii). The lack of confident predictions is most likely due 
to the limited number of regulated genes, as this analysis is primarily designed for RNA-Seq data. 
Despite the lack of significance, trends of transient corticosterone regulation of key metabolic 
pathways were predicted for the quantity of glycogen, monosaccharide and carbohydrate, 




to a limited extent lipids. Whereas, TGs, fatty acids and metabolism of carbohydrates were inhibited 
in a similar manner, synchronised to the pulse peak of pulsatile corticosterone infusion. Interestingly, 
in response to a constant corticosterone infusion, dysregulation of pathway transient activation/ 
repression was predicted for all pathways. 
Dysregulation of these pathways could induce aberrant metabolic function as found with MetS 
phenotypes. Loss of inhibitory cholesterol synthesis by the constant corticosterone infusion could 
increase cholesterol levels, which have been associated with hypertension and obesity, as well as liver 
fibrosis, steatohepatitis and steatosis (Ioannou et al., 2009; Van Rooyen et al., 2011; Ichimura et al., 
2015). Similarly, prolonged activation of methionine degradation could reduce methionine levels and 
potentially increase methionine metabolites within the liver, which are associated with fatty liver 
development and NAFLD (Mato, Martínez-Chantar and Lu, 2008; Kharbanda, 2009). Prolonged 
increases of glucose and its derivatives has long been associated with insulin resistance, 
hyperglycaemia and diabetes (de Guia, Rose and Herzig, 2014; Kuo et al., 2015; Zhou et al., 2016; 
Yaribeygi et al., 2019), whilst dysregulated growth and apoptotic pathways are associated with non-
alcoholic steatohepatitis (NASH) and fibrosis (Feldstein et al., 2003; Argo et al., 2009; Luedde, 
Kaplowitz and Schwabe, 2014).  
Despite the inability of the pathway analysis to predict significant activation or inhibition, I have 
highlighted corticosterone targets known to regulate these pathways that would be interesting to 
characterise in future studies. For example, Got, Slc37a4, G6pc and Pfkfb1 dysregulation of transient 
transcriptional control could have distinct effects for glucose whilst Scd, Lpin1, Apob and Fasn for TG, 
fatty acid and lipid homeostasis. Particularly as 28 genes enriched within the pathways highlighted 
within this thesis, were identified as robustly corticosterone regulated i.e. significant and transient 
increased or decreased regulation in response to a pulsatile corticosterone infusion, whilst constant 
corticosterone exposure dysregulated this profile and indicated prolonged levels of increased 





Figure 5.11 Corticosterone pattern regulated targets involved in pathway regulation. 
Analysis of differentially pSer2 Pol2 occupied genes identified key targets known to regulate 
inflammatory, glycogen, glucose, monosaccharide, growth and proliferative, necrotic and cell death, 
carbohydrate fatty acid, triglyceride lipid, dyslipidemic as well as canonical melatonin, serotonin and 
methionine degradative and cholesterol biosynthesis pathways. These were split into distinct dynamic 
changes in occupation. First, targets which significantly time dependent (TD) in response to pulsatile 
infusion only but enriched to VEH control at both constant corticosterone timepoints were defined as 
corticosterone pattern dependent (A). Secondly, targets similarly TD in response to a pulsatile infusion 
but not enriched to VEH by a constant corticosterone infusion were defined as pulsatile responsive 
only (B). Finally, targets that were not TD in response pulsatile corticosterone infusion but were 
enriched to VEH in response to constant corticosterone infusion only and not TD were defined as 
constant responsive (C). Degree of increased (cyan) or decreased (yellow) log2 fold change is indicated 
by colour intensity, as shown within the key towards the top of the figure. Fold changes >1.5 from VEH 
infused control and p-values <0.05 adjusted for multiple comparisons were analysed by IPA software. 
Pser2 Pol2 occupancy to VEH control were analysed in regions >620b and limited to intragenic regions 
<10kb from the TSS according to Ensembl (Rn6) co-ordinates and filtered for unique gene transcripts. 
pSer2 Pol2 differentially occupied targets which were pattern dependent (PD) at 140min and 180min 
timepoints were also indicated. 
In conclusion, analyses of the functional effects of GR and pSer2 Pol2 corticosterone pattern regulation 
provides two main findings. First, corticosterone regulated increases in transcription are more likely 




relatively short, and transcription is more likely to be decreased with an increasing distance to bound 
GR sites. Secondly, analysis of corticosterone regulated genes predicts a number of pathways in 
energy and liver growth/ death could be transiently regulated by ultradian oscillations of 
corticosterone, which are dysregulated by constant corticosterone exposure within a relatively short 
experimental time scale. These data indicate dysregulation of GCs could be a key factor in the 
development of associated pathologies such as insulin resistance, diabetes, dyslipidaemia, 




Chapter 6 Modelling the 24hour artificial ‘ultradian’ Corticosterone 
infusion pattern 
6.1 Background 
The GR and pSer2 Pol2 ChIP-Seq data revealed dynamic GR binding and transcriptional regulation 
synchronised to peak and nadir of corticosterone pulses. Interpretation of the resulting effects, using 
functional pathway analysis, highlighted how key metabolic pathways were also dynamically regulated 
during pulsatile corticosterone exposure. Notably, pulsatile infusion induced phasic activation or 
inhibition of pathways known to be important for metabolic processes within the liver, including 
inflammatory regulation, glucose homeostasis, carbohydrate, lipid and fatty acid metabolism. Phasic 
activation of the cellular proliferation pathway was seemingly counterbalanced with phasic activation 
of cellular apoptotic pathways during pulsatile corticosterone infusion.  
In contrast, constant infusion of a matched corticosterone dose significantly dysregulated the 
characteristic ultradian dynamics of GR binding and RNA Pol2 enrichment within GC target genes. 
These pattern dependent effects were found to impact upon important metabolic functional 
pathways, with notable differences in the predicted trends for pathways mentioned previously. 
Dysregulation of these pathways is known to be associated with phenotypes of MetS such as insulin 
resistance, diabetes, dyslipidaemia, liver fibrosis and NASH and NAFLD. My data now contributes to 
our understanding about how altered GC rhythms, via dysregulated action of GR and aberrant 
transcriptional regulation of GC target genes in the liver, may directly induce the early stages of 
development of these conditions.  
Despite how rapid and robust observed transcriptional changes were in response to the two GC 
patterns over the 3hr timescale in my experiments, we expect that physiological changes would take 
far longer to become apparent. In fact, development of MetS as a result of GC dysfunction and the 
pathways highlighted within this study may even take years to develop fully, therefore, a more chronic 
experimental model is needed to test whether we can start to see measurable physiological changes 
(Jia et al., 2018).  
Within this chapter, I have modelled the 24hr endogenous ultradian GC profile, based upon data I 
collected from adrenally intact rats and have designed a corticosterone replacement protocol that 
delivers hourly 20min pulses of different amplitudes into in ADX rats, to recapitulate the circadian and 





• Model the endogenous ultradian circulating total blood serum corticosterone profiles within 
the rat. 
• Design a corticosterone infusion replacement profile with both circadian and ultradian 
characteristics. 
6.3 Methods 
All methods of analysis were done according to general methods discussed within Chapter 2. 
Briefly, adult male Sprague-Dawley rats (250-300g) (Harlan, Bicester, UK) were housed under standard 
conditions, 12:12 light/ dark cycle (lights on at 06:00h) with food and water available ad libitum.  
Surgical bilateral ADX or sham, I.P. telemetry probe implantation as well as jugular vein and carotid 
artery cannulation were performed under anaesthesia. ADX rats were provided with 0.15µg/L of 
corticosterone in 0.9% saline drinking water whilst sham operated control rats were provided with 
plain water. Both groups had access to normal chow, ad libitum during the 5-day post-surgical 
recovery period. All cannulae were flushed daily with 1% heparinised saline (0.9M) to maintain 
patency every 24hrs. Telemetry recordings of activity and temperature were collected every 10mins 
throughout.  
In ADX rats, 16 hrs prior to corticosterone infusions, corticosterone supplemented saline was replaced 
with 0.9% saline for drinking, to allow adequate washout period within the circulation.  
Blood samples were collected every 10mins from either the carotid artery or jugular vein using the 
ABS system over a 28hr period and total blood serum corticosterone was measured via in-house RIA. 
Within ADX rats, 3.84µM corticosterone-HBC conjugate was infused in 20min periods at variable rates 
hourly over a total 28hr period via the jugular vein.  
6.4 Results 
To accurately model circulating endogenous ultradian corticosterone oscillations over 24hrs, blood 
samples were collected from sham ADX rats every 10mins as well as activity and core body 
temperature (°C) data.  
Assessment of individual total blood serum corticosterone profiles revealed evidence of ultradian 
hourly pulses within the circadian active period (data not shown). When the data was averaged across 
rodents, the circadian rhythm was still clearly seen but the distinct ultradian pulses were no longer 




A). The circadian corticosterone rise began at ~Zt7 (5hrs before lights off) and does not return to basal 
levels until ~Zt22 (2hrs before lights on) consistent with previously published data (Windle, Wood, 
Lightman, et al., 1998; Windle, Wood, Shanks, et al., 1998; Waite et al., 2012; Walker et al., 2014). 
Maximal corticosterone (146ng/ml ±26) was detected at Zt12:40.  
 
Figure 6.1 Circulating corticosterone, body temperature and activity profiles in sham 
adrenalectomised rats. 
Jugular vein blood samples were taken at 10min intervals over 28hrs and total blood serum 
corticosterone levels were assessed using an in-house RIA (red). Analysis identified corticosterone peak 
at Zt12:40 (A). Telemetry probes were also implanted into the intraperitoneal space recording body 
temperature (blue) (B) and activity (green) (C) and data binned into 10min segments. Robust circadian 
profiles were observed in all three metrics (D). Rats (N=6) were sham adrenalectomised and housed 
in standard conditions under a 12:12 light schedule (dark bar indicates lights off), error bars represent 
mean ± s.e.m.. 
Analysis of average activity and body temperature data indicated a high degree of similarity to 




maintained until ~Zt20-22 before returning to basal levels, of which Zt4:50 recorded the minimum 
temperature (36.8°C ±0.25) (Figure 6.1 B). Activity profiles followed a similar pattern to body 
temperature (Figure 6.1 C). Interestingly, maximal corticosterone levels coincided with the onset of 
increased body temperature and activity, however, both body temperature and activity remained 
elevated whilst corticosterone levels gradually retuned to nadir within the period ~Zt20-22.   
As my acute corticosterone replacement infusion model was 3hrs, the 24hr period was segmented 
into eight 3hr blocks. Zt11-14 was allocated as the circadian corticosterone peak period, based on 
maximal endogenous corticosterone level having been detected at Zt12:40 (Figure 6.2 A). Over this 
3hr period, the maximal rate of 1ml/hr over 20min every hour was used.   
To introduce the appropriate circadian amplitude variations into the infused corticosterone pulses, 
endogenous corticosterone data was analysed over each 3hr period by area under the curve. Fold 
decrease relative to circadian peak (Zt11-14) was calculated for each 3hr period, and infusion rates 
were appropriately reduced from the maximal rate of 1ml/hr by the calculated factor (Figure 6.2 B&C). 
Analysis and subsequent infusion profile design predicted a similar profile of relative change to 
endogenous profiles, particularly across a similar time segment (Zt2-5) as observed within endogenous 





Figure 6.2 Modelling the 24hr ‘ultradian’ corticosterone profile. 
The period between Zt11-14 was allocated as circadian peak according to 10min profiling of total 
circulating corticosterone. The rest of the 24hr period was segmented accordingly (A). Rats (N=6) were 
sham adrenalectomised and housed in standard conditions under a 12:12 light schedule (dark bar 
indicates lights off), error bars represent mean ± s.e.m..  Each 3hr section was assessed using an area 
under the curve analysis. Factor changes in results to circadian peak (Zt11-14) were used to calculate 
changes to the infused corticosterone dose, using 3.84µM for the maximal delivered dose, as used in 
the acute model (B). Modelled changes in doses within 3hr sections (C) as well as a hypothetical 
circulating corticosterone levels (normalised to circadian peak) (D) over 24hrs resembled endogenous 
ultradian profiles.  
To validate the modelled ultradian infusion model, corticosterone was infused into adrenalectomised 
rats over a 28hr period via the jugular vein, whilst simultaneous blood samples were collected from 




corticosterone levels that had passed through the circulation network. Telemetry probes were also 
implanted I.P. to confirm intact circadian activity and body temperature profiles.  
Within the infusion model, an initial increased rate for 2min 30sec was used to prime the infusion line 
and cannula with corticosterone-HBC saline prior to the modelled infusion. Due to an error in initial 
programming of the infusion pump, 5 pulses of corticosterone-HBC saline were erroneously infused 
at this rate between Zt22-3. This was corrected for the remainder of the modelled infusion (Figure 6.3 
B). 
 
Figure 6.3 Validation of the mock ‘ultradian’ corticosterone infusion. 
28hr corticosterone-HBC saline infusion profiles, modelled to mimic a typical endogenous ultradian 
corticosterone profile, were infused via jugular implanted canulae during simultaneous blood 
sampling from the carotid artery of an adrenalectomised rat. Infusion rates were modelled over a 28hr 
period (A) and total blood corticosterone levels were assessed via RIA (B). Body temperature and 
activity data was also collected over the infusion and sampling period (C). Light schedule was 12:12 




From an initial total of 8 rats, only four were successfully dual cannulated due to the high degree of 
difficulty cannulating the carotid artery which. One of the four blocked prior to experimental testing 
and two of the three remaining suffered adverse effects and were terminated prior to infusion 
completion. A full 28hr profile of corticosterone, body temperature and activity data were collected 
from a single rat. Rapid increases in circulating total corticosterone were recorded during each 20min 
infusion of corticosterone, which was rapidly cleared within 40min of each infusion, returning to basal 
levels before the next pulse (Figure 6.3 B). The amplitude of the delivered pulses varied as expected 
over the 28hr period, recapitulating previously characterised endogenous measurements. Overall, 
corticosterone increased from Zt6 to a maximal corticosterone level at Zt13:30 (209ng/ml) in response 
to the maximal infused dose of corticosterone (Figure 6.3 A). Pulse amplitude gradually decreased 
throughout the following period until reaching minimal levels at Zt23:20 (29ng/ml). Corresponding 
well with endogenous circadian nadir data. Despite the methodological error that occurred between 
Zt22-3, corticosterone data indicates the infusion model can replace circulating corticosterone in an 
adrenalectomised rat with both ultradian and circadian components.  
Analysis of telemetry data during corticosterone replacement, indicated that whilst increases in 
activity were associated with lights off similar to adrenally intact controls, body temperature did not 
and gradually decreased throughout the infusion period from ~38°C to 36.5°C (Figure 6.3 C). This is 
most likely an adverse effect associated with the dual cannulation method, as examination of 
telemetry data prior to infusion, reported drops in body temperature were associated with flushing 
of cannula to maintain patency. To fully remove any blood clots that may form within the cannula, 
heparinised saline is withdrawn until a small amount of blood (approx. 100µL) is drawn from the 
cannula. Whereupon fresh sterile heparinised saline (approx. 100µL) is infused back, clearing the 
cannula of blood and pushing a small amount into the circulation. Despite this method being used 
multiple times and no previous adverse effects observed in previous double cannulation experiments 
(Figure 2.2), these flushes may have induced a slight drop in blood pressure and thus core 
temperature.  
6.5 Discussion 
To my knowledge, GC replacement with both ultradian and circadian characteristics for use in a 
chronic model has not been shown before within the ADX rat. Within this pilot study, I have presented 
data showing that my model can deliver a physiologically realistic, hourly pulsatile corticosterone 
infusion via the jugular vein with circadian variations of amplitude across a 24hr period.  
As this characterisation has been successful in only one male ADX rat, due to adverse reactions 




of the procedure (followed by validation) is required. To avoid adverse reactions found with the 
combination of carotid and jugular cannulation used in this study, two cannulas will be inserted into 
a single jugular vein, as previously used in our group. 
Within this thesis, I have presented data showing that a 3hr pulsatile corticosterone infusion model 
will regulate synchronised, transient GR recruitment across regulated targets throughout the genome, 
which will induce similar profiles of up-regulated or down-regulated transcription of select genes 
important for regulation of metabolic pathways within the liver. I further report, loss of oscillating 
corticosterone, dysregulates both GR and transcriptional dynamics, in a manner that could modulate 
pathways integral to the development of MetS phenotypes. Despite these indications, I have not 
investigated any changes in circulating metabolic markers, nor would I expect to find any within a 3hr 
timescale as measurable physiological changes will take longer to develop. Additionally, the 3hr model 
was specifically designed to avoid having to account for circadian changes, therefore, to fully 
investigate the development of aberrant metabolic function that could be translationally significant 
for clinical studies, the infusion model has to be extended.  
Primarily, the model was designed to investigate whether metabolic action could be differentially 
regulated by a pulsatile ultradian or non-oscillatory, constant circadian pattern of circulating 
corticosterone. Therefore, I have also designed a novel matched constant circadian infusion model 
using similar methods. This constant circadian corticosterone replacement model, infuses over a 
60min period but at a reduced rate, matching the dose delivered over the 1hr to the 20min pulsatile 
infusion (Figure 6.4). 
 
Figure 6.4 Schematic of a matched modelled loss of pulsatile corticosterone infusion. 
Table describes the dose of corticosterone infusion delivered every 3hrs over a 24hr period as well as 




corticosterone would be infused over a 20min period followed by a 40min pause and repeated hourly 
according to the table. Whereas, to induce a constant infusion pattern (solid line), corticosterone 
would be infused over the full 60min period every hour, but at a reduced rate to the pulsatile infusion, 
therefore matching total dose delivered every hour between infused patterns (B). 
Based on my experience of duration of canula patency, an experimental infusion period can be 
extended up to a 5-day chronic model. This may potentially be long enough to induce changes within 
metabolic homeostatic processes and detect measurable differences in circulating fatty acid, TG and 
lipid levels. The model can also be used to investigate GC phase shifts to the photoperiod, as found 
with transmeridian travel (a.k.a. jet lag) as well as an alteration of feeding behaviour as found with 
variable shift work. This model will also be useful for investigation of other GR regulated physiological 
process, and to assess effects on other important GC target tissues such as the brain, as corticosterone 




Chapter 7 General Discussion 
7.1 Summary of findings 
In this thesis, I report novel in vivo data showing how ultradian corticosterone replacement in ADX 
rats synchronises liver GR binding to the corticosterone pulse peak, at ~ 3,000 binding sites across the 
genome. GR binding was found to be phasic in 100% of cases, with complete dissociation from all 
binding sites within the corticosterone pulse nadir, hence, ultradian GR binding dynamics are tightly 
regulated by the pulsatile corticosterone pattern. Dysregulation of the ultradian rhythm via a dose 
matched constant infusion induced prolonged GR binding at the majority of these binding sites, 
indicating that pulsatile GR dynamics are extremely sensitive to disruption when circulating 
corticosterone rhythms are dysregulated. I report that genome-wide RNA Pol2 access to the 
chromatin template is also dynamically regulated, with precise timing synchronised by pulsatile 
corticosterone. I report the first evidence for a functional consequence of dysregulated ultradian 
corticosterone exposure in liver, as constant infusion resulted in distinct and opposing transcriptional 
outcomes to pulsatile infusion. While pulsatile corticosterone predominantly induced gene repression 
in the majority of cases, constant corticosterone predominantly induced gene transactivation in the 
majority of cases at 140min. The differentially regulated genes were found to be enriched within key 
metabolic pathways known to induce insulin resistance, diabetes, obesity, dyslipidaemia, fatty liver 
disease and hepatic steatosis within dysregulated GC pathology. Taken together, my data highlights 
the importance of maintaining the ultradian GC profile for homeostatic metabolic function via tightly 
controlled regulation of GR dependent transcriptional dynamics. This is the first evidence directly 
linking dysregulated ultradian GC rhythms with early transcriptional changes in known metabolic risk 
factors for the development of MetS. Finally, I have designed a novel 24hr corticosterone replacement 
model that will be used in future research to determine how these early changes manifest into 
metabolic changes over a longer timeframe.  
My research and findings of underlying metabolic mechanisms is extremely relevant to current public 
and government interests in tackling metabolic phenotypes that have risen in parallel with rhythm 
disrupting lifestyles, chronic stress, and prevalence of long-acting synthetic steroid treatments. 
Targets found to be sensitive to rhythm disrupting GC exposure in this study will inform translational 
approaches, in particular the identification of druggable candidates for therapeutic intervention in GC 




7.2 Overview of corticosterone patterned regulation 
The main focus of my work has been to investigate the biological significance of the ultradian GC 
rhythm. Adrenal circadian GC release is synchronised to the photoperiod via the HPA axis (Weitzman, 
1976; Lightman and Conway-Campbell, 2010). Due to intrinsic delayed positive feed forward and 
negative feedback mechanisms regulating adrenal GC secretion, combined with its short half-life upon 
entering the circulation, circulating GC levels oscillate in an ultradian rhythm within the circadian 
rhythm. The majority of research investigating the importance of GC rhythms focussed on the 
circadian rhythm, with 6-12hr intervals between data collection which misses the underlying ultradian 
dynamics, despite their highly conserved nature within mammalian biology (Krieger et al., 1971; 
Holaday, Martinez and Natelson, 1977; Benton and Yates, 1990; Engler et al., 1990; Carnes et al., 1992; 
Loudon et al., 1994; Cudd et al., 1995; Windle, Wood, Shanks, et al., 1998) and have been 
demonstrated to play important roles in a diverse range of physiological functions (Windle, Wood, 
Lightman, et al., 1998; Conway-Campbell et al., 2010; Sarabdjitsingh et al., 2010, 2014, 2016; 
Kalafatakis et al., 2018). It therefore seems short sighted to ignore their potential role in metabolic 
regulatory functions, as this is a major function ascribed to GCs (Kyrou, Chrousos and Tsigos, 2006; de 
Guia, Rose and Herzig, 2014; Kuo et al., 2015) 
7.2.1 Mock ‘ultradian’ corticosterone pulses direct robust glucocorticoid receptor binding and 
synchronised transcription 
Within Chapter 3, I present novel in vivo data, showing that physiological pulsatile corticosterone 
infusion into ADX rats, induced GR binding at 87.4% of corticosterone regulated sites across the 
genome exclusively at the peak of the pulse which was lost within the pulse nadir (Figure 3.7). To my 
knowledge, similar GR dynamics in vivo have only been reported for the well characterised Per1 GRE 
~2.5kb upstream from the TSS. Authors reported that three bolus 100µg corticosterone injections 
were associated with maximal GR binding at the peak of each corticosterone pulse and dissociated to 
basal levels within the corticosterone pulse nadir after 40min. They also reported phasic hnRNA 
production of Per1 that was slightly delayed to both corticosterone and  increased GR levels (Figure 
1.9) (Stavreva et al., 2009). My work validates that not only are these dynamics replicable using a 
corticosterone replacement infusion model via the jugular vein, but also that ultradian corticosterone 
dynamics can direct GR binding across all accessible binding sites across the genome which is not 
restricted to select targets.  
As previously mentioned, the GR is an oxosteroid nuclear transcription factor, mediating 
transcriptional regulation via recruitment of co-factors for its intrinsic transactivator/ transinhibitory 




oscillating GR binding to the regulatory GRE of Per1 induced phasic hnRNA production in rat liver 
(Stavreva et al., 2009). In chapter 4, I expanded upon my GR binding data to present novel RNA Pol2 
ChIP-Seq data that indicated transcriptional regulation (gain of RNA Pol2 occupancy) of 77.3% of the 
liver corticosterone regulated genes identified in this study were similarly pulsatile. While there were 
many cases of increased transcription, gene repression (loss of RNA Pol2 occupancy) was found in the 
majority of cases (73.4%), synchronised to the corticosterone pulse peak.  Irrespective of the direction 
of change, there was a return to basal levels within the pulse nadir for the vast majority (85.1%) of 
cases (Figure 4.6) and just 14.5% of genes were differentially enriched relative to VEH control within 
the pulse nadir. These data strongly support a model whereby pulsatile GC exposure induces transient 
liver specific GR binding across the genome to mediate robust phasic transcriptional regulation of GC 
target genes in liver.  
My data in rat liver is consistent with findings from an in vitro model of GR binding and RNA Pol2 
occupancy within a mouse mammary carcinoma (3617) cell line. A series of real time live cell imaging 
experiments showed that GR recruitment to the artificial MMTV array was synchronised to pulses of 
15min corticosterone exposure, that fully dissociated within 45min of hormone withdrawal and was 
repeatable over multiple cycles of stimulation in the same cells (Stavreva et al., 2009). The authors 
expanded upon these findings using similar ChIP-Seq methods to those used in this thesis and reported 
RNA Pol2 occupancy was similarly synchronised. Their data, however, indicated corticosterone 
administration increased transcription at the majority of gene targets in response to a single 20min 
(followed by 40min washout) and 60min corticosterone administration (Stavreva et al., 2015). 
Interestingly, Affymetrix GeneChIP data analysis of nerve growth factor-determined 
catecholaminergic (PC12) cells after a 20min 100nM corticosterone pulse, indicated that the 
predominant effect was a reduction in mRNA levels at 1hr while increased mRNA levels were detected 
at a much later time of 3hrs after the corticosterone pulse (Morsink et al., 2006). The data I have 
presented here may indicate that repeated transient GR binding cycles are required to maintain 
repressive transcriptional effects as observed at the 1hr time point in PC12 cells. It is also possible that 
the delayed effects on mRNA upregulation in the Morsink study could be due to a timing delay in RNA 
processing, required to produce the mature transcript, or other post-transcriptional mechanisms. 
Alternatively, taken together with my findings, these data may highlight a potentially distinct 




7.2.2 Constant corticosterone exposure can induce prolonged GR binding and dysregulate 
synchronised transcriptional regulation  
Expanding upon these results, I presented novel in vivo data that shows how replacing ultradian pulses 
with dose matched constant infusion robustly dysregulated both GR and RNA Pol2 dynamics. Of all 
the GR binding sites identified as distinctly corticosterone regulated in this study, 87.4% were bound 
at the peak (140min) compared to 0% at the nadir (180min). GR binding in response to the dose 
matched constant corticosterone infusion whereas, was found at fewer sites than with pulsatile peak, 
with 32.0% of sites bound at 140min and 49.3% at 180min.   
A differential analysis for time dependent effects (within each pattern) confirmed the extent of 
dysregulation of phasic GR binding during constant corticosterone exposure as significant time 
dependent differences in GR binding was found for 50.7% of sites during pulsatile infusion but only 
2.5% of sites during constant infusion (Figure 3.7).  
In Chapter 4, I reported that pulsatile infusion resulted in a highly defined temporal regulation of 
transcription for GC target genes. At the corticosterone pulse peak, 77.3% of target genes were found 
to have significant changes in Pol2 occupancy, whereas, only 14.5% of genes were at the nadir to VEH 
control. This indicates a dynamic regulation of transcription coinciding predominantly with the pulse 
peak. Constant infusion markedly impacted upon the dynamics of phasic RNA Pol2 activity over time, 
with 35.5% and 38.9% of target genes found to have significant changes in Pol2 occupancy at 140min 
and 180min respectively, relative to VEH control (Figure 4.6).  
Similar to GR dynamics, differential analysis for time dependent effects (within each pattern) 
confirmed the extent of dysregulation of phasic transcriptional regulation during constant 
corticosterone exposure. Here, significant time dependent differences in relative RNA Pol2 
enrichment were found for 60.3% of sites during pulsatile infusion but just 14.1% of sites during 
constant infusion (Figure 4.6). 
As described in the previous section (4.4.6) pulsatile corticosterone was found to be more effective at 
inducing transcriptional repression of the majority of regulated targets, with reduced pSer2 Pol2 
occupancy detected at 73.4% of regulated genes at the pulse peak. In contrast, constant 
corticosterone was found to be much more effective at inducing upregulation, with increased pSer2 
Pol2 occupancy detected at 77.2% and 49.6% of total regulated genes at 140min and 180min 
respectively (Figure 4.6).  
The opposing outcome of pulsatile versus constant corticosterone treatment for GC regulation of the 




(Stavreva et al., 2015). The Stavreva study was performed in a mouse mammary carcinoma cell line, 
where no pattern dependent differential repressing or transactivating regulation was noted (Stavreva 
et al., 2015). As previously mentioned, mRNA production within PC12 cells was decreased post 1hr of 
corticosterone exposure, which was increased by 3hrs (Morsink et al., 2006). As only the Morsink et 
al. 2006 study used a similar time point to mine, one could conclude rapid, transient corticosterone 
and ultimately GR binding is required to induce inhibitory transcription. More research is required to 
confirm these dynamics, as well as clarify the discrepancies between different cell types, and in vitro 
versus in vivo observations. 
My data also highlights that constant corticosterone infusion was less effective than the 
corticosterone pulse peak at inducing GR binding, as well as regulating RNA Pol2 access to the 
chromatin template. Of the sites inducible by corticosterone, 47% were exclusively pulse peak 
dependent, whereas only 8.6% were exclusively induced by constant corticosterone (Figure 3.5). For 
the remaining 44.1% of binding sites, GR binding was commonly responsive to at least two of the three 
conditions with raised circulating corticosterone. Similar dynamics were observed in transcriptional 
regulation, as differential RNA Pol2 occupation was detected in 41.5% of regulated genes at the 
corticosterone pulse peak only, which reduced greatly to just 10.9% of regulated genes commonly 
responsive to all three conditions with raised circulating corticosterone (Figure 4.8).  
Dysregulation of RNA Pol2 dynamics during constant corticosterone exposure was more complicated 
than the simple prolonged duration effect observed with GR. There was also strong evidence for 
opposing overall transcriptional effects between pulsatile and constant corticosterone exposure as 
well as many gene specific differences evident within the data, which will be discussed in more detail 
in section 7.3.  
7.2.3 Dose-dependent effects 
To match the infused corticosterone doses between the two patterned infusion groups, the constant 
infusion rate was lower. The same dose was delivered over 60min in the constant group but over 
20min in the pulsatile group, therefore, circulating corticosterone concentration was highest at the 
pulse peak compared to any other condition and time point (Figure 2.2). Previously published data has 
indicated GR binding within the hippocampus of male ADX rats was induced at many of the same sites 
by two differing doses, however, a sub-group of sites were induced in response to the high dose only 
(Polman, de Kloet and Datson, 2013). As the data indicated distinct and opposing transcriptional 
induction by either patterned corticosterone exposure, I would hypothesise the peak dependent sites 
are more likely to be dose dependent. Despite this, I would not conclude observed transcriptional 




is distinctly robust and cannot be discounted as a primary and synergistic factor for transcriptional 
dysregulation.  
7.3 Observations between transcriptional activity and proximal or distal GR binding 
In this study I found a relationship in the data that an increased distance, between the TSS and the 
closest regulated GR binding site, increased the likelihood of transcriptional inhibition of the gene 
which I cannot identify as nGRE mediated (Figure 5.2). To my knowledge, this phenomenon has only 
been reported in vitro in response to Dex administration in A549 cells with differential mRNA 
expression analysed by RNA-Seq (Reddy, Pauli and Sprouse, 2009). As this is observed in both RNA 
Pol2 occupancy as well as mRNA production, the data in part justifies the use of RNA Pol2 occupancy 
as a proxy for transcription, as well as indicating that this may represent a novel mode of GR mediated 
transcriptional regulation.  
Regulation of GR responsive genes has been observed over long distances and via TAD domains that 
rely on chromatin reorganisation to either ‘open’ or ‘close’ sites to transcription factors and their 
complexes as well as the transcriptional machinery (Ito et al., 2006; Kuznetsova et al., 2015; Kim et al., 
2018). This suggests the mechanisms of chromatin reorganisation needed for transcriptional 
regulation may depend on the proximity of  a GR binding event (Grøntved et al., 2015; Stavreva et al., 
2015; Jubb et al., 2017; Stubbs, Flynn and Conway-Campbell, 2018). Although the majority of GR 
binding sites are located in pre-accessible ‘open’ chromatin, several sites can also be found in highly 
compacted ‘closed’ chromatin that  is non-permissive for RNA Pol2 access to the TSS and gene bodies 
within these regions (Archer et al., 1991; John et al., 2008, 2011; Reddy, Pauli and Sprouse, 2009; Jubb 
et al., 2017). However, GR binding can initiate local chromatin opening via recruitment of co-factors 
such as the HATs CBP and P300 as well as chromatin remodelling factors such as the SWI/SNF complex, 
which slide nucleosomes open to increase accessibility for RNA Pol2 and the transcriptional machinery 
(Chakravarti et al., 1996; Gerritsen et al., 1997; Koh et al., 2001; Belandia et al., 2002). Even sites 
thought to be pre-accessible can also be opened further for gene regulation following glucocorticoid 
treatment (John et al., 2008; Burd et al., 2012).  
Despite these potential mechanisms, the role of chromatin remodelling in GR transcriptional inhibition 
is not well understood and so far, a greater role of SWI/SNF in transcriptional activation and induction 
of genes has been identified (John et al., 2008). Other chromatin reorganisation mechanisms may be 
required for long distance transcriptional inhibition such as chromatin looping, bringing a distant GR 
binding site into closer proximity with the TSS (Hakim et al., 2009; McDowell et al., 2018). For this 
study the degree of pre and post chromatin accessibility within regions of inducible GR binding were 




corticosterone treatment are located within ‘open’ or ‘closed’ chromatin or whether decompaction 
occurs. Further studies are needed to explore regulation of transcriptional inhibition and why a larger 
distance may frequently be found. New techniques that could help answer this question include Hi-C 
to detect chromatin interactions, DNA-FISH to assess chromatin decompaction  and DNase1-Seq or 
ATAC-Seq to assess chromatin accessibility (Buenrostro et al., 2013; Jubb et al., 2017). I would suggest 
further studies using some of these techniques would be important to explore mechanisms of not only 
GR mediated transactivation or transrepression but also in relation to pulsatile and constant 
corticosterone exposure.   
7.4 Homeostatic metabolic implications 
Within my thesis, I present the key metabolic pathways affected by differential pattern dependent 
corticosterone treatment. Some of these were predicted to be significantly activated or inhibited in 
response to an infused corticosterone condition and/or time point, many others were only trending. 
Together this data indicates key pathways can be synchronised to ultradian corticosterone oscillations 
within the liver, the dysregulation of which could potentially lead to the development of aberrant 
metabolic phenotypes associated with GC dysfunction and the development of MetS.  
The HPA axis is a highly plastic system, with the ability to adapt natural oscillations of GC release from 
the adrenal glands in response to a range of physical and psychological stimuli, the degree of which 
can be dependent on the self-perceived degree of a stressor (Pariante and Lightman, 2008; Lightman 
and Conway-Campbell, 2010; Sarabdjitsingh et al., 2010). These processes can become maladaptive, 
as clinically depressed patients present with flattened circadian rhythmicity as well as raised 
circulating ACTH and cortisol (Deuschle et al., 1997). Most research into endocrine rhythms has mainly 
focussed on dysregulation of circadian dynamics, whilst ultradian GC dysregulation remains a 
relatively underexplored but potentially important area. For example, the application of a stressor not 
only increases the interpulse period, but the degree of the physiological, neural and behavioural 
response to stress is dependent on the pulse phase (Windle, Wood, Lightman, et al., 1998; J. Haller et 
al., 2000; Sarabdjitsingh et al., 2010). Additionally, stress responsiveness, emotional processing and 
memory are blunted by constant corticosterone infusion (Sarabdjitsingh et al., 2010; Kalafatakis et al., 
2018).  
GCs are well known to either directly or synergistically regulate key targets within metabolic pathways 
of glucose, lipid, carbohydrate and cholesterol homeostasis within the liver; therefore dysregulation 
could have serious consequences (Kyrou, Chrousos and Tsigos, 2006). It has been demonstrated that 
workers who suffer chronic stress (defined as three events a week) were twice as likely to develop 




hypercortisolism and there is an over representation of metabolic dysfunction including the 
development of significant visceral fat deposits and obesity (32-41%), dyslipidaemia (32-41%) and type 
II diabetes (20-47%) in these patients (Nieman and Ilias, 2005; Stratakis, 2008; Feelders et al., 2012; 
Buliman et al., 2016). Loss of HPA axis synchrony to the photoperiod is associated with increased 
weight gain and risk of diabetes without increasing overall food intake in rodents, which may be an 
important mechanism underlying the cause of a twofold increased risk of developing diabetes as 
observed within human studies of variable shift workers (De Bacquer et al., 2009; Karatsoreos et al., 
2011).  
As my data has indicated distinctly pulsatile GR binding and transcription in the liver, which becomes 
significantly dysregulated during constant infusion, what impact might this have for metabolic 
pathology?  
7.4.1 Glucose homeostasis 
Trends of activation within pathways regulating glycogen, monosaccharides and dietary glucose were 
predicted at the corticosterone pulse peak but not within the nadir, indicating transient activation 
which becomes prolonged in response to constant corticosterone exposure. The functional impact of 
this may include the potential for prolonged elevations in circulating glucose levels.  
Transcriptional regulation of the gluconeogenic targets Pfkfb1, G6pc and Slc37a4 were significantly 
pattern dependent and GR binding was found with varying proximity to the TSS of each of these genes. 
Pffkb1 is a bi-directional, rate limiting enzyme that is regulated in part by glucagon, switching the 
direction of glucose metabolism within hepatocytes favouring either gluconeogenesis or glycolysis. 
Within my data, I report a GR binding site (6kb upstream) that is robustly regulated and synchronised 
to circulating corticosterone infused patterns. Interestingly, RNA Pol2 was robustly increased at the 
pulse peak as well as prolonged in response to the constant infusion, indicating dysregulation of 
ultradian oscillations increases Pfkfb1 expression. As Pfkfb1 was enriched within the pathway for 
increasing quantity of glycogen, the functional impact of ultradian dysregulation may be to increase 
glycogen within the liver as shown in Dex treated fasted, ADX mice and rats (Mersmann and Segal, 
1969; Exton et al., 1976; de Guia, Rose and Herzig, 2014).Due to its glucagon regulated bi-directional 
effects however, it is difficult to predict the glucose regulated effects due to variable transcription 
rates. 
GC pathology is often associated with increased glucose production and mobilisation, and the inability 
to reduce glucose levels, leading to insulin resistance. G6pc and the associated carrier protein Slc37a4, 




with glycogen storage disease and a hypoglycaemic states (de Guia, Rose and Herzig, 2014; Kishnani 
et al., 2014; Kuo et al., 2015; Bali et al., 2016). G6pc was transcriptionally repressed at the 
corticosterone pulse peak only, whilst Slc37a4 was significantly upregulated by constant 
corticosterone infusion in a prolonged manner, with significantly increased expression relative to both 
pulsatile infusion and veh control. Two robustly pattern dependent GR binding sites (6kb and 12kb) 
upstream of G6pc TSS, and a single robustly pattern dependent GR binding site (0.1kb) upstream of 
Slc37a4 TSS were found.  
The impact of constant corticosterone exposure, via the combined changes in expression of these two 
genes, may therefore be an increased glucose production within hepatocytes. Additionally, 
overexpression of G6pc and presumably its carrier protein Slc37a4 has also been shown to precipitate 
hyperinsulinemia, decreased glycogen storage in the liver, and TG storage in peripheral tissues 
(Massillon et al., 1996; Trinh et al., 1998; Massillon, 2001; Gautier-Stein et al., 2012). Therefore, 
together these two targets are prime candidates for a causal role in inducing aberrant glucose 
metabolism during ultradian corticosterone rhythm dysregulation.  
Despite the lack of a significant prediction for the insulin resistance pathway, one of the key targets 
within the pathway, insulin like growth factor 1 (Igf1), was found to be highly pattern dependent in its 
regulation. RNA Pol2 occupancy in the Igf1 gene was reduced at the corticosterone pulse peak and at 
both constant corticosterone time points, indicating a prolonged decrease in transcription during 
constant corticosterone exposure. Significantly pattern dependent GR binding was identified 34.5kb 
downstream of the TSS. Igf1 mRNA has been reported previously to be reduced by Dex treatment in 
human KLE endometrial-like cells (Lembessis, Kalariti and Koutsilieris, 2004). There is also evidence for 
a link associating Igf1 hormone levels (either very low or very high levels) with an increased risk for 
insulin resistance and diabetes (Lembessis, Kalariti and Koutsilieris, 2004; Schneider et al., 2011; 
Friedrich et al., 2012).  
Together, this data highlights G6pc, Slc37a4 and Igf1 as ultradian regulated genes that could be key 
targets for further study regarding dysregulated GC pathology as well as corticosterone mediated 
insulin resistance. 
7.4.2 Fatty acid, TG, lipid and apolipoprotein metabolism 
Within this thesis, I present statistically significant pathway predictions of inhibited cholesterol 
production at the corticosterone pulse nadir as well as a selection of novel ultradian targets that, upon 
dysregulation by a constant corticosterone infusion, may play a role increasing storage of cholesterol, 




Pathway analysis of corticosterone regulated targets predicted a significant inhibition in the quantity 
of cholesterol at the pulse nadir in response to pulsatile infusion indicating dysregulation of ultradian 
rhythms could increase levels within the liver (Figure 5.5). Corticosterone synchronised trends of 
increased carbohydrates were also predicted at the pulse peak, but prolonged in response to a 
constant infusion (Figure 5.9), indicating a potential accumulation within the liver. Similar trends were 
not predicted for TG, fatty acid and lipid pathways, as despite evidence of synchronised ultradian 
regulation, prolonged trends of inhibition were predicted in response to a constant corticosterone 
infusion. This was disappointing as there are many studies that show an association with dysregulated 
GCs and hyperlipidaemia (Vegiopoulos and Herzig, 2007; Lemke et al., 2008; Lu et al., 2012; Kuo et al., 
2015). Upon further examination, key metabolic targets enriched within these pathways’ present ideal 
candidates for future research and potentially indicate a more chronic model of GC dysregulation is 
required for phenotypic development.  
Fasn converts the intermediate metabolite malonyl coenzymeA into fatty acids in a rate limiting 
reaction within de novo lipogenesis (Chakravarthy et al., 2005; de Guia, Rose and Herzig, 2014; Rui, 
2014). Within my data, Fasn and Scd (another factor involved in de novo lipogenesis) reported 
corticosterone synchronised losses of RNA Pol2 in response to the pulsatile infusion but not in 
response to a constant corticosterone infusion as well as corticosterone regulated binding sites 78kb 
upstream and 13kb downstream of the Fasn and Scd TSS respectively. Together, this data could 
indicate GR mediated increases in expression in response to disruption of ultradian oscillations, which 
could be important when one considers increased Scd mRNA levels are reported within obese and 
lipoatrophic diabetic mice as well as hepatic steatosis (Cohen et al., 2002; Asilmaz et al., 2004). Similar 
raised levels have been reported within NAFLD patients as well as TG accumulation within the liver 
indicating increased de novo lipogenesis could be significant with regard to aberrant metabolic 
function (Kotronen et al., 2009). Although studies within leptin-deficient (ob/ob) mice indicate just 
11% ±1 of TG within the liver originate from de novo synthesis, therefore despite indication of 
synthesis, effects could be minimal (Iizuka, Miller and Uyeda, 2006; Jensen-Urstad and Semenkovich, 
2012).  
Similarly, RNA Pol2 occupation of Lpin1 was increased in a prolonged manner by constant 
corticosterone infusion (Figure 4.2 and Figure 4.10). Pathway analysis indicated a regulatory role 
within hyperlipidaemia and dyslipidaemia pathways and similarly, over expression has been 
associated with increase adipocyte TG uptake and obesity, however, direct observations within the 
liver and its role with other Lpin variants remains to be fully elucidated (Phan and Reue, 2005; Finck 




Interestingly, my data also reported losses of RNA Pol2 at the apolipoprotein gene, Apob, were 
synchronised to the corticosterone pulse but prolonged in response to a constant infusion as well as 
a corticosterone regulated GR binding site 26kb upstream of the TSS. APOB is required for VLDL 
synthesis and function, facilitating lipid accumulation within the lipoprotein as well as endocytosis by 
intermediate density lipoproteins, lowering VLDL levels within the circulation (Powell et al., 1987; 
Atzel and Wetterau, 1993). As VLDL synthesis and function are integral to the livers ability to transport 
TG, lipids and other metabolites out of the liver and into the circulation which is a known risk factor 
of NAFLD and NASH, any dysregulation of synthesis could have significant effects over a prolonged 
period (Wetterau et al., 1992; Linton, Fame and Young, 1993; Ozcan et al., 2004; Ota, Gayet and 
Ginsberg, 2008; Jiang, Robson and Yao, 2013; Welty, 2014).  
I therefore hypothesise, dysregulation of ultradian oscillations by raised, non-oscillating GC exposure 
could increase the transcription of specific genes increasing deposition of TG, cholesterol and 
carbohydrates within the liver. Coupled with a loss in VLDL synthesis over a prolonged period could 
develop NAFLD and NASH phenotypes. Further research is required over a chronic model of GC 
replacement for confirmation and assessment.  
7.4.3 Serotonin and melatonin metabolism 
Trends of increased melatonin and serotonin degradation were predicted in a phasic manner, 
synchronized to corticosterone pulse peak and prolonged in response to the constant corticosterone 
infusion, indicating pattern dependence.  
In vivo microdialysis measurement of both serotonin and melatonin have reported diurnal variations 
within the pineal gland, however, 95% of circulating serotonin is produced within the duodenum of 
the gut which also reports a degree of circadian rhythmicity (Sun et al., 2002; Ebert-Zavos et al., 2013). 
Melatonin is produced from serotonin within the pineal gland and is also secreted in an inverted 
circadian profile to GCs (Lane and Moss, 1985; Chojnacki et al., 2012). As the liver metabolises up to 
90% of circulating melatonin within a single pass through the hepatic portal circulation, alteration in 
degradative pathways could have a large impact (Lane and Moss, 1985; Chojnacki et al., 2012). 
Increased serotonin uptake and metabolism within the liver is associated with increased 
mitochondrial reactive oxygen species and lipid peroxides. Risk factors associated with NASH and 
potentially loss of ultradian oscillations as trends indicated a prolonged increase in degradation. 
Patients with liver cirrhosis have raised melatonin levels compared to controls, potentially due to a 
loss of clearance within the liver (Iguchi, Kato and Inayashi, 1982; Nocito et al., 2007). Additionally, 




and insulin secretion and was predictive of type 2 diabetes (Lyssenko et al., 2009). Therefore, constant 
corticosterone induction of melatonin degradation could be protective. 
In conclusion, prolonged activation of serotonin and melatonin degradation could have opposing 
effects regarding liver damage but present interesting candidates for future research considering their 
well-documented role within circadian biology. 
7.4.4 Hepatocyte turnover 
Seemingly opposing pathways for growth and proliferation, and necrosis and cell death were similarly 
enriched with pattern dependent targets, potentially indicating that hepatic cell turnover rate is 
sensitive to GC rhythm disruption. This may have implications for increased risk of the development 
of liver cancer, fibrosis and NASH (Feldstein et al., 2003; Argo et al., 2009; Luedde, Kaplowitz and 
Schwabe, 2014). 
Pathway analysis of differentially occupied RNA Pol2 genes, indicated predictive trends of increased 
proliferation and liver growth synchronised to the corticosterone pulse peak, were prolonged during 
constant corticosterone infusion. Interestingly, analysis predicted similar trends of activation for 
necrotic and cell death pathways. Within the liver, hepatocyte turnover is relatively low as a study in 
male Wistar rat liver demonstrated just 0.05% of hepatocytes were in an apoptotic state at any one 
time (Columbano et al., 1985; Luedde, Kaplowitz and Schwabe, 2014). Despite this, the liver has a 
relatively rapid and specialised capacity for regeneration after lobectomy of up to 3 of its 5 lobes (2/3 
total mass) (Higgins and Anderson, 1931). Regeneration due to partial hepatectomy is a tightly 
regulated process, with two rounds of DNA synthesis and proliferation followed by apoptosis that is 
thought to correct for any over proliferation (Sakamoto et al., 1999). Considering this capacity and 
ability for liver growth or cell death, any perturbation in cellular pathways could potentially have 
serious implications. 
Motif analysis showed that 54% of GR binding regions, which contained a GRE, also contained an over-
expressed sequence that resembled a STAT5 motif, indicating a co-regulation between GR and STAT5 
at these sites (Table 3). STAT5 is activated by a signalling cascade initiated by growth hormone, which 
regulates gene expression in the liver via the membrane bound growth hormone receptor. Activated 
STAT5 and GR form a potent transactivation complex to induce transcription of growth factors in the 
liver (Engblom et al., 2007; Hennighausen and Robinson, 2008). Interestingly, loss of STAT5B can 
reduce IGF1 expression that has been linked to reduced overall body growth as well as fatty liver, 
hepatic steatosis and impaired cell proliferation, as has GR liver specific knockouts (Tronche et al., 




inhibitory and transient losses of RNA Pol2 occupancy were found in response to pulsatile but 
prolonged by constant corticosterone exposure.  
Unfortunately, there is a lack of clarity within the data, as similarly activatory or inhibitory genes 
enriched within growth/ proliferative pathways were also identified in necrotic/ cell death pathways. 
This is most probably due to multiple pleiotropic transcription factors within each pathway. For 
example, analysis listed the MYC proto-oncogene, BHLH transcription factor gene (Myc) as activatory 
of all four pathways (Zheng, Cubero and Nevzorova, 2017). c-Myc transcription can be induced via 
growth factor activation and has been identified as an immediate early gene, whose expression is 
increased by 30min post-lobectomy and reaching maximal levels twice at 2hr and 3hr time points 
(Ohgaki et al., 1996; Thorgeirsson and Santouni-Rugiu, 2003; Zheng, Cubero and Nevzorova, 2017). As 
c-MYC is a key transcription factor driving transition of hepatocytes from G0/G1 to S phase, these peaks 
in expression are associated with hepatocyte proliferation as mentioned previously (Thompson et al., 
1986). It has been shown that c-MYC sensitizes a cell to apoptosis via indirect inhibition of p53 
proteasomal degradation (Zindy et al., 1998). Hence, loss of c-MYC transcriptional control has long 
been associated with hepatic carcinoma and has been replicated within a hepatocyte specific Myc 
overexpressing mouse model (alb-Cre+/cMYCtg). Tumours developed in 40% of these mice at 45 weeks 
old, and 80% by 65 weeks (Evan and Littlewood, 1993; Hoffman and Liebermann, 2008; Freimuth et 
al., 2010). Increased collagen deposits leading to fibrogenesis and damage are also associated with 
this mutant mouse line. Increased collagen deposits have also been observed clinically and are 
postulated to further progress to hepatocellular carcinoma (Nevzorova et al., 2013; Zheng, Cubero 
and Nevzorova, 2017). Interestingly however, co-expression of c-MYC and hepatocyte growth factor 
inhibits proliferation and tumour growth (Thorgeirsson and Santouni-Rugiu, 2003). MYC function is 
not reserved just to hepatocyte proliferative and apoptotic pathways, as my analysis also listed Myc 
as activatory within the glycogen quantity pathway. This is unsurprising as evidence has shown Myc 
could be protective against HFD induced insulin resistance, obesity and hyperglycaemia due to its 
involvement in hepatic glucose accumulation and carbohydrate metabolism (Valera et al., 1995; Riu 
et al., 2003; Zheng, Cubero and Nevzorova, 2017). 
Analysis also listed Igbp1 as inhibitory of growth and proliferative pathways, despite a recent study 
indicating knockout reduced the capacity for liver regeneration after lobectomy (Leu et al., 2003). 
Within a tethered, complimentary co-factor complex, opposing or synergistic transcriptional effects 
can be dependent upon whichever co-regulator is bound to the DNA as described for NFκB or STAT 
transcription factor complexes with GR (Jonat et al., 1990; Ray and Prefontaine, 1994; Stoecklin et al., 




explain opposing observations, nevertheless, it is reasonable to conclude that targets highlighted 
within these pathways have complex interactions that are yet to be fully elucidated. Whilst this data 
does not define an overall increase or decrease in hepatocytes, it does indicate a potential for 
dysregulation of turnover rates. The outcome of this dysregulation would need to be assessed over a 
longer timeframe using my chronic infusion protocol, particularly because proliferation, cell death and 
necrosis pathways have been associated with an increased risk of cancer, fibrosis and NASH (Feldstein 
et al., 2003; Argo et al., 2009; Luedde, Kaplowitz and Schwabe, 2014). 
7.4.5 Chronic model 
Within this thesis, I have highlighted that MetS may take years to develop, therefore, detection of 
such robust, early changes within the first 3hrs of GC rhythm dysregulation is quite remarkable 
(Edwards et al., 2012; Medina-Santillán et al., 2013; Bergmann, Gyntelberg and Faber, 2014; Kaur, 
2014). The ability to detect and observe how these changes affect metabolism over an extended 
period with a chronic treatment protocol would represent an important and fascinating tool for future 
research into dysregulated ultradian and circadian GC rhythms.   
Circulating metabolites such as TGs, lipids, free fatty acids, carbohydrates and VLDLs are known to 
fluctuate in a circadian manner and aberrant regulation has long been associated with dysregulated 
GCs (Kalsbeek, la Fleur and Fliers, 2014; Poggiogalle, Jamshed and Peterson, 2018). Furthermore, 
despite numerous studies investigating manipulation of the photoperiod or characterisation within 
sustained hyper- or hypocortisolism states (as found within Cushing’s and Addison patients), no-one 
has investigated the relative contribution of the ultradian versus the circadian GC profile in 
maintaining ‘healthy’ metabolic function.  
To answer these fundamental questions, I present a novel, hourly pulsed ultradian model of GC 
replacement within the ADX rat, that incorporates circadian variation in pulse amplitude over a 24hr 
period. Here, I have presented the first evidence that dynamic oscillations in circulating corticosterone 
can be delivered via a programmable infusion pump in a manner that models both circadian and 
ultradian endogenous corticosterone rhythms, albeit only in a pilot study (n=1) so far (Figure 6.3). To 
my knowledge, this is the first physiologically realistic ultradian corticosterone replacement infusion 
model, in vivo. I expanded upon this model to also design a replacement infusion that incorporated a 
circadian aspect, but without the ultradian pulsatile rhythm.  
This infusion protocol has great potential for use over a chronic timeframe to assess functional 
changes arising from circadian and/or ultradian dysregulation. Applications extend beyond 




could be affected by chronically dysregulated GCs. In particular, cognitive impairment and depression 
have been reportedly associated with dysregulated GCs (Deuschle et al., 1997; Michaud, Forget and 
Cohen, 2009; Guo et al., 2018). Stress related aggressive behaviour, as well as appetite and weight 
loss, are not only mediated by the self-perceived degree of a stressful event, but also at what point 
within a circadian and ultradian profile it is applied (Akabayashi et al., 1994; Martí, Martí and Armario, 
1994; Rybkin et al., 1997; Windle, Wood, Lightman, et al., 1998; J Haller et al., 2000; J. Haller et al., 
2000; Shimizu et al., 2010; Ciriaco et al., 2013; Simic et al., 2013). Therefore, the ability to accurately 
interrogate system / tissue / cellular function in response to an acute or more chronic GC disruption 
paradigm within a specific circadian and/ or ultradian GC phase will be exceptionally informative about 
the processes of dynamic physiological regulation.  
7.4.6 Clinical importance 
Hypercortisolism, most commonly associated with Cushing’s disease, is associated with a myriad of 
aberrant metabolic effects such as obesity, insulin resistance, diabetes mellitus and dyslipidaemia 
(Nieman and Ilias, 2005). Interestingly, other cohorts of patients including those suffering with chronic 
depressive disorder, chronic stress conditions and chronic inflammatory disease have also been 
reported to exhibit hypercortisolism and poor metabolic profiles, albeit to a lesser extent than 
Cushing’s patients (Deuschle et al., 1997; Young, Carlson and Brown, 2001; Pariante, 2006; Pariante 
and Lightman, 2008; Lightman and Conway-Campbell, 2010; Almadi, Cathers and Chow, 2013). A 
particularly interesting and well characterised cohort of patients suffering from the chronic condition 
of obstructive sleep apnoea have been extensively assessed for associations between their 
hypercortisolism and poor metabolic profile. Analysis of 24hr blood profiling and metabolic 
assessments undertaken before and after treatment reported elevated ACTH and cortisol secretion 
along with increased incidence of metabolic syndrome pathology were mitigated by successful 
treatment with continuous positive airway pressure therapy (David E. Henley, Buchanan, et al., 2009; 
David E. Henley, Russell, et al., 2009).  
How do these clinical associations relate to my findings of altered metabolic gene regulation during 
constant GC infusion? It is first important to understand that hypercortisolism does not induce 
constant adrenal cortisol secretion. Ultradian pulsatility is still maintained, although in a significantly 
dysregulated form. Therefore, the clinical cases described above are not exposed to completely steady 
state GC levels, as experienced by the rats in my experimental protocol. It is, however, important to 
note that one of the defining features of hypercortisolism is elevated GC levels during the ultradian 
nadir (in most cases) and during the circadian nadir (in some cases). My data has demonstrated that 




inducing profound dysregulation of genes enriched within pathways known to induce MetS 
phenotypes. Overtime, chronic elevation in nadir GC levels may lead to the more severe manifestation 
of metabolic phenotypes observed in patients suffering with hypercortisolism.  
In contrast, hypocortisolism is adrenal insufficiency (such as found in Addison disease patients) and is 
commonly treated with a GC replacement therapy regime of two to three oral hydrocortisone pills per 
day. Clinicians are already aware of the importance of the circadian rhythm of GC secretion and 
attempt to artificially reinstate the circadian component of endogenous GC release as the first of three 
doses is to be taken within the morning and is equivalent to 2/3 of the total dose taken within 24hrs 
(Charmandari, Nicolaides and Chrousos, 2014). Despite this ‘optimal’ replacement regime, patients 
suffer from a range of metabolic side effects that are directly related to GC replacement dose and 
pattern (Filipsson et al., 2006). This is potentially relevant to my premise as delivery via oral dosing 
produces a smooth rise of GCs in the circulation which is prolonged over many hours. But perhaps, to 
mitigate these observed side effects, preservation of ultradian GC dynamics is required rather than 
simply the right dose in a general circadian manner. Based upon the dynamics of the intracellular GR 
and transcriptional machinery that have been explained in my data, it is likely that the prolonged 
hydrocortisone exposure in these patients will similarly induce prolonged GR activation and aberrant 
transcriptional regulation of many of the same metabolic pathway targets identified in my study. 
Therefore, again, the lack of pulsatile GC dynamics in these patients may be a root cause of their poor 
metabolic profiles. 
Due to their powerful anti-inflammatory properties, sGCs have become a cornerstone in the 
treatment of a wide range of inflammatory conditions; with 0.85% of patients >18years of age 
prescribed oral sGCs within the UK (Fardet, Petersen and Nazareth, 2011). sGCs have been rationally 
designed with structural similarity to the endogenous GCs, however, they are not metabolised in the 
body as rapidly. The half-lives of sGCs are significantly prolonged compared to their endogenous 
counterparts as the circulating prednisolone half-life has been reported at just over 2 hrs and Dex at 
3hrs. The biological half-life has however been described to be considerably longer. Recent evidence 
has indicated that methylprednisolone and Dex can induce GR binding in peripheral GC targets such 
as the pituitary for over 6hrs and 12hrs respectively, and in the brain for over 3hrs and 6hrs 
respectively (Al-Habet and Rogers, 1989; Uhl et al., 2002; Earl et al., 2017; Nicolaides et al., 2018). 
Disregarding potential ligand specific effects, clinical corticosteroid treatment was shown to primarily 
precipitate the development of type II diabetes in a cohort of patients that did not present underlying 
risk factors (Simmons et al., 2012). Similarly, 5 days of oral Dex treatment within paediatric acute 




levels despite complete metabolism of Dex (Warris et al., 2016). Finally, a recent meta study concluded 
prescription of the sGC Dex and prednisolone were significant risk factors for development of insulin 
resistance within individuals with no underlying pathology (Zhou et al., 2016).  
In all the clinical cases described in this section, it is apparent that there are some common elements. 
First, prolonged and/or dysregulated GC dynamics with the potential for inducing prolonged and/or 
dysregulated GR dynamics are common factors. Most importantly, in all cases loss of pulsatile nadir 
GC levels appears to be the defining feature for increased risk of MetS development. My data provides 
a potential mechanism whereby phasic GR recruitment and dissociation from the DNA is needed to 
optimally regulate metabolic homeostatic pathways in the liver.  
Together, these data emphasise the clinical importance of strategies aimed at reinstating HPA axis 
rhythms and adrenal GC secretory dynamics in conditions such as chronic stress, depression and 
inflammatory diseases. For GC replacement therapy in adrenal insufficiency and GC treatment in a 
broad range of inflammatory conditions, more consideration should be given to understanding and 
recapitulating endogenous rhythms of hormones and their intracellular systems when developing 
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